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Mesenchymal stem cells (MSCs) are bone marrow derived, non-hematopoietic stem 
cells, which home to sites of injury and inflammation. They have also been identified at 
tumour sites where they can have pro- or anti-tumourigenic effects. It is unclear which 
specific signalling molecules and proteases secreted by the tumour cells are responsible for 
mobilising MSCs to the tumour sites. However, as MSCs migrate to tumour sites, they could 
be utilised for cancer therapy, as engineered MSCs would be able to precisely deliver gene 
or protein treatment to tumour sites.  
Here, the role of a protease, cathepsin D, in the homing of MSCs to tumour sites is 
described through in vitro studies. MDA-MB-231 and HT29 cells or their conditioned media 
were co-cultured in Boyden chambers with MSCs with or without protease inhibitors to 
analyse the migration and invasion of the MSCs. The migration and invasion of MSCs was 
induced by the cancer cells and their 3 day conditioned media. Since increased levels of 
proteases play a major role in regulation of the tumours, we focussed on identifying proteases 
which attract MSCs to the tumour cells. Migration was decreased with protease inhibitors 
pepstatin A and GM6001 in both the cell lines. Pepstatin A is a potent inhibitor of cathepsin 
D. Furthermore, cathepsin D expression was strongly detected in tumour cells when 
compared to the MSCs. To confirm the effects of cathepsin D, its expression was inhibited 
by siRNA which also resulted in a decrease in the migration and invasion of MSCs. The 
signalling pathway MAPK/ERK was found to be activated in MDA-MB-231 and HT29 cells 
and addition of pepstatin A reversed this activation to a significant level. 
Wild-type FOXL2 and tissue inhibitor metalloproteinases (TIMPs) proteins were 
trialled to target cancer through engineered MSCs. To target adult type ovarian tumour 
granulosa (KGN cells), which is characterised by a single missense point mutation of the 
FOXL2 gene, the wild-type FOXL2 gene was overexpressed in KGN cells and MSCs using 
a tdTomato expressing lentiviral vector. Cisplatin and etoposide, the first line treatment 
drugs, were tested on KGN and MSC cells with and without wild-type FOXL2 expressing 
genes. The cancer cells co-culture incubated with MSCs expressing wild-type FOXL2 
showed IC50 values of almost half when compared to cells with the mutated gene. Cell cycle 
distribution, DNA fragmentation and mitochondrial cell death evaluation showed significant 
G2/M arrest, DNA cleavage and mitochondrial permeabilisation in wild type expressing 
KGN cells when compared to mutant gene expressing KGN control cells. Angiogenesis 
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inhibition by MSCs, demonstrated using HUVECs in tube formation assays, was also 
increased by co-culture with MSCs expressing the wild-type FOXL2 gene, compared to 
MSC-only controls. 
TIMPs are the endoproteinases that inhibit matrix metalloproteinases (MMPs), which 
are partly responsible for tumour metastasis. TIMP genes were successfully cloned into a 
tdTomato-expressing vector and overexpressed in MSCs by lentiviral infection. 
These findings provide the first evidence that cathepsin D is an important protease that 
plays a role in attracting MSCs to tumours. We demonstrated that cancer cells secreted 
cathepsin D which increases migration and invasion of MSCs and that the ERK signalling 
pathway may be involved in this MSC migration by cancer cells. In addition, we showed 
that wild-type FOXL2 gene expressing KGN cells were more susceptible to the drugs 
cisplatin and etoposide than the cells carrying only the mutated form of the gene, suggesting 
that it may be clinically useful to deliver the protein using MSCs as part of the treatment 
regime. However more in vitro and in vivo studies are required to confirm and optimise these 
results. We have therefore further explored the homing of MSCs to tumour sites and taken 
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Cancer is a broad term, defined as the uncontrolled growth of abnormal cells within the 
body. The process by which healthy cells develop into malignant cancerous cells is complex, 
with a number of endogenous and exogenous factors contributing to cancer development. 
However, recent research has identified a range of common hallmarks acquired by cells 
during carcinogenesis, which allow the abnormal cells to proliferate and spread throughout 
the body (Hanahan et al., 2011). 
Current common treatment strategies for cancer include chemotherapy, surgery, 
radiation and a combination of these strategies.  The relatively non-selective cytotoxic 
therapeutics target broad-based characteristics of the tumour cells, such as rapid division. 
However, these chemotherapy agents are often accompanied with various toxic side effects 
due to their inability to distinguish healthy cells involved in high division, for example bone 
marrow, resulting in immunosuppression, mucositis and alopecia. Further developments in 
cancer knowledge have elucidated many essential biochemical pathways and deregulated 
proteins involved in tumour cell proliferation and survival, which have provided new targets 
for therapeutics to arrest tumour growth (Vanneman et al., 2012). The more modern cancer 
treatments have been developed to target many specific molecular tumour processes in an 
attempt to protect healthy cells, but are still accompanied by numerous toxic side effects 
(Nicolson et al., 2008). Therefore, still more selective therapeutic targets are required to 
better treat the developing cancer, while providing the least impact on the patient’s quality 
of life. 
In order to develop the selective therapy for cancer, understanding different stages of 
cancer is important. The three different stages of cancer include initiation (Section 1.5.4, 
Chapter 4), development (Section 1.1, Chapter 3) and metastasis (Section 1.1.6, Chapter 5). 
This study used three different approaches using mesenchymal stem cells (MSCs) as 
delivery vehicles, each targeting the individual stage of cancer.  
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 TUMOUR DEVELOPMENT 
1.1.1 Carcinogenesis and tumour development 
The process of carcinogenesis, the development of a tumour phenotype from a normal 
healthy cell, is a widely studied area; however, despite decades of research new information 
is still being discovered. Cancer cells acquire a series of gene alterations that activate 
oncogenes, inactivate tumour suppressor genes and inactivate stability genes which often 
increases the mutations of other genes (Costello et al., 2012). These genetic changes provide 
the alterations in cell physiology that allow a tumour to become independent of normal 
growth signals, evade growth inhibition signals and programmed cell death (apoptosis), and 
develop uncontrolled replication capabilities, contributing to the accelerated growth and 
proliferation that dictates a tumour cell’s malignant phenotype (Vineis et al., 2010). As a 
tumour develops, it requires support from the surrounding tumour microenvironment, known 
as the stroma (Lorusso et al., 2008; Pietras et al., 2010).  
1.1.2 Stroma and tumour stroma 
In general, the stroma is comprised of the extracellular matrix (ECM) found in the 
intercellular spaces which connects blood vessels, nerves and a community of stromal cells 
which may include organ specific parenchyma cells, fibroblasts, myofibroblasts, glandular 
cells, smooth muscle cells, endothelial cells and inflammatory cells (Worthley et al., 2010). 
The ECM is a meshwork of fibrous proteins including laminin, proteoglycans, collagen IV 
and fibronectin (Radisky et al., 2002). The basement membrane  is a specialised ECM that 
separates the epithelium from stroma of any other tissues and serves as a mechanical 
substratum for cell adhesion, divide the tissues into compartments and regulate the cell 
behaviour (Kalluri, 2003). 
The cancer cells interact with the surrounding stromal microenvironment which plays a 
critical role in tumour formation and progression (Liotta et al., 2001; Walker et al., 2018). 
Cancer cells, supported through paracrine signalling from the stromal cells, set in motion a 
sequential set of changes in ECM components by the secretion of ECM modifying enzymes 
(Chang et al., 2017). Using these changes and other factors, tumours then attract new cells 
or change the phenotype of the existing cells to form the tumour supporting and promoting 
cells and incorporate them into the tumour mass (Junttila et al., 2013; Kalinski et al., 2017). 
4 
 
1.1.3 Cells of the tumour stroma 
The tumour stroma consists of a diverse population of cells that are either activated or 
recruited to the local microenvironment such as carcinoma-associated fibroblasts, 
leukocytes, bone marrow-derived cells, other inflammatory cells and cells that comprise the 
vascular system including the lymphatic vessels. Primary and metastatic tumours also 
actively attract mesenchymal stem cells (MSCs) from the bone marrow and the other sites 
such as adipose tissue where they contribute to the tumour. All the cells that comprise the 
tumour stroma are recruited through the release of many inflammatory mediators, including 
reactive oxygen species, various types of proteases, interleukins, interferons and cell 
proliferation factors such as tumour necrosis factor (TNF), which mediate homing of the 
stromal cells (Lorusso et al., 2008; Tlsty et al., 2006). This inflammation mediated 
recruitment of cells to the stroma results in the enlistment of a variety of cells with both pro- 
and anti-tumourigenic activities, which together with inflammatory signals, resembles a 
wound healing site, and leads the tumour site to be described as a “wound that never heals” 
(Dvorak, 1986). Once absorbed into the tumour stroma, MSCs appear to differentiate into a 
variety of cells including tumour associated fibroblasts (TAFs), fibroblasts, adipocytes, 
pericytes and osteoblasts (Direkze et al., 2004). No study has yet defined the conditions 
under which each cell type might be found.  
For example, when the origin of tumour-associated fibroblasts (TAFs) and vascular 
stromal elements in tumour stroma was investigated in E0771 breast tumours,  the majority 
of the TAFs in the tumour stroma was found to originate from mesenchymal stem cells and 
most of the vascular and fibrovascular stroma originated from surrounding adipose tissue 
(Kidd et al., 2012). Adenocarcinoma xenograft models including breast, pancreatic and 
ovarian cancer studies concluded that between 20-90% of TAFs are derived from MSCs 
(Kidd et al., 2012; Spaeth et al., 2009). 
1.1.4 Tumour-stromal interactions  
The stromal cells provide chemo- and cytokine cross-talk causing alterations in the 
ECM and the molecular mechanisms that contribute to the progression of tumours (Hu, Roth, 
et al., 2008). Growth factors such as members of the epidermal growth factor and fibroblast 
growth factor family, as well as various other cytokines and chemokines, are commonly 
expressed in the stroma by fibroblast-like cells (which includes MSCs), providing the 
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continual cell growth stimulation required for rapid tumour expansion (Bhowmick et al., 
2005). Chemokines and cytokines play an essential role in tumour-stromal interactions, as 
several chemokine receptors such as CXCR4, have been detected on cancer cells and 
receptor specific ligands were found to be expressed at the primary tumour site, suggesting 
that receptor mediated signalling plays an important role in tumour growth and metastasis 
(Lorusso et al., 2008). The ECM also becomes a central target of stromal and tumour cells, 
through cells that secrete specific proteolytic enzymes that mediate ECM degradation and 
remodelling to allow for the invasion of the tumour cells away from the primary tumour 
microenvironment (Mason et al., 2011). Other studies have concluded that the stroma may 
possess the ability to suppress the progression of the tumour cells, or even reverse the 
malignant phenotype attained by some cells by epigenetically reprogramming metastatic 
tumour cells (Costa et al., 2009). However, during the early development of the tumour 
microenvironment, it seems that the protective effects of the stroma are abolished through 
conditions such as chronic inflammation, causing the promotion of a pro-proliferative state 
(Joyce et al., 2009). 
1.1.5 Cancer growth and cell death 
Cancers arise by an evolutionary-like process, where cells escape the restraints of 
normal cell cycle regulation to proceed towards proliferation and expansion (Lowe et al., 
2004). Solid tumours are neoplasms composed of proliferating cancer cells. Sustained 
proliferation is the most prominent characteristic of cancer cells. Proliferation can be due to 
several reasons: deregulated autocrine and paracrine proliferation signals, overexpression of 
growth factor receptors or activated mutations of downstream receptor signalling factors 
(Hanahan et al., 2011). Furthermore, loss of negative-feedback loops promotes the 
constitutive proliferation of cancer cells. Programmed cell death has been established as an 
anticancer defence mechanism; therefore, any modification to the related pathways leads to 
uncontrolled cell proliferation and oncogenesis (Danese et al., 2017).  
The most common and well-defined form of programmed cell death is apoptosis. 
Apoptotic cell death is characterised by a relatively rapid reduction of cytoplasmic and 
nuclear volume, nuclear fragmentation and plasma membrane blebbing. This mode of cell 
death often involves the programmed engulfment of apoptotic bodies by surrounding 
phagocytic cells, clearing the cellular debris and preventing an inflammatory response 
(Galluzzi et al., 2007). Apoptosis is triggered explicitly by defined (intrinsic or extrinsic) 
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signals by the cell itself, often resulting from damage, stress or as a barrier against 
tumourigenesis. In addition to apoptosis, various other biological processes can lead to cell 
destruction. Anoikis is related to apoptosis as it is a caspase-dependent cell death mechanism 
triggered by the detachment of cells from the extracellular matrix. Necrosis, as opposed to 
the highly regulated apoptosis, is an accidental death occurring spontaneously following 
external stresses that block normal physiological processes. The disorganised nature of this 
form of death leads to the release of cellular debris into the surrounding tissue which may 
affect its function. Senescence is a process in which cells enter a form of cell-cycle arrest 
and permanently lose their ability to divide. Senescent cells cannot be stimulated to 
proliferate by known physiological stimuli (Danhier et al., 2017). 
The intrinsic and extrinsic cell death mechanisms are well-defined; however, the 
distinctions are muddied by the extensive cross-talk between the pathways. The intrinsic 
pathway of apoptosis is responsive to the signals of survival factors, cell stress and injury 
(Danial et al., 2004). Mitochondria play a significant role in this pathway, as they sequester 
a variety of pro-apoptotic factors, which when released lead to cell death. Mitochondrial 
permeability is determined by the balance between pro-apoptotic BAX/BAK proteins and 
the anti-apoptotic Bcl2 proteins (Cory et al., 2003). One important pro-apoptotic factor is 
cytochrome-c which triggers the activation of caspase-9, that initiate the downstream 
proteolytic cascade which involves caspase-3 and caspase-7 (Green et al., 2004). This 
intrinsic apoptotic pathway is activated in adult type-ovarian tumour granulosa KGN cells 
that express the wild-type FOXL2 (Forkhead box L2) gene (Kim et al., 2011). 
1.1.6 Cancer metastasis 
The deadliest cancer cell type is one that has acquired an invasive or metastatic 
phenotype. Due to the difficulty of treating multiple tumour sites in vivo, metastasis is 
regarded as the most complicated cancer process for therapy and accounts for the greater 
than 90% of cancer-related mortality (Sethi et al., 2011). 
Metastasis is defined as the spread of cancer cells from the primary tumour site towards 
distant sites, resulting in the development of secondary tumours (Weng et al., 2012). In this 
process, cancer cells must first leave the primary tumour site by invading through the local 
tissue to enter the circulation system, infiltrate the secondary site through the surrounding 
interstitial fluid and parenchyma and finally establish tumour growth (Liotta et al., 1991). 
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Thus, metastasis involves many complex sequential steps, including invasion, migration, 
adhesion, infiltration, colonization at a distant site and subsequent formation of new 
capillaries (Weng et al., 2012). 
Traditionally, metastasis was thought to be a late-stage cancer process; however, more 
recently it has been identified as initiated at an early stage. Malignancy and invasion have 
been linked to several driving factors and altered protein expression profiles that may include 
the up-regulation of proteases (Sethi et al., 2011; Wilkins-Port et al., 2012). Proteases allow 
tumour cells to invade into the surrounding stroma through the ECM. Following invasion, 
primary tumour cells can migrate using integrins that bind to ECM proteins including 
collagen I, fibronectin, laminin, and vimentin (Liotta et al., 1991). 
To invade into tissues and vessels, cells must break their adhesions with the surrounding 
tissues and acquire the ability to migrate. This is initiated by the formation of pseudopodia 
at the leading edge of the cell, which can attach to the ECM (Shankar et al., 2010; Weng et 
al., 2012). The tumour cell attachments to ECM components are mediated via protein-
protein interactions, most often involving integrin receptors such as α2β1 and α11β1 
(collagen I), or α4-9β1 and α5β1-8 (fibronectin) (Hynes, 2002). Adhesion may also be 
mediated through the expression of proteins other than integrins, including vascular cell 
adhesion molecule-I (VCAM-1), which is expressed on tumour cells and facilitates cellular 
adhesion through interactions with integrins. The expression of VCAM-1 has been linked to 
an increase in bone metastasis in prostate and breast cancer, therefore may provide a target 
for anti-metastatic therapy (Rahim et al., 2014). 
Processes throughout the invasion and migration of cancer cells are mediated by the 
expression of proteases released by the tumour cells and surrounding stromal cells (Sevenich 
et al., 2014). These proteases can increase the cell penetration of the host cells and the 
surrounding ECM, by degrading the physical barriers and increasing tumour cell motility to 
distant tissues (Liotta et al., 1991). Many studies investigating migration of cancer cells 
focus on the enzymes, matrix metalloproteinases (MMPs). In addition, the proteases 
cathepsin (cath) D and urokinase plasminogen activator (Achour et al.) also play an 
important role in increased risk of metastasis in breast cancer and also colon adenocarcinoma 
(Maynadier et al., 2013; Waszkiewicz et al., 2012). Upregulation of these enzymes are 
mediated by inflammatory cytokines, such as tumour growth factor-β, interleukin1-β, and 
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tumour necrosis factor-α or stromal derived factor-1α may have an indirect effect by up-
regulating these lytic enzymes (Ries et al., 2007).  
Due to the multifaceted nature of cancer metastasis, which involves multiple signalling 
pathways, inhibition may require the simultaneous targeting of several mechanisms. As 
opposed to investigating cancer cell metastasis as a whole, it may be beneficial to investigate 
individual mechanisms that are involved at several points along the way. As MSCs were 
considered to be one of the major factors to playing a role in metastasis after becoming a 
part of tumour stroma, they are a focus of our studies. 
 MESENCHYMAL STEM CELLS 
1.2.1 Introduction to mesenchymal stem cells 
MSCs are generally found in stromal environments within the body and can be easily 
isolated from various tissues and organs. The most commonly used sources of MSCs are 
bone marrow (Li et al., 2016) and adipose tissue (Baer, 2014). But, they also can be isolated 
from umbilical cord (Davies et al., 2017), placenta (Roberts et al., 2019), amniotic fluid 
(Phermthai et al., 2013), chorionic villi (Roselli et al., 2013), dental pulp (Meng et al., 2015), 
endometrium (Vinogradov et al., 2017), brain (Pombero et al., 2016), skin (Chinnici et al., 
2014), synovial membrane and synovial fluid (de Sousa et al., 2014), sweat glands (Ma et 
al., 2018) and nasal mucosa (Hwang et al., 2017). Although the MSCs from different origins 
show similar aspects, their function depends on the tissue of origin along with the biological 
characteristics and differentiation abilities (Confalonieri et al., 2018). 
MSCs localise to sites of inflammation and injury, and can give rise to the cell lineages 
including bone, cartilage, fat and muscle and have effects on connective tissue repair and 
ECM remodelling (Pittenger et al., 1999). MSC differentiated cell types also include 
pericytes, myofibroblasts and endothelial cells (Uccelli et al., 2008). The differentiation of 
MSCs into lineage-specific cells depends on external factors in the environment, including 
cell-cell and cell-ECM adhesion and cytokine, chemokine and growth factor availability 
(Bergfeld et al., 2010). MSCs are distributed throughout other tissues, where they are 
thought to serve as local sources of dormant stem cells (Karnoub et al., 2007).  
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This study used bone-marrow derived MSCs due to their favourable clinical 
applications when compared to MSCs of other tissue origins (ClinicalTrial.gov). Bone-
marrow derived MSCs were first isolated in the 1960s and described as fibroblast-like-cells 
(Friedenstein et al., 1966). MSCs in these original studies were identified as merely the cells 
that adhered to the plastic ware, following several days of culture (Friedenstein et al., 1992). 
However, according to International Society of Cellular Therapy, the minimum criteria for 
cells to be defined as MSCs include being positive for the cell surface markers including 
CD105, CD73 and CD90 and negative for hematopoietic markers CD45, CD34, CD14 or 
CD11b and CD79α or CD19 (Dominici et al., 2006).  
1.2.2 Factors and mechanisms behind the migration of MSCs to the tumour site 
As MSCs home to tumours and contribute to the tumour stroma, it is important to find 
out how they are being recruited to these sites. Understanding this mechanism may provide 
information on how MSCs become a part of tumour stroma and how MSCs could be 
potentially utilised to selectively deliver targets for cancer therapy.  
A number of studies have investigated MSC homing to the tumour stroma. Initial studies 
used allogeneic bone marrow transplantation, but more recent work has used animal and 
patient models. For example, GFP-positive bone marrow was transplanted into a transgenic 
C57BI/6 mouse model before delivering the mice ID8 murine ovarian tumour cells, and 
assessing the contribution of bone marrow-derived cells to the tumour stroma, which was 
found to be around half of all the cells in the tumour mass (Kidd et al., 2012). 
MSCs are actively recruited to the site of injury in many pathological conditions such 
as inflammation, tissue repair and also neoplasia (Hall et al., 2007b). This recruitment is due 
to the response of MSCs to stress or injury in a manner that is similar to adaptive and innate 
immune system cells responding to pathogen exposure and is mediated by gradients of 
cytokines, chemokines, prostaglandins, proteases, inflammatory mediators, antimicrobial 
proteins or apoptosis generated signals (Bissell et al., 2001; Dimarino et al., 2013). It is 
assumed that the MSCs follow the same physical process to move through barriers, as is 
found in leukocyte homing during pathogenesis or tissue injury (De Becker et al., 2016). 
Growth factors such as insulin-like growth factor-1 (IGF-1) (Li et al., 2007), epidermal 
growth factor (EGF) (Nwabo Kamdje et al., 2017), vascular endothelial growth factor 
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(VEGF) (Schichor et al., 2006), transforming growth factor β (TGF-β) (Tabatabai et al., 
2006), stromal-derived factor-1 (SDF-1) (Ryu et al., 2010) and platelet-derived growth 
factor (PDGF) (Hata et al., 2010) were found to have a significant role in MSC homing. For 
example, it was determined that the number of MSCs which migrated was proportional to 
the levels of PDGF-BB expressed by the human U87 glioma cells both in vitro as well as in 
an intracranial mouse model (Hata et al., 2010). Also, IGF-1 increased the migration and 
proliferation of the MSCs via chemokine receptor signalling which further increased the 
response of MSC to SDF-1 (Li et al., 2007).  
Cytokines and chemokines are cross-talk communication agents, important for MSCs 
tropism to tumour sites mediated through autocrine/paracrine signalling pathways. The 
chemokine SDF-1 was found to be overexpressed in MSCs exposed to MDA-MB-231 breast 
cancer cell conditioned medium and inhibitors of SDF-1 blocked signalling via the 
CXCR4/ERK pathway, which played a crucial role in the homing of MSCs to the tumour 
stroma (Gao et al., 2009; Ryu et al., 2010; Worthley et al., 2009). Other cytokines such as 
IL-6 (Karnoub et al., 2007), IL-8, neurotrophin-3 and transforming growth factor-β (TGF-
β) are also involved in the attraction of MSCs by glioma cells (Birnbaum et al., 2007). The 
inflammatory chemokines MIP-1δ and MIP-3α were also critical in MSC migration towards 
Huh-7 hepatoma cells via activating the ERK signalling pathway (Lejmi et al., 2015). In 
addition, chemokine receptor overexpression also showed an effect on MSC migration. For 
example, chemokine receptor-7 overexpression increased the migration and proliferation of 
mouse (C57BL6) bone marrow derived MSCs with the increased secretion of CXCL12 and 
MMP-2 (Liu et al., 2018). 
In the crosstalk between the MSCs and the cancer cells, cytokines and chemokines 
induce cancer stem cell growth and regulate the phenotype of tumour-associated MSCs. 
MSCs transplanted into the bone marrow can expand the putative breast cancer stem cell 
population via a cytokine loop involving IL-6 and CXCL7 (Liu et al., 2011). Specifically, 
the secretion of IL-1 by human carcinoma cell lines induced prostaglandin E2 (PGE2) 
secretion by MSCs in vitro and PGE2 in combination with upregulation of cytokines by 
MSCs led to the activation of β-catenin signalling in cancer cells and subsequent formation 
of cancer stem cells (CSCs) in vivo and in colon and breast carcinomas induced in nude mice. 
The plastic nature of CSCs and the dynamic interactions between CSCs and MSCs is 
important in cancer progression and maintenance (Li et al., 2012).  
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The transmigration of MSCs through the endothelial layer and the underlying basement 
membrane during tumour recruitment is facilitated by proteolytic enzymes, such as matrix 
metalloproteinases (MMPs), which cleave and remodel the components of basement 
membrane (De Becker et al., 2016). Further description of the role of MMPs in tumour 
development is given later in this chapter (Section 1.4). 
Overall, growth factors, cytokines, chemokines and proteases together play a key role 
in MSCs migration to the tumour sites. Understanding the underlying molecular mechanisms 
by which they are regulated is important in understanding MSC tumour tropism, potentially 
leading to new targets in cancer therapy. 
1.2.3 Pro- and anti-tumourigenic activity of mesenchymal stem cells  
MSCs in the tumour stroma can act in a pro or anti-tumourigenic manner. However the 
details of the cross-talk between MSCs and the tumour stroma are not fully elucidated and 
the precise mechanisms of this process are complex and can vary (Li, Luo, et al., 2015). 
Within tumours, the functional switch of MSCs between pro- and anti-tumourigenic roles 
was partly explained. The two different phenotypes of MSCs were used where one led to 
anti-tumourigenic effect and the other to pro-tumourigenic effect (Waterman et al., 2012). 
Many studies were performed to understand this functional switch by tracking the MSCs in 
vivo and isolating them from a tumour for further studies (Guo et al., 2016; Liu et al., 2016). 
Many studies have concluded that MSCs contribute to pro-tumourigenic activity. As 
MSCs isolated from different regions of the body have been shown to induce or promote 
cancer growth, late-stage cancer progression, motility, invasion, and metastasis. For 
example, MSCs promoted the migration and invasion of the tumour cells via chemokine 
receptor upregulation such as CXCR4 in human osteosarcoma and hepatocellular carcinoma 
in vitro (Fontanella et al., 2016) and rat hepatoma in vitro (Li, Luo, et al., 2015). Tumour 
associated fibroblasts (TAFs) secreting CXCL-12 (SDF-1) were found to directly promote 
the growth of CXCR4 expressing tumours both in vivo and in vitro (Orimo et al., 2005). 
Also, the production of CCL-9 and CCL-5 chemokines by MSCs promoted invasion in 4T1 
mammary tumour cells (Swamydas et al., 2013) and CCL-5 alone increased MDA-MB-231 
breast cancer cell metastasis to lungs (Karnoub et al., 2007).  
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In animal studies, an increase in peritoneal metastasis of colorectal cancer HCT116 cells 
by approximately 18% and LOVO cells by approximately 20% was noticed when bone-
marrow derived MSCs conditioned media was injected in nude mice along with the cancer 
cells intraperitoneally. The increase in migration was shown to occur via AMPK/mTOR-
mediated NF-κB activation (Wu et al., 2016). When human umbilical cord MSCs with 
Eca109 oesophageal carcinoma cells were injected subcutaneously together, the tumour 
volume increased significantly when compared to the mice injected just with the Eca109 
cells alone. The metastasis of the cancer cells to lymph nodes was also promoted (Xiaoya et 
al., 2014).  Adipose tissue-derived stem cells, when mixed with MDA-PCa 118b prostate 
cancer cells and injected subcutaneously, increased the tumour volume 4 times compared to 
MDA-PCa cells injected alone in Swiss nude mice (Prantl et al., 2010). An increase in 
migration of MDA-MB-231 (36% and 75% with 10% and 20% serum respectively) and 
MCF-7 (41% and 51% with 10% and 20% serum respectively) breast cancer cells was 
observed in the presence of umbilical cord MSCs (Li, Zhang, et al., 2015; McAndrews et 
al., 2015). Co-injection of MSCs with Daudi Burkitt’s lymphoma cells promoted the 
engraftment and proliferation of a tumour injected subcutaneously (Roorda et al., 2010). 
Another pro-tumourigenic effects of MSCs in the tumour stroma promotion of the 
secretion of pro-angiogenic factors such as TGF-β, VEGF and IL-6. The secretion of these 
factors increased when the bone marrow-derived MSCs were exposed to 4T1 mammary and 
DU145 prostate cancer cells by 4.8-fold (P <0.05), 2.17-fold (P <0.05), 2.8-fold (P <0.05) 
and 4.36-fold (P <0.05) for TGF-β, VEGF, IL-6 and MIP-2 respectively (Zhang et al., 2013). 
MSCs also stabilised blood vessels and influenced immune system function with an overall 
immunosuppressive effect (Da Silva Meirelles et al., 2008).  
However, there are also a number of conflicting studies in which MSCs were shown to 
have anti-tumourigenic activity. MSCs suppressed the metastasis of MHCC97-H 
hepatocellular carcinoma cells by downregulating TGFβ. TGFβ usually maintains the net 
balance of MMP/TIMP levels, and this reduced the expression of MMPs (Li et al., 2010). 
Migration and invasion of MDA-MB-231 and T47D cells were reduced after exposure to 
MSCs, due to the production of 40-fold higher levels of TIMP-1 and TIMP-2 (Clarke et al., 
2015). 
Human MSCs also delayed tumour formation by 36 days after co-injection with H7402 
cells when compared with the cancer cells alone, where detectable tumours were formed in 
13 
 
5-7 days. Z3 MSCs inhibited tumour cell proliferation of H7402 hepatoma cells by 
downregulation of the Wnt signalling pathway in co-culture and also when injected into the 
xenograft of a cancer SCID mouse model. The tumour growth of Kaposi sarcoma implanted 
subcutaneously in athymic nude mice was reduced by around two thirds when the MSCs 
were injected intravenously, which was mediated through via inactivation of the Akt-
mediated pathways (Khakoo et al., 2006).  
Inhibition of tumour growth was observed in non-Hodgkin lymphoma when bone 
marrow derived MSCs were injected intraperitoneally 4 days after injection of lymphoma 
cells. The median survival rate was increased to 40 days with SKW6.4 cells and MSCs 
compared to 27 days with SKW6.4 cells alone. In in vitro investigations, the decrease in 
tumour growth was correlated with secretion of pro-angiogenic cytokines that promoted 
endothelial cell apoptosis (Secchiero et al., 2010). Similar results were also observed in 
models of lung adenocarcinoma using CL1-5, A549 and H1299 cell lines, in which MSCs 
were found to decrease the migration and invasion of lung adenocarcinoma cells by the 
secretion of cytokine oncostatin M (Wang et al., 2012). 
Taking all the studies into consideration, it is difficult to conclude if the MSCs are pro- 
or anti-tumorigenic in cancer. However, it does seem that contribution of the MSCs is highly 
context-dependent, and depends upon the stage of the tumour and the specific tumour models 
investigated. This was previously demonstrated in an in vivo hepatocarcinoma models, 
Where MSCs were trialled by intravenously injecting in the initial stage or progressive stages 
of tumour formation. MSCs in the initial stage showed anti-tumourigenic activity, while in 
the progressive stage pro-tumourigenic activity was found (Zong et al., 2018). The variations 
in treatment response may also depend on the source of MSC collection and whether they 
are derived from a healthy person or a patient. Other factors causing variation include the 
experimental conditions such as co-injection of MSCs to the tumour site (Melzer et al., 2018) 
or route of injection such as intraperitoneal or intravenous and also the time when the MSCs 
were injected relative the tumour stage. 
1.2.4 Mesenchymal stem cells as potential vectors of gene/miRNA/virus/drug  
MSCs can potentially act as delivery vehicles for cancer treatment. In recent years, 
MSCs have been identified as vectors of gene, drug, mi RNA or virus delivery to a tumour 
in a targeted way, since they migrate and reside in the sites of a tumour (De Becker et al., 
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2016). The exogenously cultured and injected MSCs can specifically home to and integrate 
into the tumour sites without being incorporated into normal tissue (Kidd et al., 2009). MSCs 
are also capable of crossing the well-regulated blood-brain barrier (BBB) which usually 
prevents the extravasation of immune cells and drugs to brain parenchyma. In a previous 
study of experimental glioma, when MSCs were administered via the carotid artery, it was 
reported that at 1 h post injection MSCs were clustered near blood vessels, suggesting the 
entry of MSCs through the intracellular spaces between the endothelial cells (Ho et al., 
2013). The recruitment of MSCs to the tumours increased with the time in pancreatic cancer 
(Direkze et al., 2004; Ishii et al., 2003), suggesting that a blockage of this homing process 
may alter the tumour proliferation and progression. In addition, MSCs have demonstrated 
low immunogenicity in vitro and in vivo (Lee et al., 2014), meaning MSCs can be injected 
into patients without immune rejection (Droujinine et al., 2013). This is due to a lack of 
MHC class II molecules and a relatively low level of MHC class I molecules (Squillaro et 
al., 2016). However, in spite of encouraging results reported for in vitro and in vivo, only 
few therapies have progressed to clinical trials. 
Cytokines and chemokines have been shown to be effective anti-cancer agents when 
delivered by MSCs. An intravenous injection of IL-12-expressing MSCs completely 
eradicated tumour growth in B16 melanoma, 4T1 breast and HCA hepatoma injected mice. 
An increase in the apoptotic index and decrease in lymphatic sprouting were also found after 
a 20-day course of IL-12 MSCs (injected every 5 days intravenously) (Chen et al., 2008). 
The same IL-12-expressing MSCs also showed anti-tumour effects without any toxic side 
effects in renal cell carcinoma where average survival increased from 40 days to 80 days for 
treatment group (Gao et al., 2010). In C26 colon and B16F10 melanoma mouse models, 
chemokine (C-X3-C-motif) ligand-1 expressing MSCs reduced metastatic lung nodules 
down to 36% of the control increased survival to 46 days when compared to the controls 
which survived for 21 days on average (Xin et al., 2007). Examining the PDGF-BB cytokine 
effect on homing of MSCs to tumour sites, the partial block of the PDGF-β receptors was 
shown to reduce MSC recruitment, which in fact proportionally reduced the tumour size and 
metastasis (Hata et al., 2010).  
In another study, TRAIL and PTEN-mRNAs (apoptotic genes) were synthesized and 
transfected into MSCs. The migration ability of the genetically engineered MSCs increased 
when compared to non-transfected MSCs. Glioma cells were engineered with a luciferase 
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gene and the viability of the cells verified by bioluminescence. When both the modified cells 
were injected, the growth of the xenografts was significantly inhibited, implying that the 
MSCs transferred the apoptotic genes efficiently to the xenografts when injected 
intravenously (Guo et al., 2016). Adenoviral co-transfer of TIMP-2 and PTEN to U87 
glioma cells also showed suppression in invasion ability of glioma cell number to 19.17 ± 
5.45 when compared to U87 cells transfected with the empty vector number 55.63 ±13.27 
(Lu et al., 2004b). 
MSCs have also been transfected with synthetic fluorescently labelled miRNA mimics 
and co-cultured with glioma and glioma stem cells labelled with green fluorescent cell 
tracker. The delivery of miR-124 and miR-145 from MSCs to the glioma cells was examined 
using these trackers. The migration of the glioma cells via Transwell migration assays 
decreased along with the self-renewal of the glioma stem cells HF2485 and HF2414 when 
co-cultured with miR-145-expressing MSCs, effectively suggesting that MSCs can deliver 
the miRNAs efficiently (Lee et al., 2013). 
In another example, MSCs were transfected with synthetic fluorescently labeled 
miRNA mimics and co-cultured with glioma and glioma stem cells labelled with green 
fluorescent cell tracker. The delivery of miR-124 and miR-145 from MSCs to the glioma 
cells was examined using these trackers in vitro. The migration of the glioma cells via 
Transwell migration assays decreased along with the self-renewal of the glioma stem cells 
when co-cultured with miR-145-expressing MSCs, effectively suggesting that MSCs can 
deliver miRNAs efficiently (Lee et al., 2013). 
MSCs have also been used as a vehicle for the tumour-specific delivery of viruses, 
including a conditionally replicating oncolytic adenovirus injected intraperitoneally in an 
orthotopic model of renal cell carcinoma. After MSCs with oncolytic adenovirus injections, 
tumour growth indicated by bioluminescence was decreased to 95-fold approximately when 
compared to controls injected with only MSCs, which had 200-fold bioluminescence 
approximately. Necrotic areas were present in 70-95% of treated tumours, in a dose-
dependent manner. These were lacking when the virus was not packaged in MSCs for 
delivery (Hsiao et al., 2012). In addition, a recombinant adenoviral vector with apoptin (anti-
tumour gene) was constructed and MSCs were infected with this vector. The modified MSCs 
with apoptin were injected into a mouse model containing liver carcinoma and were able to 
inhibit tumour growth by up to 35% in vivo (Zhang et al., 2016). 
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MSCs can also be used as drug delivery vehicles. Exposure of MSCs to paclitaxel led 
to incorporation of paclitaxel into the MSCs (Pessina et al., 2011). However, to increase the 
drug loading capacity, MSCs have also been loaded with nanoparticle (NP) encapsulated 
forms of drugs. Thus, nanoengineered MSCs with paclitaxel in poly (L-lactide-co-glycolide) 
(PLGA) loaded NPs were used. These MSCs demonstrated a dose-dependent cytotoxicity 
against A549 lung adenocarcinomal cells and MA148 human epithelial ovarian carcinoma 
cells (Sadhukha et al., 2014). The same MSCs also showed therapeutic efficacy in an 
orthotopic rat glioma developed by injecting C6 glioma cells (Wang et al., 2018). 
Pharmacokinetic and biodistribution studies showed improved results with MSCs loaded 
with paclitaxel NPs when compared to just MSCs (Sadhukha et al., 2014; Wang et al., 2018). 
MSCs have also been used in prodrug strategies in many studies. Thymidine kinase 
(TK) overexpressing MSCs, which convert the prodrug ganciclovir to the active form, were 
used to treat mice injected intravenously with prostate cancer PC3 cells. The inhibition of 
tumour growth with the TK-MSCs was significant (up to 99.5%) when compared to controls 
injected with just the MSCs (Song et al., 2011). Cytosine deaminase (CD) expressing MSCs 
delivered the CD transgene in the tumour site, and it was used to convert 5-fluorocytosine 
to 5-fluorouracil in HT29 colon adenocarcinoma and A375 melanoma cancers both in vitro 
and in vivo (Kucerova et al., 2007; Kucerova et al., 2008). In another study, MSCs were 
engineered with rabbit cholinesterase (rCE) which converted a camptothecin derivative 
(CPT-11) to the cytotoxic drug SN-38, a topoisomerase inhibitor. Human esterase poorly 
activates CPT-11, so the modified rCE-MSCs were employed. The survival rate of rats with 
F98 glioma increased to 24 days when the rats were injected with rCE-MSCs and CPT-11 
compared to rats injected with the CPT-11 only, which had a median survival of 19 days, 
and was also significantly longer than rats treated with PBS only, with median survival of 
15 days (Choi et al., 2012).   
Therefore, MSCs have been tested as potential gene/miRNA/virus/drug delivery 
vehicles. Although MSC-based therapies hold promise as potential therapeutics, there are 
relatively a few clinical trials underway (ClinicalTrial.gov, 2019). However, there are a 
number of clinical trials using MSCs based therapies in diseases such as ischemia, chronic 
obstructive pulmonary disease, Crohn's disease, and graft-versus-host disease in which no 
incidence of toxicity has been reported (Dimarino et al., 2013).  
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The apparent lack of toxicity with MSC treatments in combination with their homing 
ability to tumour sites, availability, expandability and intratumoural distribution makes the 
MSCs an ideal therapeutic for cancer treatment. In addition, in an uninjured mouse, 
exogenous intravenously injected MSCs rapidly accumulated within lungs and were cleared 
via the liver within a few days. Moreover, MSCs are not detectable in the mouse body after 
seventh day of intravenous injection (Kidd et al., 2009). The pattern of accumulation in 
lungs, followed by the clearance within days markedly lowers the possible risk of long-term 
side-effects. The use of MSCs are advantageous due to minimal ethical considerations when 
compared to the other embryonic stem cells (Mahla, 2016). Another advantage of using 
MSCs is resistance to chemotherapeutics, which makes these therapies applicable clinically 
(Hayal et al., 2019). 
1.2.5 Challenges to face to use mesenchymal stem cells as potential targeting agents  
Although MSCs are considered as delivery agents for cancer therapy with reported safe 
usage so far, but there are some limitations of this therapy which are yet to be addressed. 
There are likely to be biological differences in the cells, depending on the source and 
collection method. For example, MSCs can be harvested from different tissues such as 
adipose tissue, bone marrow, umbilical cord and so on, or from different individuals such as 
healthy people or patients or allogenic or autogenic origin. These cells are likely to share 
similar features such as morphology and cell surface markers. However, they exhibit 
differences in other biological properties such as differential capabilities and context 
dependent effects (Wagner et al., 2005; Xu et al., 2017). As a result of heterogeneity 
therefore there is a need for standardised universal good manufacturing practices (cGMP) 
for the collection, isolation, purification, expansion and preservation of MSCs to ensure the 
consistency of cells being used for therapy (Le Blanc et al., 2018). 
Several aspects concerning MSCs safety are still incompletely understood. For example, 
the possible issues arising from the ex vivo expansion, undertaken to obtain sufficient 
number of cells for administration, such as lack of genetic stability, senescence or 
transformation have not yet been settled (Martin et al., 2016; Roselli et al., 2013). In 
addition, various cell culture factors such as the amount of fetal bovine serum (FBS) added, 
concentration of supplements such as growth factors or hypoxic conditions, lead to 
variability in the properties of MSCs (Hwang et al., 2017; Potier et al., 2007). 
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The International Society for Stem Cell Research (ISSCR) provided guidelines for best 
practices for addressing ethical and scientific issues ensuring integrity in stem cell based 
therapies which might solve some of the problems of using MSCs clinically (Hyun et al., 
2008). In addition, preclinical studies must characterise cells, evaluate potential toxicity, 
biodistribution, tumourigenicity risks and long term effects initially (Neri, 2019; Squillaro 
et al., 2016). The FDA has also issued various guidelines for stem cell and gene based 
therapies to ensure the desired standard of products (Mendicino et al., 2014). 
Overall, it is clear that bone marrow derived MSCs are recruited to tumour stroma with 
the help of several cellular factors of which proteases are of special interest. MSCs could 
also be used as potential therapeutics for cancer if we can solve any safety or consistency 
problems that may occur due to their use. In this study, we will use engineered MSCs 
expressing fluorescent markers which will make it easier to track MSCs in vivo. Also, we 
make an attempt to develop MSCs as a therapeutic agent for adult type-granulosa cell 
tumours by overexpressing the FOXL2 gene and for paediatric glioblastoma by 
overexpressing TIMP proteins. 
 PROTEASES 
Proteases are enzymes that irreversibly hydrolyse peptide bonds in proteins, which 
results in important and irreversible post-translational modifications. The human genome 
encodes for over 569 proteolytic enzyme homologues, which constitute the second largest 
class of human enzymes (Masson et al., 2010). Proteases are assigned to five classes on the 
basis of the active site residue that executes the nucleophilic attack on the target peptide 
bond: aspartic, cysteine, serine, threonine and metalloproteinases. Proteases are implicated 
in normal physiological processes and deregulation of their expression and/or enzyme 
activity is noticed in disorders such as cancer (Masson et al., 2010). 
The families of proteases which have been implicated in cancer motility, invasion, 
extravasation, proliferation and metastasis include the aspartic acid protease cathepsin D 
(cath D) (Liaudet-Coopman et al., 2006), the cysteine cathepsins (cath B and cath L) 
(Palermo et al., 2008), serine proteases (uPA, uPAR and PAI1) (Smith et al., 2010) and the 
metalloproteinase family (Roy et al., 2009). Since our studies focus on cath D and matrix 




1.3.1.1 Introduction to cathepsins 
Cathepsins (cath) are a class of globular lysosomal peptidases. They can be divided into 
three subgroups, based on their active amino acid site and also their structure, catalytic 
mechanism and substrate specificity. Cathepsins B, C, F, H, L, K, O, S, V, W and X are 
cysteine proteases of the papain family and represent the largest and best-known class. 
Cathepsins A and G are serine carboxypeptidases (Kuester et al., 2008) and cathepsins D  
and E are aspartic acid proteases (Masson et al., 2010). Cathepsins have been found localised 
in the cytoplasm, especially in multi-vesicular bodies, mainly lysosomes, as inactive 
proenzymes (Kuester et al., 2008). 
Apart from several physiological processes such as cell growth and tissue homeostasis, 
cathepsins also participate in inflammatory processes such as periodontitis, rheumatoid 
arthritis, atherosclerosis, pancreatitis, and gastritis (Roessner et al., 2000). It was also found 
that cath B, L and D expression levels were increased in melanoma and carcinoma of the 
lung, colon, prostate and breast (Nomura et al., 2005). Enhanced production and release of 
cathepsins in tumour cells have been shown to lead to tumour cell growth, invasion and 
metastasis (Palermo et al., 2008). Cath D also has mitogenic properties, stimulating the 
release of basic fibroblast growth factor, activates pro-cathepsins B and L and inactivating 
their active forms. Cathepsins B, L and D are capable of degrading extracellular matrix 
molecules including collagen, fibronectin, proteoglycans and elastin along with basement 
membrane components including laminin and type IV collagen (Kuester et al., 2008; 
Palermo et al., 2008). 
1.3.1.2 Introduction to cath D 
Cath D is a ubiquitous, lysosomal, aspartic endoproteinase that requires acidic pH to be 
proteolytically active. It has been considered for a long time that the primary function of cath 
D was to degrade proteins in lysosomes at acidic pH (Liaudet-Coopman et al., 2006).  
However, it has  now also been shown that cath D activates the precursors of biologically 
active proteins in the pre-lysosomal compartments of cells (Liaudet-Coopman et al., 2006).  
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Acidic pH is therefore unsurprisingly thought to be required to trigger degradation of 
the constituents of the ECM and basement membrane by the cathepsins released from the 
lysosome in tumours. This proteolytic effect can occur in the tumour environment as it is 
slightly more acidic than those surrounding normal cells, in the range of pH 6.8-7.0 (Chai et 
al., 2012). Pepstatin A, a natural inhibitor of aspartic proteases isolated from various 
actinomycetes, has often been used not only for affinity chromatography purification of cath 
D but also to study its function in in vivo and in vitro systems (Hu, Roth, et al., 2008; Liaudet-
Coopman et al., 2006). 
1.3.1.3 Maturation of cath D 
Mechanisms associated with the processing and activation of lysosomal proteases are 
partially known (Liaudet-Coopman et al., 2006). Cath D is synthesised on the rough 
endoplasmic reticulum (rER) as pre-pro-enzyme, which undergoes several proteolytic 
cleavages during biosynthesis to produce the mature form. The signal peptide of 20 amino 
acids (aa) is removed during the co-translational translocation of cath D across the ER 
membrane, generating an inactive pro-cath D (52 kDa) (Khalkhali-Ellis et al., 2014; Zaidi, 
Maurer, et al., 2008). Following this, sugars are attached at two separate N-linked 
glycosylation sites on the surface of the folded protein and then pro-cath D is transported to 
the Golgi stacks. Glycosylation is required for the targeting of the enzyme to lysosomes 
(Zaidi, Maurer, et al., 2008). 
Transport of pro-cath D from the Golgi complex to the downstream acidic lysosomal 
compartments is mainly mediated by the mannose-6-phosphate (M-6-P) pathway. Thus, in 
the Golgi complex, the two N-linked oligosaccharides of cath D are covalently modified and 
their mannose residues are phosphorylated to form mannose-six-phosphate. It is the cation-
independent M-6-P groups that segregates lysosomal hydrolases in the trans-Golgi network 
and help package the cath D into building transport vehicles that deliver their contents to late 
endosomes and thereby to lysosomes (Liaudet-Coopman et al., 2006). However, there is 
another more minor pathway, which is M-6-P receptor-independent, that also targets pro-
cath D to lysosomes, which is not fully understood (Pranjol et al., 2015). 
Once transported to the lysosomes, which have low pH similar to that of late endosomes, 
the pro-cath D dissociates from the M-6-P receptors, and subsequently the phosphate group 
is removed. This is followed by an initial proteolytic step which removes the pro-peptide (44 
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aa) from pro-cath D to generate an active intermediate (48 kDa) single chain molecule 
(Masson et al., 2010). The pro-peptide is reported to be essential for the correct folding, 
activation and delivery of protein to lysosomes. The single intermediate is not generated by 
the autocatalytic activity. Instead, cysteine proteases cath B and L are involved in the process 
(Liaudet-Coopman et al., 2006; Palermo et al., 2008).  
The 48 kDa intermediate is further processed into a mature form, consisting of an 
amino-terminal light chain (14 kDa) and a carboxy-terminal heavy chain (34 kDa). These 
chains can remain associated with each other, by hydrophobic interactions. Also, in vitro 
studies have demonstrated that pro-cath D, upon acidification, auto-catalytically generates 
proteolytically active pseudo-cath D, an enzyme species that retains 18 residues of the pro-
segment (Zaidi, Maurer, et al., 2008). 
1.3.1.4 Role of cath D in cancer progression 
In many studies, cath D was shown to be overexpressed and hyper-secreted in various 
cancers and was therefore suggested to act as a potential biomarker in breast cancer 
(Mbeunkui et al., 2007), endometrial cancer (Losch et al., 1996), lung cancer (Lou et al., 
2007), malignant glioma (Fukuda et al., 2005), melanoma (Zhu et al., 2013), prostate cancer 
(Chen et al., 2011) and also ovarian cancer (Pranjol et al., 2015). Cath D can potentially act 
as a protease to degrade or activate both intracellular and extracellular substrates. As an 
extracellular protease, cath D may liberate growth, and angiogenic factors entrapped in the 
extracellular matrix and consequently stimulate angiogenesis due to the release of fibroblast 
growth factor-2, as has been shown both in vitro in breast cancer cells and in vivo in tumour 
xenografts in nude mice (Rochefort et al., 2003).  
Cath D has been shown to directly or indirectly cause both cancer cell proliferation and 
tumour angiogenesis independent of its proteolytic activity. For example, when 3Y1-Ad12 
rat tumour cells, which cannot secrete cath D, were transfected with human cath D, the cells 
grew faster at both low and high cell densities in vitro and presented an increased 
experimental metastatic potential in vivo (Rochefort et al., 1990). The in vivo expression of 
both human cath D and its catalytically inactive counterpart in the 3Y1-Ad12 tumour 
xenografts correlated with proliferation, angiogenesis and apoptosis, independent of its 
proteolytic activity (Berchem et al., 2002). Cath D also induced angiogenesis in an athymic 
breast carcinoma mouse model. The number of microvessels was increased significantly by 
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1.5 fold or 1.9 fold in the cath D and cath D-Asn 231 (proteolytically inactive) groups 
respectively (Pranjol et al., 2015). However, the exact mechanisms by which cath D affects 
the cancer cells were not examined.  
In the conditioned media of MDA-MB-231 cells, cath D contributes to tumour growth and 
proliferation by triggering a proteolytic cascade via the activation of plasminogen at 
extracellular slightly acidic pH. These effects were reversed by the inhibitor pepstatin A 
(Maynadier et al., 2013). Studies showed that cath D antisense RNA, stably transfected into 
MDA-MB-231 cells, inhibited cell proliferation both in vitro (in a 3D Matrigel system) and 
in vivo, when injected subcutaneously or intravenously into nude mice (Rochefort et al., 
2003).  
Molecules that contribute to the increased expression of cath D in cancer cells include 
thrombin, a blood clotting factor (Hu, Roth, et al., 2008). Thrombin increased the secretion 
of cath D by 3- to 8-fold and enhanced chemotaxis (approximately 2 fold) in 4T1 murine 
mammary cells, which was completely inhibited with the knockdown of cath D (Hu, Roth, 
et al., 2008). Increased expression of S100p, a calcium binding protein also increased cath 
D levels (Whiteman et al., 2007).  
High expression of cath D is associated with an increased risk of recurrence and 
metastasis in breast cancer patients. In oestrogen receptor (ER)-positive breast cancer cells 
of patients, cath D gene transcription is increased by oestrogen and growth factors, whereas 
in ER-negative breast cancer cells it is constitutively expressed by an unknown mechanism 
(Foekens et al., 1999). A study was conducted to compare the total concentration of cath D 
(precursor and mature enzyme) in 122 breast cancer patients, this showed that the cath D 
levels were high in breast cancer patients before surgery when compared to after surgery 
(Rochefort et al., 1990). The interstitial fluid perfusing the breast tumour after surgery also 
showed an increase in cath D levels (Celis et al., 2004). 
The pro-peptide of cath D also plays a role in increased risk of recurrence and metastasis 
in cancer patients. This was confirmed by inducing a mutation in the propeptide region of 
pro-cath D. The pro-cath D mitogenic effect was evaluated using in vitro and the metastatic 
potential of the HBL-100 cells increased when evaluated by the invasion assays. In addition, 
the tumour growth rate was determined in Balb/c athymic nude mice and found to be 
increased (Ohri et al., 2008). Further studies have reported that as a mitogen, pro-cath D acts 
23 
 
as a protein ligand, rather than enzymatically, with the purified pro-cath D from MCF-7 
breast cancer cells shown to stimulate MCF-7 cell growth (Pranjol et al., 2015). Also, stable 
adenoviral-mediated transfection of human pro-cath D stimulated the growth of a rat tumour 
cell line derived from embryo fibroblasts both in vitro and in vivo (Garcia et al., 1990). 
There is an equal number of conflicting studies reporting that cath D has anti-tumour 
properties. For example, cath D cleaves and inactivates the chemokines MIP-1α, MIP-1β 
and secondary lymphoid tissue chemokine (SLC) which play a major role in the migration 
of MCF-7 and T47D breast cancer cells. This proteolysis by cath D may affect the generation 
of the anti-tumoural immune response, which was blocked by pepstatin A (Wolf et al., 
2003). In contrast to cath D favouring angiogenesis, it was shown that cath D secreted by 
human prostate cancer cells in vitro was responsible for angiostatin generation, which is a 
potent inhibitor of angiogenesis (Morikawa et al., 2000). Higher expression of cath D was 
also related to the activation of in cancer cells, leading to the sensitivity of cancer cells to 
anti-cancer drugs (Han et al., 2015).  
Cath D is a crucial protease that affects many fundamental functions in cells. Its 
deregulated synthesis, processing, targeting and activity are part of the transition from a 
normal tissue microenvironment to the one which favours tumour growth and progression 
to metastasis. However, the molecular mechanism by which cath D affects cancer 
progression is only partly elucidated. In this work, we will focus on this protease, to find 
further mechanisms by which cath D affects tumour progression. 
 MATRIX METALLOPROTEINASES AND THEIR INHIBITORS 
1.4.1 Introduction to matrix metalloproteinases 
Matrix metalloproteinases (MMPs) are a group of zinc-dependent enzymes, a part of a 
large family of metzincins, which have a zinc ion in the active site. The family of MMPs 
consists of 28 members (Lukaszewicz-Zajac et al., 2014) (Figure 1). They are subdivided 
based on their sequence homology as well as specificity for ECM components into 
collagenases (MMP-1, -8, -13, -18), gelatinases (MMP-2, -9), stromelysins (MMP-3, -10, -
11, -19), matrilysins (MMP-7, -26), membrane type  (MMP-14, -15, -16, -17, -24, -25) and 
other MMPs (MMP-12, -20, -23, -28) (Jezierska et al., 2009; Lukaszewicz-Zajac et al., 
2014). Also, at least eight structural classes have been identified, among them, five are 
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MMPs are secreted as zymogens, latent proenzymes (pro-MMPs), which require 
activation via cleavage of the propeptide domain of the molecule. Most of the MMPs are 
activated by other MMPs or serine proteases outside the cell. The activity of the majority of 
MMPs is very low in normal steady-state tissues (Yamamoto et al., 2015). The expression 
of these enzymes is controlled by various inflammatory cytokines, growth factors and 
hormones as well as cell-cell interactions (Morgia et al., 2005; Roy et al., 2009). 
MMPs are produced by various cells such as macrophages, leukocytes, endothelial cells, 
fibroblasts and tumour cells as well as by astroglia, microglia and neurons. They are involved 
in a wide range of physiological processes. MMPs play a key role in tissue remodelling in 
tissue regeneration, wound healing, bone growth, remodelling and embryonal development. 
Furthermore, these enzymes regulate tissue and cellular functions including cell survival, 
signalling, angiogenesis, inflammation, macrophage infiltration and axonal growth cone 
extension (Lukaszewicz-Zajac et al., 2014; Nagase et al., 2006).  
Under normal physiological conditions, as well as having low activity levels, MMPs are 
consistently expressed at very low or undetectable levels. However, upregulation of MMP 
expression can occur during normal bodily turnover, or under various pathological 






























Figure 1: Brief classifications of matrix metalloproteinase (MMPs) enzymes. 
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conditions such as osteoarthritis, rheumatoid arthritis or autoimmune disorders of the skin. 
Some clinical investigations have proven that these proteins play a role in the pathology of 
the central nervous system, including in cerebral stroke, multiple sclerosis and Alzheimer’s 
disease as reviewed (Lukaszewicz-Zajac et al., 2014), and also in cardiovascular diseases 
such as coronary artery disease, stenosis, myocardial infarction, coronary aneurysm, stroke 
and large artery stiffness (Nagase et al., 2006). MMPs were also found to be overexpressed 
in several neoplasms such as breast, pancreatic, lung, bladder, colorectal, brain and prostate 
cancers as reviewed (Roy et al., 2009). 
1.4.2 Role of MMPs in cancer progression and metastasis 
During cancer progression, tumour cells interact with a number of factors within the 
stroma, such as the ECM, growth factors, cytokines and the various cells present within the 
microenvironment. All these interactions have been shown to regulate proteases, which aid 
in essential carcinogenesis processes including migration, invasion, metastasis and 
angiogenesis. MMPs are essential for the remodelling of ECM and loss of cell-to-cell 
adhesion molecules, as reviewed by Cruz-Munoz et al. (2008). 
One of the mechanisms through which MMPs remodel the ECM is through the 
invadopodia, the special protrusions of the cell membrane of invasive tumour cells, which 
facilitate cancer cell migration through the basement membrane (Bourboulia et al.). 
Invadopodia are rich in MMPs, especially MT1-MMP (also known as MMP-14), which 
activates proMMP-2, thus initiating the MMP activation cascade (Jacob et al., 2015). 
However, the molecular mechanism behind this activation remains unidentified. The MT1-
MMPs contain a catalytic domain known as MT-LOOP, which is critical for their function. 
This catalytic domain has been therapeutically targeted, but this therapy was unsuccessful, 
as many other MMPs share this domain. The hemopexin domain, another key region, when 
blocked by intratumoural injections of a novel hemopexin inhibitor, resulted in the inhibition 
of MCF-7 breast carcinoma growth in a mouse model to 366 ± 123 mm3 when compared to 
control tumour growth of 933 ± 169 mm3 (Remacle et al., 2012). 
 MMP activity can also be induced by physical means. MDA-MB-231 breast cancer 
cells, initially encountered mechanical resistance when cultured on Matrigel in a Petri plate, 
later, a significant fraction of the cells invaded through Matrigel, mediated by proteases, by 
formation of invadopodia and high MT1-MMP activity (Aung et al., 2014). The increased 
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contractility of pancreatic cancer cells mediated by myosin II together with ECM stiffness 
lead to an increase in the expression of MT1-MMP and vice versa. The matrix stress-induced 
activation of MMP-7 has been shown to promote the invasion of chondrosarcoma cells in 
vitro (Haage et al., 2014). 
Recent investigations have highlighted the mechanistic interactions of MMPs with pro-
invasive pathways at different stages of carcinogenesis. For example, in breast cancer, an 
essential contribution of individual MMPs in promoting the transition from in situ 
malignancy to invasive malignancy has recently been identified (Brown et al., 2015). MMP-
1 and MMP-7 were overexpressed in high invasion potential MDA-MB-231 and ZR-75-1 
breast cancer cells when compared to mammary epithelial cells (Kousidou et al., 2004). 
Increased expression of MMP-13 (Mendonsa et al., 2015) is associated with more aggressive 
tumour growth in colorectal cancers in both in vitro and in vivo in MMP-13 knockdown 
C57Bl/6 mice. Also, MMP-10 (stromelysin 2) over expression is correlated with 
hepatocellular carcinoma progression and in MMP-10 knockout mice, tumour metastasis to 
lungs and liver was reduced by 40% when compared to wild-type mice (Garcia-Irigoyen et 
al., 2015). 
MMP-9 also plays a major role in tumour migration and invasion. Melanoma cells with 
an amoeboid shape degraded collagen I more efficiently than melanoma cells with an 
elongated-mesenchymal morphology. The formation of the amoeboid shape of cells is 
promoted by secreted MMP-9. A key role of MMP-9 in promoting tumour invasion was also 
shown in lung cancer cell migration in lung carcinoma xenograft mouse models formed with 
A549 or H1299 cells (Cheng et al., 2015). In addition, MMP-9 was found to bind to tumour-
associated fibroblasts’ cell surface and thus interact with the surrounding stromal cells, 
enhancing tumour migration and invasion by promoting TGF-β activation and induction of 
alpha-smooth muscle actin (α-SMA) in vitro, which was investigated in various cell lines 
such as HT1080 (fibrosarcoma), TMLC, U251 (glioblastoma), U2OS (osteosarcoma) and 
MDA-MB-231 (breast carcinoma) (Dayer et al., 2015). 
Although MMPs are involved in a diverse range of pro-metastatic mechanisms, their 
central role in metastasis is degradation and remodelling of ECM to allow migration into 
and out of the stroma (Kessenbrock et al., 2010). MMPs-1, -2, -3, -7, -9, -10, -13 and -14 
have been identified as the central MMPs implicated in the turnover of ECM constituents 
such as collagen and fibronectin. Membrane-bound MMPs also provided direct cellular-
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ECM proteolytic activity for migrating cells (Deryugina et al., 1998; Kessenbrock et al., 
2010) and thus these proteases also represent essential therapeutic and diagnostic targets for 
the treatment and detection of human cancers (Roy et al., 2009). In this study, to understand 
more about the role of MMPs in cancer, the effects of MMP inhibition through 
overexpression of tissue inhibitors of metalloproteinases (TIMPs), were investigated. Also, 
the possibility of TIMP overexpression as a way to target MMPs was explored. 
1.4.3 Introduction to matrix metalloproteinase inhibitors 
Activated metalloproteinases are inhibited by naturally occurring tissue inhibitors of 
metalloproteinases (TIMPs) (Gong et al., 2014). These are a family of four small (~21 kDa) 
proteins, which, except for TIMP-3, are secreted in a soluble form. These endogenous, 
secreted proteins have been characterised with respect to structure, activity and biological 
function. TIMPs inhibit all MMPs but also have specificity and selectivity against members 
of ADAMs (a disintegrin and metalloproteinase family, which are membrane-anchored) and 
ADAMs with thrombospondin domains (ADAMTSs, which are secreted) (Arpino et al., 
2015). Each TIMP targets multiple enzymes and each metalloproteinase has a wide range of 
protein substrates that are capable of triggering fundamental cellular responses 
(Lukaszewicz-Zajac et al., 2014). Therefore, TIMP-mediated inhibition controls a pyramidal 
cascade affecting tissue homeostasis (Arpino et al., 2015). 
TIMPs are proteins of approximately 184-194 amino acids with ~40% identity, with 
TIMP-2 and -4 sharing the most homology and TIMP-1 being most unique. The larger 
amino-terminal domain and smaller carboxyl-terminal domain of the proteins evolved 
separately, with the inhibitory capacity wholly residing within the amino-terminal domain 
(Jackson et al., 2017). 
TIMPs specifically bind non-covalently to active metalloproteinases in a 1:1 molar 
stoichiometry. However, TIMP-1 is a weak inhibitor of some membrane-type 
metalloproteinases, including MMP-14, -16, -19 and -24 but a potent inhibitor of MMP-3 
and -7 (Brew et al., 2010). TIMPs also interact with the proforms (zymogen forms) of 
MMPs, but in a non-inhibitory manner: TIMP-1 and -3 interact with proMMP-9 and TIMP-
2 and -4 with proMMP-2. In these cases, only the carboxyl-terminus is involved, leaving 
amino-terminus free to associate with a second MMP molecule (Jackson et al., 2017). In 
addition to inhibiting most MMPs, TIMP-2 has a unique function. It plays a crucial part in 
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the formation of the MT1-MMP-TIMP-2 complex responsible for the activation of 
proMMP-2 on the cell surface (Daniele et al., 2016). 
TIMPs show tissue-specific constitutive or inducible expression patterns, which are 
regulated at the transcriptional level by various cytokines and growth factors. TIMP-1 is 
widely expressed in many mammalian tissues, notably in reproductive organs. In the central 
nervous system (CNS), TIMP-1 expression is restricted to regions of persistent neuronal 
plasticity, such as the hippocampus, olfactory bulb and cerebellum (Lukaszewicz-Zajac et 
al., 2014). TIMP-2 is constitutively expressed in most tissues but is not inducible by common 
growth factors (Ries et al., 2007). TIMP-3 is expressed in many tissues and often found as a 
significant matrix protein in the basement membrane of the eye, bone and kidney (Arpino et 
al., 2015). The relatively restricted tissue distribution of TIMP-4 in heart, kidney, pancreas, 
colon, testes, brain and adipose tissue suggests that it plays an important role in specific 
physiological functions, but its role is relatively understudied (Jackson et al., 2017). 
1.4.4 Role of TIMPs in cancer progression and metastasis 
The role of TIMPs in cancer development is ultimately linked to inhibition of MMPs, 
where expression of both MMPs and their inhibitors is often changed within the tumour 
microenvironment. However, unlike MMPs, which are over-expressed in many cancer types, 
TIMP expression is more complicated. In some cancers, TIMP over-expression has been 
related to poor prognosis and increased tumour progression, while in other cases down-
regulation has resulted in similar outcomes (Cruz-Munoz et al., 2008).  
An association of TIMP-1 expression with poor prognosis was found in lung, brain, 
prostate, breast, colon and several other cancers. TIMP-1 levels are increased in more 
advanced-stage tumours, as well as in patients with endometrial, breast and brain cancer, 
which have a short time to relapse (Jiang et al., 2002). TIMP-1 and TIMP-2 are associated 
with distant metastasis and decreased survival in breast carcinoma patients, with 5 out of 19 
patients alive 5 years after diagnosis compared to those without TIMP-1 and TIMP-2 
expression, where all patients survived (Ree et al., 1997). However, TIMP-1 has also been 
reported to inhibit tumour growth in several model systems such as mouse 3T3 cells, 
Burkitt’s lymphoma, fibromatosis and pancreatic cancer (Bigelow et al., 2009). It was also 
found to inhibit cell growth in MCF10A breast epithelial cell by around 10-fold through its 
ability to stabilize the p27 cell cycle regulatory protein (Taube et al., 2006). From these 
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contradictory findings, TIMP-1 may inhibit as well as promote tumour growth and 
development. Furthermore, TIMP-1 inhibited human dermal microvascular endothelial cell 
migration in a concentration dependent manner in vitro (Akahane et al., 2004), however, in 
xenograft models, TIMP-1 overexpression stimulated angiogenesis in a breast carcinoma 
model by secretion of VEGF (Yoshiji et al., 1998) and  inhibited angiogenesis in Burkitt’s 
lymphoma model to a statistically significant level of 50% (Guedez et al., 2001). 
TIMP-2 is a bifunctional protein with growth factor and anti-proteolytic activities, 
shown to control several cell functions including migration, proliferation and apoptosis 
through MMP-dependent and -independent mechanisms (Valacca et al., 2015). TIMP-2 also 
plays a biphasic role in the activation and inhibition of MMP-2. The activation of proMMP-
2 requires the collaboration of TIMP-2 and MT1-MMP, which takes place on the surface of 
the cell. The optimal ratio of TIMP-2/MT1-MMP to activate proMMP-2 is 0.05 (Murphy et 
al., 2003). It has been shown that TIMP-2 can activate MMP-2 in human glioblastoma cells 
at a concentration range of 50-700 ng/ml. However, when the concentration exceeded 
900ng/ml, the activation of MMP-2 was inhibited by TIMP-2. Indicating that at high 
concentrations TIMP-2 acts as an inhibitor (Li et al., 2014; Li et al., 2001). While other 
TIMPs are capable of interaction with various pro-MMPs, they rarely result in enzyme 
activation (Brew et al., 2010; Itoh et al., 2001). 
TIMP-2 upregulation promoted the proliferation and growth of SH-1 leukaemia cells, 
human choriocarcinoma, A2058 human melanoma cells, osteosarcoma, glioma and A549 
lung adenocarcinoma cells in vitro (Li et al., 2014; Yang, Wang, et al., 2015). It enhanced 
tumour cell invasion up to approximately 120% in U87 glioma cells (Lu, Jong, et al., 2004). 
In addition, anti-tumourigenic effects include TIMP-2 overexpression protecting MDA-MB-
435 melanoma cells from apoptosis in vitro (Valacca et al., 2015). However in HT-1080 
fibrosarcoma cells, invasion was decreased by approximately 85% when exogenous purified 
TIMP-2 was added (Wang et al., 2015) and TIMP-2 reduced tumour growth rates by 60-
80% in murine lung cell carcinoma, murine colon cell carcinoma C51 cells and breast 
carcinoma MDA-MB-231 cells. Lung metastasis was reduced >90% in murine lung cell 
carcinomas in vivo (Li et al., 2001). Unlike TIMP-1, which showed no effect on endothelial 
vessel formation, TIMP-2 restricted angiogenic sprouting approximately 4-fold when 
compared to control, and it inhibited endothelial cell proliferation in lung adenocarcinoma 
both in vitro and in nude mouse A549 xenografts (Bourboulia et al., 2011).  
30 
 
TIMP-3 upregulation was found to decrease tumour progression. Metastasis and 
progression of primary cutaneous melanoma were decreased in TIMP-3 highly expressing 
patients by 76% when compared to lower expressing TIMP-3 patients (Das et al., 2016). In 
human Saos2 and MG63 osteosarcoma cells, TIMP-3 knockdown inhibited migration and 
invasion and promoted sensitivity to the anti-cancer drug cisplatin (Han et al., 2016). TIMP-
3 deficiency was associated with the progression of oesophageal and gastric cancers (Gu et 
al., 2008). When B16F10 melanoma cells were injected in TIMP-3 knockout mice, the loss 
of protein in the host, but not in the cancer cells also enhanced tumour growth and 
angiogenesis (Cruz-Munoz et al., 2006). TIMP-3 deficiency also enhanced tumour invasion 
and prostate inflammation in a prostate cancer mouse model (Adissu et al., 2015). Also, 
TIMP-3 induced apoptosis in several non-endothelial cells such as the moderately invasive 
HeLa cervical carcinoma cells, highly invasive HT1080 fibrosarcoma cells, melanoma, 
colon carcinoma, non-invasive MCF-7 adenocarcinoma cells and MDA-MB-435 breast 
carcinoma cells in vivo (Qi et al., 2015). 
In contrast to the above studies, endogenous TIMP-3 was also reported as having a 
tumour-promoting role in vivo in a breast cancer mouse model (Jackson et al., 2015). It is of 
note that TIMP-3 exerted an anti-angiogenic effect by inhibiting proliferation, migration and 
tube formation of endothelial cells via direct interaction with VEGF receptor-2 using chick 
embryo chorioallantoic membrane assay (Qi et al., 2003). 
TIMP-4 is an active inhibitor of MT1-MMP and binds to proMMP-2. However, TIMP-
4’s inability to promote the activation of proMMP-2 by the MT1-MMP enzyme may be due 
to the structural similarities between both the MMP proteins (Nagase et al., 2006). TIMP-4 
is comparatively less well characterised than the other TIMPs. Elevated levels of TIMP-4 
have been found in breast, ovary, cervical, prostate, brain, colon endometrium and papillary 
renal tumours, whereas downregulation was observed in pancreatic and clear cell renal 
tumours (Melendez-Zajgla et al., 2008). TIMP-4 was shown to protect breast cancer cells 
from apoptosis (Jiang et al., 2001), whereas, in Ca SKi cervical cancer cells, it triggered 
apoptosis after death receptor ligand (TNF-α and TRAIL) and serum starvation treatment 
(Lizarraga et al., 2015). It also regulated stemness in the HeLa cervical cancer cells 
(Lizarraga et al., 2016). TIMP-4 was found to inhibit the formation and growth of endothelial 
projections, thus confirming its anti-angiogenic properties. Furthermore, TIMP-4 was found 
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to regulate this property via inhibiting MMP-1 in U251 MG and T98G glioblastoma 
multiforme cell lines (Pullen et al., 2012). 
Genetic mutations in various TIMP genes have also been associated with differences in 
breast cancer development. Various polymorphisms in the TIMP-2 and TIMP-3 genes were 
shown to increase cancer likelihood by as much as 5 times, while some mutations decreased 
disease-free survival by 4-fold (Peterson et al., 2009). This suggests a connection between 
TIMP expression and tumourigenicity in which TIMPs could be anti-tumourigenic by 
inhibiting MMPs and thereby decreasing tumour metastasis. This observation provides an 
avenue for the use of TIMPs as a possible therapeutic for cancer treatment.  
1.4.5 Targeted MMP inhibitors as possible therapeutics 
Given the considerable evidence implicating increased MMP activity in various aspects 
of cancer progression, inhibiting MMPs has long seemed to be a promising therapeutic 
approach for treatment. In addition, MMPs appear to be ideal drug targets as they are disease-
associated, extracellular enzymes with a dependence on zinc for activity. For this reason, 
many MMP specific inhibitors (MMPIs) have been designed and tested in animal models 
and also in human clinical trials. 
PCK3145, a synthetic inhibitor of MMP-9, inhibited proliferation to approximately 50% 
at a concentration of 5 µM and induced apoptosis of MCF-7 breast cancer and HT29 colon 
cancer cells in a dose-dependent manner (Kostopoulos et al., 2015). The inhibitor also 
regulated MMP-9 mediated ECM breakdown during tumour cell metastasis. This was seen 
in HT-1080 fibrosarcoma cells treated with PCK3145, through the shedding of CD44 
receptors on the membrane surface of the tumour cells. CD44 is responsible for cell 
signalling and interactions with ECM in cell adhesion, so this ultimately antagonised the 
metastatic process (Annabi et al., 2005). The small MMP inhibitors (MMPI) batimastat and 
marimastat were used in clinical applications. They potently inhibit MMPs by reversibly 
chelating the zinc atom at the active site of MMPs (Gong et al., 2014). Batimastat (BB-094) 
inhibited the invasion of DU145 cells through Matrigel and in a murine diaphragm assay 
(Knox et al., 1998). Studies reported an inhibitory effect of batimastat on Mat-LyLu cancer 
cells’ proliferation in vitro and on tumour growth in an orthotopic prostate cancer rat model 
where the tumour weights were reduced by 50% (Lein et al., 2000). Unfortunately, there are 
no data available on the clinical evaluation of this compound. Marimastat (BB2516) was the 
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first MMPI to complete phase I and phase II trials in prostate cancer patients. In a phase I 
study, there was a 58% response rate. In a phase II study, among thirty-nine patients that 
were treated, a significant decrease in the tumour size was noticed with the 20 mg group 
when compared with the 5 mg group. However, increasing musculoskeletal toxicity was 
associated with higher doses (Nemunaitis et al., 1998). Phase III trials of marimastat 
unfortunately showed less convincing results with no improvement in progression-free 
survival of patients, when receiving the MMPI with first-line chemotherapy for metastatic 
breast cancer, compared to placebo (Sparano et al., 2004). 
The development of MMPIs has often been problematic and has faced many challenges 
that led to less than desirable clinical trial results. There have been several reasons proposed 
as to why MMPIs have failed during these trials. Adverse effects often limited the dose that 
could be administered to patients, due to the extensive involvement of MMPs in 
physiological processes and the non-specific nature of many of the MMPIs trialled. This is 
what resulted in effects such as the musculoskeletal structural problems, which caused pain 
and immobility in various joints (Fingleton, 2008). It is thought that often the administration 
of the MMPI missed the optimal treatment window when MMP inhibition is crucial, with 
MMPIs administered in advanced cancers, in which the majority of the metastatic process 
had already occurred. Another major limitation to MMPI clinical trial assessment seemed to 
be the inability to evaluate the efficacy of these drugs in vivo accurately, which led to the 
development of various MMP-sensitive imaging probes that release fluorescence when 
cleaved by certain MMPs (Coussens et al., 2002; Roy et al., 2009). Following on from this, 
there is therefore a necessity to develop MMP inhibitors that specifically target tumour sites. 
In this study, we proposed to achieve this goal by choosing MSCs as the therapeutic vector, 
since MSCs specifically home to the tumour site. The objective was to reduce MMP activity 
in cancer by overexpressing TIMP genes in MSCs. 
 ASPECTS OF STUDY DESIGN 
1.5.1 Introduction to breast cancer 
Breast cancer is the most common cancer in women, contributing to ~30% of female 
cancer registrations, and is the second leading cause of cancer deaths in New Zealand among 
females (Ministry of Health, 2013). At present, the main clinical therapeutic strategies 
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include chemotherapy, surgery and radiotherapy, but all of these have side effects. 
Moreover, the ability of these cancers to metastasise, as well as their heterogeneity, makes 
breast cancer difficult to treat. These aspects may be overcome by new therapies that target 
specific genes or proteins actively engaged in the physiopathology of breast cancer rather 
than the conventional cytotoxic chemotherapy, which is often hampered by toxicity or 
resistance problems. A targeted therapy allows more efficacies and less toxicity. For 
example, a human epidermal growth factor receptor-2 (HER-2) targeted drug such as 
trastuzumab for the treatment of HER2-positive breast cancer was well tolerated by patients 
and responses of up to 60-70% are noted  (Gibbs, 2000).  
The metastatic adenocarcinomal MDA-MB-231 cells are a triple-negative breast cancer 
(TNBC) cell line. TNBCs are tumours that are negative for oestrogen receptor (ER), 
progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). TNBCs 
are typically associated with poor prognosis due to their aggressive tumour phenotype(s) 
when compared to the ER-positive cell lines such as MCF-7 (Mersin et al., 2008). Presently, 
TNBCs have no clinically established targeted therapies. MDA-MB-231 cells are different 
from some other TNBC cells due to the presence of several proteins including MKP3, FAK 
and Nedd4 (Lonne et al., 2009), and mutations in p53, PTEN, RBI and SMAD4 genes in 
different base pair positions from other TNBCs, and the loss of vimentin expression which 
makes them more aggressive (Pala et al., 2015; Rangel et al., 2016). TNBCs have been 
described as randomly growing spindle-shaped cells, which are distinct from fibroblasts. 
MDA-MB-231 cells were isolated from a pleural effusion from a metastatic adenocarcinoma 
of the breast from a 51-year-old Caucasian woman (Cailleau et al., 1978). The MDA-MB-
231 cell line exhibits stronger resistance to treatment and has a tendency to show recurrence 
and metastasis when compared to other breast cancer cell lines (Li, Zhang, et al., 2015).  
1.5.2 Introduction to colorectal cancer 
Colorectal carcinoma is one of the most common gastrointestinal cancers and represents 
one of the most diagnosed cancers in both men and women, with ~14.1% of cancer 
registrations in 2010. Colorectal carcinoma is the second most leading cause of deaths in 
males and third most in females in New Zealand (Ministry of Health, 2013). 
The HT29 cell line is a human epithelial colon adenocarcinoma, isolated in 1964 from 
the colon tumour of a 44-year old Caucasian female. Ultrastructural features reported for 
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HT29 cells include microvilli, microfilaments, large vacuolated mitochondria with dark 
granules, smooth and rough endoplasmic reticulum with free ribosomes, lipid droplets and 
few primary and many secondary lysosomes (Chen et al., 1987). These cells express 
urokinase receptors but do not have detectable plasminogen activator activity. In many in 
vitro studies, HT29 are experimental models for nutrient uptake, multidrug resistance, 
attachment assays, colonisation and mechanistic studies (Cencic et al., 2010). Compared to 
other colon cancer cell lines, HT29 cells are more malignant (Akhtar et al., 2014). HT29 
cells were shown to have a p53 mutation (R273H) (O'Connor et al., 1997), and loss-of-
function mutations in the adenomatous polyposis coli (APC) tumour-suppressor gene and β-
catenin at the phosphorylation site (Tetsu et al., 1999). 
1.5.3 Introduction to paediatric glioblastoma 
Glioblastoma multiforme (GBM) is the most common malignant primary brain 
neoplasm and the most severe form of glioma. It is one of the most diffusely growing, highly 
invasive and aggressive forms of tumour (Mersin et al., 2008). The median overall survival 
for GBM is one to two years and it has a five-year survival rate of less than 10% (Cohen-
Inbar et al., 2016). There were 318 brain tumour registrations (including glioblastoma) in 
2010 in New Zealand over all age groups and 238 deaths in total. In the under 25 year age 
group, of the 51 deaths that occurred across all cancer types in New Zealand, brain tumours 
resulted in the highest number of deaths in males and second highest in females (Ministry of 
Health, 2013). 
First-line treatment for GBM patients includes a combination of surgery, chemotherapy 
(temozolamide) and radiotherapy, which in adults provides a small increase in survival of 3-
6 months (Cohen-Inbar et al., 2016; Stupp et al., 2005). Due to the lack of chemotherapeutic 
agents that are active against paediatric high-grade glioma, the same treatment as adult 
patients is being used despite the lack of evidence for therapeutic benefit (Broniscer et al., 
2006). 
GBM is a diffuse brain tumour, formed with infiltrating cells along the periphery of a 
tumour invading the surrounding normal brain cells (Bennewitz et al., 2012). Surgical 
intervention in GBM treatment is complicated due to limitations in neuroimaging 
(Bennewitz et al., 2012), as the location of a tumour is not restricted to a defined area. Also, 
GBM is multicentric, and identifying all the lesions is difficult, which results in the tumour 
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tissue being incompletely removed and the majority of patients dying from the recurrence of 
a tumour from the resected area (Hochberg et al., 1980). 
Childhood tumours account for the most severe form of glioblastoma, where 70% to 
90% of patients die within 2 years of diagnosis. Although paediatric tumours are 
morphologically similar to the malignant glioma that arise in adults, increasing evidence 
indicates that the molecular pathways activated in brain neoplasms in children substantially 
differ from those in adults. Thus, adult findings cannot be interpolated to the paediatric forms 
(Paugh et al., 2010). Paediatric forms of glioblastoma are less explored and hence this project 
focussed on three different paediatric cell lines KNS42, UW479 and SF188. KNS42 and 
SF188 are glioblastomal cell lines, while UW479 is an anaplastic astrocytomal cell line (Bax 
et al., 2009). 
1.5.4 Introduction to ovarian cancers 
Ovarian cancers are the most common fatal malignancies and one of the leading causes 
of deaths among females in New Zealand (Ministry of Health, 2013). Ovarian tumours are 
primarily categorised by their histopathology and cell type. They are classified into three 
main groups: sex cord-stromal tumours, epithelial ovarian tumours and germ cell line 
tumours. A fourth group is the secondary tumours in the ovary that arise from primary lesions 
elsewhere and metastasise to the ovary (Jamieson et al., 2012). 
Sex cord-stromal tumours represent approximately 8% of all ovarian tumours and are 
believed to arise from the combination of sex cord and stromal components of the developing 
gonad (Jamieson et al., 2012). In females, the embryonic sex cords develop into granulosa 
cells (GC), whereas stroma develops into theca and stromal leutin cells of the ovary. Hence, 
ovarian tumours of this type may comprise a varying combination of one or more of these 
cell types (Jamieson et al., 2012).  
1.5.4.1 Granulosa cell tumours of the ovary (GCT) 
Granulosa cell tumours are the most frequently diagnosed sex cord-stromal tumours, 
accounting for 90% of the tumours of this type and 8% of all the ovarian cancers. The ovarian 
follicle is comprised of these granulosa cells, which function to produce the sex steroids and 
other growth factors required for folliculogenesis and ovulation. GCTs are malignant ovarian 
tumours that are thought to arise from the granulosa cells (Jamieson et al., 2012). The tumour 
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cells of GCTs demonstrate several morphological, biochemical and hormonal features of 
normal proliferating pre-ovulatory granulosa cells (Rosario et al., 2014). GCT can be 
categorised into two subtypes, the juvenile and adult forms, based on their clinical behaviour 
and histopathological characteristics (Schumer et al., 2003). 
The adult form of GCT occurs most commonly in perimenopausal or early 
postmenopausal female with the average age reported to be 50-54 years (Schumer et al., 
2003). Juvenile GCT is reported in patients aged 10 years or younger. There are also a few 
cases identified in women between 11 and 30 years. However, the median age at diagnosis 
is 7-8 years (Young et al., 1984). Although extremely uncommon, adult GCT can be 
occasionally found in children and also cases of juvenile GCT have been reported in 
postmenopausal women (Calaminus et al., 1997). 
GCT exhibits a molecular profile similar to follicle stimulating hormone (FSH)-primed 
proliferating granulosa cells of the preovulatory follicle, including the expression of 
functional FSH receptors with FSH binding and synthesis of oestrogen (Chu et al., 2002). 
Due to their unique hormonal activity and because of the clinical endocrine manifestations, 
this commonly results in early-stage detection and as a result, GCTs are generally considered 
to have a better prognosis than other epithelial ovarian tumours. However, due to their slow 
progression and high rate of tumour recurrence, and also resistance to therapy, 
approximately 80% of patients with advanced stage or recurrent tumours die from their 
disease (Amsterdam et al., 1997). 
The most common symptoms associated with GCT are related to oestrogen secretion by 
the tumour, reflecting the normal role of granulosa cells in steroidogenesis. Most patients 
with GCT also face nonspecific symptoms of abdominal pain, distention or bloating due to 
large ovarian mass (Young et al., 1992). In prepubertal females, the effects may manifest as 
isosexual precocious pseudopuberty, including precocious breast development, increased 
pubic hair, vaginal bleeding and advanced growth and bone age (Zaloudek et al., 1982). In 
the reproductive age group, patients may have menstrual irregularities such as menorrhagia, 
intermenstrual bleeding or secondary amenorrhea and in postmenopausal women, vaginal 
bleeding is the most frequent symptom (Segal et al., 1995). High vascularization of GCT 
results in abdominal pain due to acute haemoperitoneum caused by the tumour rupture (Crew 
et al., 2005). In addition, prolonged exposure of the endometrium to tumour-derived 
estradiol has been associated with endometrial hyperplasia and concomitant endometrial 
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adenocarcinoma (Jamieson et al., 2012). Since GCTs are characterised by a somatic 
missense mutation in the FOXL2 gene, the detailed study of this gene is thought to be crucial 
for understanding this disease. 
1.5.4.2 Introduction to FOX proteins 
Forkhead box proteins are a family of transcription factors which have a characteristic, 
highly conserved 80-100 amino acid DNA binding domain, known as the “forkhead 
domain”. The term “forkhead” is derived from the Drosophila melanogaster gene, in which 
mutations cause the embryonic replacement of both the anterior and posterior gut by spike-
formed head structures (Weigel et al., 1989). More than 170 forkhead (FOX) genes have 
been identified in 14 species, which includes 50 in the human genome. These genes are 
categorised into 19 subfamilies, from FOXA to FOXS, based on the degree of conservation. 
They are involved in a wide spectrum of physiological processes including development, 
stem cell differentiation, metabolism and immunity (Leung et al., 2016). The differential 
expression of FOX genes plays a major role in a number of pathologies from metabolic 
disorders to autoimmunity. Also, these genes are differentially expressed in several cancers. 
Their role may be pro-tumourigenic or as a tumour suppressor, depending on the cell type 
and FOX family member (Jackson et al., 2010).  
The FOXL2 gene encodes a member of the forkhead domain/winged-helix family of 
transcription factors. FOXL2, similar to other family members, contains a characteristic 
winged helix DNA binding domain of approximately 100 amino acids that binds to DNA at 
a 7-bp core recognition motif (Kaufmann et al., 1996). The expression of FOXL2 was 
detected initially in bovine endometrial physiology (Eozenou et al., 2012). In humans as 
well as mouse and goat, FOXL2 has been found to be expressed in the eyelid and 
predominantly in the granulosa cells of the foetal and adult ovaries (Crisponi et al., 2001). 
All other human and goat tissues studied, such as heart, lungs, pancreas, testis, digestive 
tract, thymus, thyroid, kidney, spleen and uterus were devoid of the FOXL2 protein (Cocquet 
et al., 2002). 
1.5.4.3 FOXL2 and its functions 
FOXL2 is the earliest marker of ovarian development. The expression of FOXL2 is 
detected from 12.5 days post-coitum in mice, and its expression is sustained in the female 
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reproductive system throughout life. Apart from early sex determination, it is required to 
maintain the phenotype of the ovary (Schmidt et al., 2004). It is considered as the earliest 
marker of differentiation, showing strong expression in granulosa cells, moderate expression 
in stromal cells and no expression in oocytes (Pannetier et al., 2006). 
Conditional deletion of FOXL2 in sexually mature female mice leads to changes 
indicative of sex reversal, including oocyte degeneration, and autonomous reprogramming 
of granulosa cells into Sertoli cells. In addition, SOX9 expression was markedly increased 
(Uhlenhaut et al., 2009). Interestingly, overexpression of FOXL2 in XY transgenic male 
mice induces seminiferous tubule disorganization and the development of ovotestis-like 
gonads (Ottolenghi et al., 2007). In the postnatal ovary, FOXL2 regulates granulosa cell 
differentiation and it is also required for follicular growth. Without granulosa cell transition, 
follicular growth was blocked (Schmidt et al., 2004). FOXL2, along with SMAD3, activin 
and FSH, promotes granulosa cell differentiation, induces LH receptors and stimulates 
aromatization of hormones; all of them together are essential for the follicular development 
(Roybal et al., 2014). 
FOXL2 was shown to interact with DP103, a DEAD box helicase-containing protein 
(Batista et al., 2007). This molecular association of FOXL2 and DP103 potentiated apoptosis 
in heterologous Chinese hamster ovarian cells and rat granulosa cells. However, the extent 
of FOXL2 promotion of apoptosis depended on the cellular and signalling context (Lee et 
al., 2005). In a comparative study between the wild-type and mutant-type type of the FOXL2 
gene in human-derived GCT cell line KGN, it was shown that apoptosis driven by wild-type 
was dependent upon the upregulation of death receptors such as TNF-R1 and Fas, while the 
mutant form of FOXL2 is a weak inducer of cell death, most likely because it cannot affect 
death receptor levels. Thus, wild-type FOXL2 may function as a tumour suppressor in 
normal granulosa cells by modulating apoptosis signalling pathways and this may account 
at least partially for the pathophysiology of adult GCT (Kim et al., 2011). 
According to a transcriptome study, low FOXL2 activity or under-expression might also 
favour metastasis in cancer, since FOXL2 negatively regulates matrix metalloproteinases 
such as MMP23 (Batista et al., 2007). This matrix remodelling activity may be important in 
the final stages of folliculogenesis, to regulate cellular adhesion. Remodelling driven by 
FOXL2 has been shown to cause breakdown of the ovarian cortex, thereby regulating 
ovulation and subsequent luteinization (Caburet et al., 2012). 
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FOXL2 has other roles in the ovary. Steroidogenic acute regulatory protein (Kleinman 
et al.) is localised in the thecal layer of the ovary and is a marker of granulosa cell 
differentiation. The expression of StAR is confined to preovulatory follicles where FOXL2 
suppresses the promoter activity of StAR (Pisarska et al., 2004). It has been reported that in 
both rat and human granulosa cells, FOXL2 binds to the DNA-binding domain of 
steroidogenic factor-1 (SF-1) to negatively regulate the transcriptional activity of SF-1 and 
inhibit the SF-1-induced CYP17 transcription that is involved in androgen production (Park 
et al., 2010). Conversely, the FOXL2-SF-1 complex mediates the regulation of CYP19 
which is involved in the conversion of androgen to oestrogen (Uhlenhaut et al., 2009). Thus, 
FOXL2 is involved in sex determination, granulosa cell proliferation and differentiation, 
folliculogenesis, apoptosis promotion, matrix remodelling and steroidogenesis. 
1.5.4.4 FOXL2 mutation in adult GCTs 
The mutation of FOXL2 in ovarian follicles may lead to adult-ovarian GCT. A landmark 
study using whole transcriptome paired-end RNA sequencing analysis discovered a novel 
single somatic mutation in the FOXL2 gene in approximately 97% of the adult type GCT 
(Shah et al., 2009). Subsequent studies to confirm the presence of a mutation in adult GCT 
also showed the same results (Schrader et al., 2009). This single missense point mutation 
(substitution of C with G at position 402) results in a single amino acid substitution of 
tryptophan for cysteine at position 134 (C134W). This mutation is unique to adult GCTs 
only and not observed in the juvenile subtype or other ovarian cancers (Jamieson et al., 2012; 
Kobel et al., 2009; Shah et al., 2009). The FOXL2 mutation was also reported in men with 
adult GCT in the testicle in a smaller proportion (2 out of 5 cases), (Lima et al., 2012). The 
mutation of FOXL2 was consistently reported at a high prevalence of 97% in all cases, in 
several other studies as well (Jamieson et al., 2010; Kobel et al., 2009; Takahashi et al., 
2013). 
The FOXL2 mutation as an etiology in the development of the GCTs seems to make 
targeting FOXL2 for a prognostic and therapeutic approach clear-cut, but it remains to be 
determined whether the mutation of FOXL2 is sufficient for tumourigenesis. Also, a 
mutation in FOXL2 obviously does not explain the differences in tumour stage, the 
progression of the disease from stage I to the advanced aggressive disease and disease 
recurrence. However, these findings so far suggest a role for FOXL2 as a novel tumour 
suppressor gene in which the FOXL2 mutation C134W could be inducing a dominant 
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negative effect, giving silencing of FOXL2 tumour-suppressing abilities in cancer cells. The 
tumour-suppressing abilities of FOXL2 aligns it with other  members of super family of 
forkhead transcription members that are already known to be involved in tumour suppression 
(FOXO, FOXA) and tumour progression (FOXM, FOXP, FOXC) (Myatt et al., 2007).  
Many studies conducted on the molecular pathogenesis of GCT have focused on the 
examination of signalling pathways associated with FSH-stimulated cell proliferation and 
those associated with the normal granulosa cell development and differentiation (Fuller et 
al., 2004). Despite these extensive efforts, very little else is known about the molecular 
changes that give rise to GCT. So, our work has focussed on the FOXL2 C134W mutation 
which is associated with the adult GCTs. By using MSCs as delivery vehicles, adult type-
GCT was targeted by overexpressing wild-type FOXL2 in MSCs.  
1.5.4.5 Human-derived GCTs  
To investigate adult type-granulosa cell tumourigenesis, a human-derived GCT cell line, 
KGN, has proven to be a useful in vitro model. The KGN cell line was established in 1994 
from a 63 year old patient who was diagnosed with stage III ovarian cancer, with 
histopathological diagnosis indicating adult type-granulosa cell carcinoma (Nishi et al., 
2001). The single missense mutation in adult GCT in the FOXL2 gene (C134W) was then 
identified in the KGN cell line (Benayoun et al., 2010; Schrader et al., 2009). Little or no 
secretion of estradiol was observed in this cell line, which expresses a functional FSH 
receptor (Nishi et al., 2001). KGN cells are heterozygous for the FOXL2 C134W mutation 
and show abundant FOXL2 expression (Jamieson et al., 2010). FOXL2 mutations associated 
with blepharophimosis ptosis epicanthus inversus syndrome (BPES) have been found to 
induce nuclear aggregation or cytoplasmic delocalization, subcellular protein 
mislocalization and aggregation. Whereas, in the case of GCTs, the protein remains 
diffusible and nuclear, demonstrating that there are no signs of restrictions of it to reaching 
the target promoters (Benayoun et al., 2010). It was also identified that the FOXL2 mutation 
contributes to an alteration in steroidogenesis by binding to steroidogenic factor 1 (SF-1), 
which could also play a major role in the pathogenesis (Fleming et al., 2010). Since we 
intend to study compensating for the mutation in the FOXL2 gene in adult-type GCT using 


















Tumour cells secrete a wide range of factors such as proteases, chemokines, cytokines and 
growth factors which enter into the circulation. These factors might lead to the migration of 
MSCs via paracrine signalling to the tumour sites. The figure is modified from the personal 
images and images sourced with permission (Cheng et al., 2019; Marofi et al., 2017). 
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Figure 2: Mesenchymal stem cell migration to the tumour sites. 
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Hypothesis I: Given the presence of mesenchymal stem cells (MSCs) in the tumour 
stroma, it is predicted that these cells can migrate towards the tumour stroma due to the 
proteases secreted by the tumour cells. It is also predicted that the proteases alone would 
increase MSC migration (Figure 2).  
In order to explore hypothesis I, the study had the specific aim: 
Aim 1: To determine the effect and expression of the protease cath D in cancer cells 
and investigate how decreasing cath D might affect tumour stroma development.  
Hypothesis II: We hypothesise that MSCs could be used to deliver wild-type FOXL2 
and TIMPs proteins to tumours to affect development and cell death including metastasis 
(Figure 3). 
In order to explore hypothesis II, the study was divided into two specific aims: 
Aim 2: To analyse the susceptibility of wild-type FOXL2 expressing KGN cells for cell 
death with cisplatin and etoposide and assess the effective delivery of wild-type FOXL2 by 
MSCs during the treatment with the same drugs.  
Aim 3: To confirm that MSCs play a role in tumour cell migration in vitro and 
















Figure 3: Schematic diagrams depicting the use mesenchymal stem cells as gene/protein 
delivery vehicles. 
In the first step, mesenchymal stem cells that were isolated from bone marrow from a group 
of humans and characterised would be purchased from the suppliers. Next, the gene of 
interest would be inserted into a vector and MSCs would be reprogrammed to stably express 
the gene of interest. The MSCs with the gene of interest would be examined in vitro for the 
anti-tumour effect and if the result is positive, then they would be injected intravenously into 
the SCID mice containing xenograft to conduct preclinical studies. The figure is modified 





mesenchymal stem cells 
Insertion of 
















CHAPTER – 2 




 CELL CULTURE 
2.1.1 Materials 
Dulbecco’s Modified Eagle Medium (DMEM), DMEM and Ham’s F12 (DMEM/F12) 
media foetal bovine serum (FBS), 0.5% trypsin EDTA and penicillin/streptomycin (10,000 
units/mL of penicillin and 10,000 μg/mL) were purchased from Gibco, a Thermo Fisher 
Scientific (Waltham, MA, USA). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) were purchased from Sigma-Aldrich (St Louis, MO, USA). Dimethyl 
sulfoxide (DMSO) was purchased from Scharlau (Sentmenat, Barcelona, Spain). The 
VacuCap® 90 filter unit was from Sigma-Aldrich (St. Louis, MO, USA). Heraeus Pico-17 
centrifuge was purchased from Thermo Fisher Scientific (Waltham, MA, USA). Olympus 
CKX41 light microscope was from Olympus (Center Valley, PA, USA). Cytell cell imaging 
system was purchased from GE health care (Chicago, Illinois, USA), located in cancer 
genetics group, Department of Biochemistry, University of Otago. Benchmark Plus 
Microplate Spectrophotometer was purchased from Bio-Rad (Hercules, CA, USA). The 
Corning Transwell apparatus was purchased from Sigma-Aldrich (St. Louis, MO, USA). 
2.1.2 Cell lines 
MDA-MB-231 breast cancer cells were a kind gift from Prof. Rhonda Rosengren, 
Department of Pharmacology and Toxicology. The HT29 colorectal cancer cell line was 
purchased from American Type Culture Collection (ATCC) (Manassas, VA, USA). The 
immortalised mesenchymal stem cell line RCB2157 (MSCs) were purchased from the Riken 
BioResource Centre through the National Bio-Resource Project of the MEXT, Japan (used 
in chapter 3 and 5). MSC-hTERT-T0523 cell line was kind gift from Dr Paul Turner, Center 
for Innovation, University of Otago (used in chapter 4). The primary MSCs were purchased 
from Rooster Bio (Maryland, USA) (used in chapter 5). KNS42, UW479 and SF188 
paediatric glioblastoma cell lines were a kind gift from Prof. Chris Jones, Institute of Cancer 
Research, London. KGN ovarian tumour granulosa cells were a kind gift from Prof. Andrew 




Table 1: MSCs used in the thesis 











MSCs Rooster Bio Not immortalised 












2.1.3 Cell culture and maintenance 
HT29 and MDA-MB-231 cells were maintained as monolayer cultures in DMEM 
supplemented with 5% heat-inactivated FBS and 1% penicillin-streptomycin (100 units/mL 
of penicillin and 100 µg/mL of streptomycin). KNS42, SF188, UW479, KGN cells were 
maintained in DMEM/F12 media supplemented with 10% heat-inactivated FBS and 1% 
penicillin-streptomycin (100 units/mL of penicillin and 100 µg/mL of streptomycin). MSCs 
were maintained in DMEM supplemented with 10% heat-inactivated FBS and 1% penicillin-
streptomycin (100 units/mL of penicillin and 100 µg/mL of streptomycin).  Media was 
prepared from powder as per the manufacturer’s instructions; pH was adjusted to 7.2-7.3, 
filtered through a 0.22 µM filter and stored at 4°C. The cell lines were incubated at 5% CO2 
and 37°C. They were passaged using 1% trypsin-EDTA and re-seeded.   
2.1.4 Preparation of conditioned media 
Conditioned media with 10% serum or without serum was collected when media had 
been incubated with MSC cells for either 1 day or 5 days and MDA-MB-231, HT29 cells 
for either 1 day or 3 days. The media was centrifuged to remove any cell debris present, 
filtered and stored at -80°C until used. 
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2.1.5 MTT assay 
The MTT assay is a colourimetric assay that measures the reduction of yellow 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) by metabolically active cells 
to a dark purple formazan product. Through the action of dehydrogenase enzymes, cells 
generate NADH and NADPH which reduce MTT. The formazan product is solubilised with 
an organic solvent (DMSO) and the colour measured spectrophotometrically (Mosmann 
1983). 
For migration and invasion assays, a 1:10 ratio of MTT: DMEM was mixed in both the 
top and bottom well of the Boyden chamber and incubated at 37°C for 3 h (final 
concentration of MTT 0.5 mg/mL). The MTT mixture was then removed, inserts swabbed 
free of any cells on the upper surface of the membrane and DMSO was added to the bottom 
compartment. Samples were then transferred to a 96-well plate and read at 560 nm using the 
Microplate spectrophotometer and the Microplate Manager 5.2.1 software to quantify the 
comparative number of cells that had migrated/invaded through the membrane. The 
absorbance values were normalised against control for each corresponding experiment prior 
to statistical analysis. 
For cell viability assays, treated cells were analysed by MTT assay at 24, 48 and 72 h 
posttreatment. The media was removed and a 1:10 ratio of MTT: DMEM was mixed and 
added to the 96 well plates, incubated for 3 h and the plates were read at 560nm. The 
absorbance values for the treated samples were normalised against the untreated group for 
each corresponding time point prior to statistical analysis. 
 CELL MIGRATORY ASSAYS 
2.2.1 Materials 
Matrigel basement membrane matrix was purchased from BD Biosciences (San Jose, 
California, USA). Collagen I was purchased from Corning (New York, NY, USA). The 
Corning Transwell Boyden chamber apparatus and Bradford reagent were purchased from 
Sigma-Aldrich (St. Louis, MO, USA). Protease inhibitors pepstatin A, GM6001 and 
chlorhexidine were purchased from Merck Millipore (Darmstadt, Germany).  
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2.2.2 Migration assay 
The migration assay employed a collagen I coating of the Transwell Boyden chamber 
to assess cancer cell migration. The inferior surface of the insert was coated with 20 μL of 
150 μg/mL collagen I (diluted in 1x PBS) (Figure 4).  
 
Figure 3: Boyden Chamber Apparatus for Migration of cells 
Insert placed in a standard 24 well-plate section displaying the two compartments separated 
by a microporous membrane. The upper well contains MDA-MB-231, HT29s or MSC cells 
in DMEM with 0% serum; while the lower compartment contains various conditions that 
provide a nutrition gradient promoting cancer cell migration (Chen, 2005).  
To evaluate the protease cath D, various migration assay conditions for both upper and 
lower wells were used (Table 1). Preparation of the upper well compartment of the assay 
involved adding 30,000 mesenchymal stem cells per well suspended in 200 µL DMEM 
without serum. The lower compartment of the Boyden chamber contained 600 μL of 0% or 
10% conditioned media or serum-free media with or without MDA-MB-231 or HT29 cells. 
MDA-MB-231 or HT29 cells were counted using a haemocytometer, pelleted by 
centrifugation at 400 g for 3 min, the supernatant discarded and 20,000 cells re-suspended 
in 0% DMEM per well. The lower compartment of the Boyden chamber contained 600 μL 
of 0% or 10% conditioned media or serum-free media with cancer cells. For the migration 
experiments for cells were left to migrate for 48 h at 37oC and the MTT assay was then used 




Table 2: Various Conditions for Migration of MSCs towards cancer cells (MDA-MB-
231 or HT29) 
Condition Abbreviation Upper Well Lower Well Purpose 
1  
 
DMEM only 0% 0% Serum 
DMEM + 
MSCs 
0% Serum DMEM 
without any cells 
No serum control 












in 0% or HT29 





0% Serum DMEM 
with MDA-MB-
231 or HT29 cells 
Investigate the direct 
effects of cancer cell 
culture without serum on 
migration of MSCs 
4 MDA-MB-231 
in 10% or HT29 









Investigate the direct 
effects of cancer cell 
culture with serum on 
migration of MSCs 
5 1d CM 0% 0% Serum 
DMEM + 
MSCs 
1 day conditioned 
media of MDA-
MB-231 or HT29 
cells without serum 
Investigate whether the 
cancer cells’ conditioned 
media changes cell 
migration of MSCs 
6 1d CM 10% 0% Serum 
DMEM + 
MSCs 
1 day conditioned 
media of MDA-
MB-231 or HT29 
cells with 10% 
serum 
Investigate whether the 
cancer cells’ conditioned 
media changes cell 
migration of MSCs 
7 
 
3d CM 0% 0% Serum 
DMEM + 
MSCs 
3 day conditioned 
media of MDA-
MB-231s or HT29 
without serum 
Investigate whether the 
cancer cells’ conditioned 
media changes cell 
migration of MSCs 
8 3d CM 10% 0% Serum 
DMEM + 
MSCs 
3 day conditioned 
media of 231s or 
HT29s with 10% 
serum 
Investigate whether the 
cancer cells’ conditioned 
media changes cell 
migration of MSCs 
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For the migration experiments, cells were left to migrate for 48 h at 37oC and the MTT 
assay was then used to quantify the cancer cell migration. 
To evaluate the proteases of the TIMP family, the various migration assay conditions 
were used (Table 2). Preparation of the upper well compartment of the assay involved cancer 
cells suspended in 200 µL DMEM without serum. Cancer cells (MDA-MB-231, HT29, 
KNS42, SF188, UW479) were counted using a haemocytometer, with cells pelleted by 
centrifugation at 400 g for 3 min, the supernatant discarded, and the 20,000 cells re-
suspended in 0% DMEM per well. The lower compartment of the Boyden chamber 
contained 600 μL of 0% or 10% MSC conditioned media or serum-free media with 30,000 
MSCs/well. MSCs were allowed to migrate for 72 h at 37°C and the MTT assay was then 






Table 3: Various Conditions for Migration of cancer cells (MDA-MB-231, HT29, 
KNS42, SF188, UW479) towards MSCs 
Condition Abbreviation Upper Well Lower Well Purpose 
1 
 
DMEM 0% 0% Serum DMEM 
+ one of the cancer 
cells  
0% Serum DMEM 
without any cells 
No serum control 
2 DMEM 10% 0% Serum DMEM 
+ one of the cancer 
cells  
10% Serum DMEM 
without any cells 
Nutrient gradient control 
3 
 
MSCs 0% 0% Serum DMEM 
+ one of the cancer 
cells  
0% Serum DMEM 
with MSCs 
Investigate the direct 
effects of MSC culture 
without serum on cancer 
cell migration control 
4 MSCs 10% 0% Serum DMEM 
+ one of the cancer 
cells  
10% Serum DMEM 
with MSCs 
Investigate the direct 
effects of MSC culture 
with 10% serum on cancer 
cell migration  
5 1d CM 0% 0% Serum DMEM 
+ one of the cancer 
cells  
1 day conditioned 
media of MSCs 
without serum 
Investigate whether the 
MSCs conditioned media 
changes cell migration 
6 1d CM 10% 0% Serum DMEM 
+ one of the cancer 
cells  
1 day conditioned 
media of MSCs with 
10% serum 
Investigate whether the 
MSCs conditioned media 
changes cell migration 
7 
 
5d CM 0% 0% Serum DMEM 
+ one of the cancer 
cells  
5 day conditioned 
media of MSCs 
without serum 
Investigate whether the 
MSCs conditioned media 
changes cell migration 
8 5d CM 10% 0% Serum DMEM 
+ one of the cancer 
cells  
5 day conditioned 
media of MSCs with 
10% serum 
Investigate whether the 
MSCs conditioned media 




MSC cells were allowed to migrate for 72 h at 37°C and the MTT assay was then used 
to quantify the cancer cell migration. 
2.2.3 Invasion assay 
To investigate whether the chosen conditions could alter the invading properties of cells, 
an invasion assay was performed. This set-up used the same Boyden chamber apparatus as 
previously described (Section 2.2.2). As well, Matrigel was defrosted and 30 μL was 
transferred to the superior surface of the membrane within the insert to cover the whole 
surface of the membrane, making sure to avoid any bubbles. The inserts were then left to dry 
for an hour before the upper and lower wells were filled. The invasion assay for all the cell 
types were incubated at 37°C for 72 h, before performing an MTT assay to quantify the cell 
invasion. The well conditions were identical to the migration assays (Table 1 and Table 2). 
2.2.4 Migration assay with protease inhibitors 
Migration assays were performed in the presence of protease inhibitors GM6001, 
chlorhexidine and pepstatin A at non-cytotoxic concentrations of 1 µM, 0.01 µM, and 20 
µM respectively. Protease inhibitors were added to both the upper and lower compartments 
of Boyden chamber apparatus in a 24-well plate and incubated for 48 h, before performing 
an MTT assay to quantify the cell migration. In the dose response experiments, protease 
inhibitors were added twice at an interval of 24 h. 
 TUBE FORMATION ASSAY 
2.3.1 Materials 
HUVECs were from American Type Culture Collection (Manassas, VA, USA), 
HUVEC growth medium was from Sigma-Aldrich (Auckland, New Zealand). The rest of 
the materials were mentioned in Section 2.1.1. 
2.3.2 Experimental setup 
In order to assess the potential of the combination against angiogenesis and vascular 
mimicry the in vitro tube formation model was used. Matrigel was defrosted at 4oC and 40 
μL of Matrigel was placed in the base of each well of a 96-well plate and placed in a 37oC 
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incubator to solidify for 45 min. Following this, 20,000 human umbilical vein endothelial 
cells (HUVEC)/well were seeded in combination with MSC-hTERT-T0523 cells with and 
without FOXL2 gene/protein at 2500, 5000, 7500 and 10,000 cells/well suspended in total 
volume 100 μL HUVEC growth media in the wells containing the solidified Matrigel. The 
cells were allowed to fix to the basement matrix. Following 20 h of cell plating, pictures of 
the resulting tube formation were taken at 4x magnification.  
 WESTERN BLOTTING 
2.4.1 Materials 
Bovine serum albumin (BSA), Tween® 20, sodium dodecyl sulphate (SDS), Trizma®-
base, Trizma®-hydrochloride, Triton® X-100, β-mercaptoethanol (MeSH) and 
tetramethylethylenediamine (TEMED) were purchased from Sigma-Aldrich (St Louis, MO, 
USA). 30% acrylamide/bis solution 29:1 and ammonium persulfate (APS) were purchased 
from Bio-Rad Laboratories Ltd (Hercules, CA, USA). Ethylenediaminetetraacetic acid 
(EDTA) was purchased from BDH/VWR International Ltd (Radnor, PA, USA). 
PageRuler™ Prestained Protein Ladder, CL-XPosure Film, Pierce® Protein Inhibitor 
Tablets and dithiothreitol (DTT), iBlot transfer stacks, NuPage LPS Sample Buffer (mini, 
nitrocellulose) were purchased from Thermo Fisher Scientific (Waltham, MA, USA). 
Amersham ECL Prime Western Blotting Detection Reagents were purchased from GE 
Healthcare (Little Chalfont, UK). Pam’s non-fat milk powder was purchased from New 
World supermarket (Pam’s products, Auckland, NZ). 
Cassettes (1.0 mm), 12 well Western combs, Zoom dual power (100-120 VACS 47-60 
Hz) supply and the XCell SureLock Mini-cell electrophoresis system were purchased from 
Thermo Fisher Scientific (Waltham, MA, USA). The 100Plus X-ray film processor was 
purchased from All-Pro Imaging (Melville, New York, USA). The GS-710 Calibrated 
Imaging Densitometer bench-top scanner in conjunction with Quantity One 1-D analysis 
software was from BIO-RAD (Hercules, CA, USA).  
2.4.2 Antibodies 
Cath D antibody was purchased from Abcam (Cambridge, England: AB75852), -actin 
antibody was from Santa Cruz Biotech (Dallas, TX, USA: SC-47778), phospho-ERK 
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(M9692) and ERK (M5670) were purchased from Sigma-Aldrich (St. Louis, MO, USA), 
goat anti-mouse (AB97265), mouse anti-rabbit (AB97200) were from Abcam (Cambridge, 
England).  
2.4.3 Cell Sample and conditioned media preparation for Western blotting 
Lysis buffer consisting of 150 mM NaCl, 50 mM Tris base, 0.05% SDS and 1% Triton 
X-100 at pH 8.0, was made up with ultrapure water with a tablet of protease inhibitors and 
phosphatase inhibitors (10 mM NaF, 10 mM Na3VO4, 0.1 mM PMSF, 1 mM Na4P2O7), 
which were added just prior to use. Lysis buffer was added to the plate containing cells and 
was incubated on ice for one hour. The cell monolayer was then scraped to free cells into the 
solution with the resulting lysate collected and stored as aliquots in Eppendorf tubes at -
20oC.  
2.4.4 Protein determination 
A Bradford assay was used to determine the protein concentrations of all the samples. 
1 μL of each sample, 99 μL of ultrapure water and 100 μL Bradford reagent was added 
together in a 96 well plate and the absorbance of the samples was measured at 592 nm using 
the microplate spectrophotometer with protein concentration interpolated against a standard 
curve ranging from 1-7 mg/mL of BSA protein. 
2.4.5 Running samples and blot preparation 
Protein samples of 5-10 µg for cell lysates and 5 µg for conditioned media concentrated 
by freeze-drying were prepared by diluting them with lysis buffer to 20 µL. Five µL of 
NuPage LDS Sample Buffer was added to samples and the samples were heated at 100oC 
for 5 min. Five μL of protein ladder and 25 μL of cell lysate was loaded onto a 10-15% 
acrylamide: bisacrylamide (29:1) gel. The proteins were then separated by electrophoresis 
in glycine running buffer (25 mM Tris-base, 190 mM glycine and 0.1% SDS) using the 
XCell SureLock Mini-cell electrophoresis system with the Zoom dual power supply at 125 
V, 100 mA and 200 W for 90 min. Proteins were transferred from the gel onto a 
nitrocellulose membrane in transfer buffer (25 mM Tris-Cl, 192 mM glycine, 20% (v/v) 
methanol pH 8.4) with the Zoom dual power supply at 30 V, 100 mA and 200 W for 120 
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min. Following transfer, membranes were blocked for 90 min at room temperature in 0.1% 
PBS-Tween with 5% (w/v) milk powder. 
2.4.6 Antibody staining and visualisation 
The primary antibodies were diluted in 10 mL 0.1% PBS-Tween with 1% BSA and 
incubated with the membrane overnight at 4oC. Antibodies were diluted as follows: anti-cath 
D (1:5000), anti-β-actin (1:2000), anti-ERK (1:10,000) and anti-phospho-ERK (1:2000) 
according to the information sheet provided. After overnight incubation, the membrane was 
then washed three times for 10 min in 0.1% PBS-Tween. Horseradish peroxidase-conjugated 
secondary antibodies (anti-mouse (1:1500) and anti-rabbit (1:5000)) were diluted in 10 mL 
0.1% PBS-Tween with 1% BSA and incubated with the membrane for 1 h. The wash was 
repeated and then the membrane was covered with working solution from the ECL Advanced 
Western Blotting Detection Kit for a 1 min to develop chemiluminescence. Membranes were 
visualised after exposure to blue X-ray film for varying times and developed using the 
100Plus X-ray film processor and scanned using the GS-710 Calibrated Imaging 
Densitometer and analysed using Quantity One software. Expression of the target protein 
was normalised to the loading control β-actin, the housekeeping gene. One-way analysis of 
variance (Dunnett’s posthoc test) was then used to determine the significance of the 
quantified mean band densities.  
 TRANSFECTION 
2.5.1 Materials 
Transfection reagent Lipofectamine 2000, various siRNA against human cath D 
(Silencer Select 4390824) and Cy3-labelled negative control number 1 siRNA (AM4621), 
RNaseZap were from Thermo Fisher Scientific (Waltham, MA, USA). 
2.5.2 Experimental setup 
MDA-MB-231 and HT29 (30,000/well) cells each were plated in a 24 well plate. After 
24 h of incubation, media was removed, cells were washed with PBS, and serum-free 
DMEM media without antibiotic was added to the plate prior to transfection. The workbench 
was cleaned with RNaseZap to remove the RNase present. Cells were transfected in serum-
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free DMEM media with 10 pM siRNA duplex against human cath D gene using 2 µL 
Lipofectamine 2000 per well according to the manufacturer’s recommended protocol and 
incubated for 48 h. Cy3 labeled scrambled siRNA was used as a negative control. Images of 
Cy3 labelled siRNA were taken to visualise the transfection and Western blotting and qPCR 
were performed as described (Section 2.4 and 2.6) to analyse the percentage of knockdown 
of cath D when compared to the Cy3 control. The effect of cath D knockdown on cancer 
cells for the migration and invasion of MSC were analysed by the migration and invasion 
assays (Section 2.2.2 and 2.2.3). 
 QPCR EXPERIMENTS 
2.6.1 Materials 
The RNeasy mini RNA isolation kit was purchased from Qiagen (Hilden, Germany). 
The Superscript VILO cDNA synthesis kit and TRIzol reagent were from Thermo Fisher 
Scientific (Waltham, MA, USA). Primers were from Integrated DNA technologies 
(Coralville, IA, United States). The SsoFast EvaGreen supermix and FOXL2 primers were 
purchased from BIO-RAD (Hercules, CA, USA). 
2.6.2 RNA isolation 
RNA isolation was carried out with the RNeasy Mini Kit. 1mL of TRIzol reagent was 
added per well to a 6 well plate containing 5-10x106 cells and mixed by pipetting. The 
solution was collected into an Eppendorf tube. RNA was isolated following the 
manufacturer’s instructions and DNA was digested using DNAses (30 Kunitz units/ 
reaction). The concentration and purity of the RNA were determined by the 
spectrophotometry (Nano-Drop 2000, Thermo Fisher Scientific) and stored at -80°C for the 
further use. 
2.6.3 cDNA synthesis 
cDNA synthesis was performed (adding 4 μL of 5x VILO reaction mix, 10x SuperScript 
enzyme mix and 1μg RNA to the final volume of 20 μL with nuclease free water) using the 
following conditions: Primer annealing at 25°C for 10 min, reverse transcription at 42°C for 
57 
 
60 min, and finally denaturation of the enzyme at 85°C for 5 min to stop the reaction. The 
final cDNA products were stored at -80°C until further use. 
2.6.4 Primer designing 
The cDNA and genomic DNA sequences were obtained from the NCBI database and 
TIMPs were aligned (Human accession numbers for TIMPs were: TIMP1-NM-003254.2, 
TIMP2-NM-003255.4, TIMP3-NM-000362.4, TIMP-4-NM-003256.3). Ideally, one primer 
either side of the intron were targeted to differentiate between genomic DNA and RNA in 
the sample. The likelihood of primer dimer formation was checked using the Beacon 
designer program (Url: http://www.premierbiosoft.com/qOligo/Oligo.jsp?PID=1). Finally, 
primer BLAST was performed to crosscheck the amplification of the gene of interest. The 
primer sequences used for cath D qPCR were 5’-CAG GCA CTT CCC TCA TGG TG and 
5’-CAC AGG GGA TCA TGT ACT CGC and for GAPDH qPCR were 5’- CCC ACT CCT 
CCA CCT TT and 5’- TTG CTG TAG CCA AAT TCG TTG T. 
2.6.5 Experimental setup 
The cDNA template (Section 2.6.3) was diluted 1:10 using the PCR grade water. 
Reaction conditions were as follows: one cycle of 95C 1 min (for heat activation of PCR 
mix), 40 cycles of 95C 5 sec for denaturation and 60C 30 sec for annealing, one cycle of 
95C 10 sec for extension and final cycle of 65C to 95C raising 0.5C for 10 sec to generate 
melt curve data. Reaction master mix was prepared (10 μl of the SsoFast EvaGreen 
supermix, 0.6 μl of forward primer (10 M), 0.6 μl reverse primer (10 M) and 3.2 μl of 
PCR grade water) and 5 μl of the cDNA template was added to 20μl reaction volume. All 
the reactions were performed in triplicate for three independent experiments. GAPDH was 
used as the reference gene. The threshold cycle number for product detection (Δ∆CT value) 
was used to calculate the relative expression levels. Statistical analysis was conducted to 
determine the significance between mean concentrations within sampling groups. One-way 
analysis of variance (Dunnetts posthoc test) was then used to determine the significance of 





One shot Stbl3 chemically competent E.coli cells, Superscript Vilo cDNA synthesis kit, 
Platinum Taq DNA polymerase, quick gel extraction kit and quick plasmid extraction kit, 
the Gene Ruler 1kb plus DNA ladder, DNA loading dye, dNTP molecular biology grade and 
T4-DNA ligase were purchased from Thermo Fisher Scientific (Waltham, MA, USA). The 
restriction enzymes Xho I and Not I and ampicillin were purchased from Roche (Mannheim, 
Germany). The NucleoSpin extract II PCR purification kit was purchased from Macherey-
Nagel (Duren, Germany). The pLVX-IRES-tdTomato Vector and pLVX-ZsGreen1-C1 
Vector were purchased from Clontech (Mountain View, CA, USA). Primers were purchased 
from Integrated DNA technologies (Coralville, IA, USA). The Gel DocTM XR+ was 
purchased from BIO-RAD (Hercules, CA, USA). The Mighty bright UV Trans illuminator 
was purchased from Hoefer (San Francisco, CA, USA). All the other chemicals were from 
Sigma-Aldrich (St Louis, MO, USA) unless otherwise mentioned. FOXL2 plasmid was 
designed and the designed plasmid was synthesised by GenScript (Piscataway, NJ, USA). 
2.7.2 FOXL2 plasmid design 
A secretable and cell penetrable form of transcription factor FOXL2 was constructed 
based on the strategy presented for the protein Smac (Khorashadizadeh et al., 2015). The 
construct used a mutant form of the viral Tat protein (Tatm) which will allow the protein to 
cross the cell membrane. Stop codon was attached to Tatm protein. A furin cleavage site 
linked the part of the construct with murine signal peptide Ig-k, will target the vector to the 
endoplasmic reticulum of the cell. The signal peptide will be cleaved after entering to the 
endoplasmic reticulum. The construct was also linked to the restriction sites at the ends. This 
construct was cloned into pLVX-IRES-tdTomato vector at the multiple cloning sites with 
the restriction enzymes BamHI and EcoRI (Figure 5). This designed plasmid was 
synthesised by GenScript which was verified by plasmid digestion by restriction enzymes 





Figure 4: Schematic representation of the secretable and penetrable FOXL2 vector. 
The construct was designed with Tatm, furin cleavage site attached to murine signal peptide 
Ig-k along with wild-type FOXL2 gene. These links make the protein cells secretable and 
penetrable. 
2.7.3 Transformation 
Work with genetically modified organisms was approved by the University of Otago 
Institutional Biological Safety Committee (Approval numbers were GMD101730 and 
GMD101715 for human and E.coli cells). Plasmid DNA were transformed into one shot 
Stbl3 chemically competent E. coli cells as per the manufacturer’s instructions. The pUC19 
plasmid was used as a positive control. The super optimal broth with catabolite (SOC) media 
(0.5% (w/v) yeast extract, 2% (w/v) tryptone, 10 mM NaCl, 2.5 mM KCl, 20 mM MgSO4, 
20 mL of 20% glucose, added by filter sterilisation at the end after autoclaving and cooling 
the media) was added to the transformed cells and the solutions containing cells were 
incubated for 1 h at 180 rpm in a shaking incubator and 100 μL of this was spread on the 
pre-warmed Luria-Bertani (LB) agar plate (10 g/L NaCl, 10 g/L tryptone, 5 g/L yeast extract, 
15 g/L agar in distilled water, autoclaved) containing 100 μg/mL ampicillin and incubated 
at 37°C overnight. Transformation efficiency of cells was calculated using the following 
formula which gives the number of colony forming units per μg of DNA.  
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# of colonies x 106pg x total volume of transformed solution x dilution factor 
           10pg of pUC19 DNA x μg x μL of the volume plated 
2.7.4 Growing colonies 
The transformed cells grown on the LB agar + 100 μg/mL ampicillin plate were selected 
(two colonies per each plate) and each colony was inoculated into a tube containing 5 mL 
LB broth (10 g/L NaCl, 10 g/L tryptone, 5 g/L yeast extract in distilled water and autoclaved) 
containing ampicillin (100 μg/mL) and incubated overnight at 37°C with shaking (150 rpm). 
2.7.5  Plasmid DNA isolation 
Bacteria grown overnight at 37°C in 5 ml of LB-medium containing the ampicillin 
antibiotic were transferred to an Eppendorf tube and centrifuged at 20,000 g for 30 sec. This 
was repeated till all the cells were pelleted. The supernatant was discarded and the pellet was 
completely resuspended in the resuspension buffer. Plasmid DNA was isolated as per the 
manufacturer’s instructions and was eluted with TE buffer. The concentration of DNA was 
measured using spectrophotometry (Nano-Drop 2000, Thermo Fisher Scientific) and stored 
at -20°C for further use. 
2.7.6 TIMP family plasmid synthesis 
RNA was isolated from MDA-MB-231 cells, cDNA was synthesised and TIMP PCR 
products were obtained. These PCR products were restriction digested and ligated into the 
pLVX-IRES-tdTomato vector which is described in detail (Figure 45). 
2.7.6.1  RNA isolation 
RNA isolation was carried out as described previously in section 2.6.2 
2.7.6.2 cDNA synthesis 
cDNA synthesis was performed as described previously in section 2.6.3 
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2.7.6.3 Primer designing for PCR 
Primers were designed using Prime3 software. Primers were designed to contain XhoI 
(Forward Primers) and NotI (Reverse Primers) cleavage sites (Table 3). PRIMER BLAST 
was performed to test the specificity of primer pairs. 
Table 4: Primers for amplification of TIMP genes 
GENE PRIMER OLIGO (5’     3’) 
TIMP-1 Forward primer 
 
Reverse primer 
ATA AGA ATC TCG AGA AGA ACC 
CAC CAT GGC CC 
ATA AGA ATG AAT TCG CGG CCG 
CTC AGG CTA TCT GGG ACC GC 
TIMP-2 Forward primer 
 
Reverse primer 
ATA AGA ATC TCG AGC CAT GGG 
CGC CGC GGC CCG 
ATA AGA ATG AAT TCG CGG CCG 
CTT ATG GGT CCT CGA TGT CG 
TIMP-3 Forward primer 
 
Reverse primer 
ATA AGA ATC TCG AGA AGC AGC 
GGC AAT GAC CC 
ATA AGA ATG AAT TCG CGG CCG 
CTC AGG GGT CTG TGG CAT TGA 
TIMP-4 Forward primer 
 
Reverse primer 
ATA AGA ATC TCG AGA ATG CAG 
TGT CAT GCC TGG 
ATA AGA ATG AAT TCG CGG CCG 
CCT AGG GCT GAA CGA TGT CAA 
 
2.7.6.4 Polymerase chain reaction 
TIMP PCR products were amplified using Platinum Taq DNA polymerase using the 
manufacturer’s instructions. Typically each reaction contained 10x high fidelity PCR buffer, 
2 mM dNTP mixture, 50 mM MgSO4, 10 μM forward primer, 10 μM reverse primer, 
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template cDNA, Platinum Taq and PCR-grade water. Due to the high activity of the DNA 
polymerase at room temperature, all the reactions were set up on ice to limit non-specific 
amplification. All the reagents were thawed and mixed carefully. Gradient PCR (with 
temperature range of 65°C to 50°C) was employed to find the approximate annealing 
temperature for the primers. The thermal cycle for the PCR was as follows (Table 4). 
Table 5: Thermal cycle conditions for TIMP genes 
STEP TEMPERATURE DURATION CYCLES 
Initial  
Denaturation 
95°C 3 min x1 
Denaturation 95°C 15 sec  
 
x35 
Annealing x°C 15 sec 
Extension 72°C 45 sec 
Final Extension 73°C 1 min x1 
Final Cool Down 12°C ∞  
 
Annealing temperatures (TIMP1-58°C, TIMP2-58°C, TIMP3-56°C, TIMP4-64°C) 
were set up accordingly and the reaction was carried out. 
2.7.6.5 Agarose gel electrophoresis 
Agarose gel was prepared (1% for most PCR amplified products and 0.8% for fragments 
over 1 kb) by melting agarose in 1x TBE (89 mM Tris (pH 7.6), 89 mM boric acid, 2 mM 
EDTA). Ethidium bromide was added at a concentration of 250 ng/mL to 1x TBE running 
buffer. Samples premixed with 6x loading dye (10 mM Tris-HCl (pH-7.6), 0.03% 
bromophenol blue, 0.03% xylene cyanol, 60% glycerol and 60 mM EDTA) and were run at 
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180 V for 20-30 min. The separated DNA fragments were visualised by exposing the gel to 
UV light in the Gel DocTM XR+. 
2.7.6.6 DNA extraction from the gel 
The entire PCR reaction for each TIMP gene was run on 1% agarose gel and the gel was 
visualised under UV light on UV trans illuminator. The region containing the specific TIMP 
PCR product was excised from the gel using a scalpel, and DNA was purified using the quick 
gel extraction kit, as per the manufacturer’s instructions. 
2.7.6.7 Restriction digestion of plasmid and PCR product 
Plasmids and PCR products for cloning were digested by the restriction enzymes Not I 
and Xho I. Typically DNA (3 µg of plasmid or 1 µg of PCR) was digested in a 50 µL reaction 
with 1x buffer, 5 U of Xho I and 5 U of Not I and were incubated for 2 h at 37°C. Digested 
Plasmid DNA (1/10 reaction volume) was visualised on a 1% agarose gel for the 
confirmation of DNA digestion. 
2.7.6.8 Purification of PCR product 
PCR products require purification to remove buffers and salts as they interfere with the 
activity of several enzymes (e.g. Restriction Enzymes) used in downstream applications. The 
Nucleospin Extract II kit was used to purify the PCR product following the manufacturer’s 
instructions.  
2.7.6.9 DNA ligation 
Ligation of DNA was performed using T4 DNA ligase. The reaction (1:3 or 1:6 ratio of 
vector and DNA, 1U ligase, 2 µL of 10x DNA ligase buffer) was set up and incubated for 1 
h at 22°C. Ligase was heat inactivated for 10 min at 65°C. Transformation of Stbl3 E.coli 
cells was performed with 10 μL of the ligation mixture and 100 μL of the cells (section 
2.7.3). The cells were inoculated on LB agar plates containing 100 µg/µL ampicillin and 
incubated overnight at 37°C. Single colonies were selected and inoculated into 5 mL of LB 
broth containing 100 µg/µL ampicillin and incubated overnight at 37°C. Plasmid isolation 
was performed the following day (section 2.7.5).  
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2.7.6.10 Restriction enzyme analysis of single colonies 
After transformation (section 2.7.3), single bacterial colonies were picked from a LB 
selection plate and suspended thoroughly in 6 µL of LB. Three µL of the suspended colony 
was added to 8 μL of 0.5% Tween 20. The samples were heated at 100°C for 30 sec in a 
thermal cycler. Once the sample cooled down to 4°C, 2 µL of the digestion mix (1U each of 
Xho I and Not I and 1 μL of the reaction buffer) were added and the reaction mix was 
incubated for 30 min at 37°C. Loading buffer was added (1x) and the samples were run on 
1% agarose gel. The rest of the 3 μL was inoculated in the LB media and incubated overnight 
at 37°C.  
2.7.6.11 DNA sequencing  
To sequence, pLVX-IRES-tdTomato Vector and pLVX-ZsGreen1-C1 Vector reactions 
were prepared by adding 3.2 pmol of the CMV forward primer (5’- CGC AAA TGG GCG 
GTA GGC GTG -3’) and 200 ng of plasmid in a final volume of 5 μL with PCR grade water. 
The samples were sequenced by Sanger sequencing by Genetic Analysis Services, 
University of Otago.  
 LENTIVIRAL PRODUCTION AND TRANSDUCTION 
2.8.1 Materials 
Lenti-XTM 293T cells, Lenti-XTM Single shots, Lenti-XTM GoStixTM, Tetracycline-free 
Foetal Bovine Serum and Lenti-X Concentrator were purchased from Clontech (Mountain 
View, CA, USA). Primers were from Integrated DNA technologies (Coralville, IA, United 
States). Polybrene was from Sigma-Aldrich (St Louis, MO, USA). Puromycin 
dihydrochloride was purchased from Gold Biotechnology (St. Louis, MO, USA). 
2.8.2 Lentiviral vector construction and packaging  
All the lentiviral protocols to work with genetically modified organisms were approved 
by the University of Otago Institutional Biological Safety Committee (approval numbers 
were GMD101730 and GMD101715). The open reading frames of TIMP family genes 
(TIMP-1, -2, -3 and -4) were amplified by PCR from cDNA synthesised from the MDA-
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MB-231 cells. Restriction digestion was performed using the Xho I and Not I restriction 
enzymes and the PCR products were subcloned into the multiple cloning site of the pLVX-
IRES-tdTomato vector. This vector constitutively expresses tdTomato and so could be used 
to show transfection. The nucleotide sequence of the cloned plasmid was verified by 
sequencing (section 2.7.6.11). The packaging of the pLVX-IRES-tdTomato, pLVX-IRES-
tdTomato expressing TIMPs and pLVX-ZsGreen1-C1 vectors was performed by transient 
transfection into Lenti-X 293T cells (modified HEK 293 cells) using lyophilised Lent-XTM 
Single shots containing vesicular stomatitis virus glycoproteins (VSV-G) pseudotyped 
lentivirus diluted with a vector of interest as per the instructions given by the manufacturer. 
Lentiviral particles were harvested from the supernatant after 48 h, centrifuged at 500 g for 
10 min and filtered through a 0.45 µm filter to remove the cell debris. Particle titres were 
determined using the Lenti-X GoStix, and then the particles were concentrated. Exact 
particle titre value was then confirmed by qPCR. 
2.8.3 Viral titre determination by Lenti-X GoStix 
Twenty μl of the viral supernatant was added to the sample well of the GoStix cassette 
and 4 drops of the chase buffer was added to the sample well as per the manufacturer’s 
protocol. A control band always appeared and the test band appeared at a maximum intensity 
in 10 min if the sample contained >5x105 IFU/mL. This method does not provide an accurate 
titre value, and thus the titre value by was determined by the qPCR method. 
2.8.4 Lenti-viral particles concentration 
Harvested lentivirus-containing supernatants were pooled together and combined with 
Lenti-X concentrator reagent in the 1:3 ratio of concentrator to supernatant. The contents 
were mixed with gentle inversion and incubated at 4°C overnight as per the manufacturer’s 
instructions. The mixture was then centrifuged at 1500 g for 45 min at 4°C. The pellet formed 
after centrifugation was resuspended in 1/100th of the original volume using PBS and 




2.8.5 Viral titre determination by qPCR 
Since the Lenti-X GoStix only indicated if the viral particle number was greater than 
5x105 IFU/ml titre number, the exact titre number was determined by qPCR. RNA was 
isolated from 10 μl of the concentrated lentiviral particles (section 2.8.4) and converted into 
cDNA (section 2.6.3). cDNA was diluted 1:10 using PCR grade water. The primer sequences 
used for qPCR were designed to amplify the viral gag gene using 5’- CCT TTC CGG GAC 
TTT CGC TTT forward primer and 5’- GCA GAA TCC AGG TGG CAA CA reverse 
primer. Standard curve samples were prepared by diluting plasmid DNA, using PCR grade 
water, to 1:1000, 1:10,000 and 1:100,000. The concentration of the viral cDNA and the 
plasmids was determined using qPCR. The reaction conditions of qPCR were as described 
in section 2.6.5. All the reactions were performed in triplicate. Unknown viral titre value 
was determined from the standard curve obtained from different plasmid concentrations. 
2.8.6 KGN ovarian tumour granulosa cells transduction 
KGN cells were transduced as described for the KNS42 cells (section 2.8.6) with 80% 
transduction at 500 MOI of pLVX-ZsGreen1-C1 vector. The puromycin growth kill 
concentration was found to be 0.75 µg/mL. The cell proliferation assay was also performed 
after transduction by MTT assay (section 2.1.5). 
Five hundred thousand KGN cells were plated day before transduction and were 
transduced with pLVX-IRES-tdTomato or tdTomato with FOXL2 in a T-75 flask. The cells 
were visualised and images were taken. The cells were then sorted by fluorescence-activated 
cell sorting (FACS) with the help of tdTomato (red fluorescence) at emission wave length 
581 nm and excitation wave length 554 nm, and re-cultured in the flasks. FACS was 
performed by Michelle Wilson from Microbiology and Immunology, University of Otago. 
2.8.7 MSC transduction 
Five hundred thousand MSCs were plated a day before the transduction in a T-75 flask. 
The cells were transduced with Lentivirus containing tdTomato or tdTomato with TIMP-1, 
-2, -3 or -4 at a MOI of 384, 218, 232, 20 or 344 respectively. The cells were visualised and 
images were taken after 48 h. The transduced cells were then sorted by FACS with the help 
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of Michelle Wilson at emission wave length 581 nm and excitation wave length 554 nm, and 
re-cultured in the flasks. 
Similarly, MSCs were also transduced with pLVX-IRES-tdTomato or tdTomato with 
FOXL2 in a T-75 flask and the transduced cells were then sorted by FACS with the help of 
Michelle Wilson at emission wave length 581 nm and excitation wave length 554 nm, and 
re-cultured in the flasks. 
2.8.8 Fluorescence microscopy 
Cells were visualised using an upright Olympus CKX41 light microscope with green 
and red illumination from a mercury fibre illuminator lamp through 4x and 20x Nikon 
objective lens. Images were captured using NIS Elements Microscope Imaging Software 
through a tetramethylrhodamine (TRITC) filter for red fluorescence (tdTomato) and 
fluorescein isothiocynate (FITC) filter for green fluorescence (ZsGreen). Also, some of the 
fluorescent images were captured by digital imaging in Cytell cell imaging system. Images 
were captured and for image adjustments, the captured images were merged and examined 
using ImageJ software.  
 FLOW CYTOMETRY 
2.9.1 Materials 
FACSCantoII® flow cytometer and FACS tubes were purchased from BD Biosciences 
(San Jose, CA, USA). Propidium iodide and tetramethylrhodamine ester (TMRE) were 
purchased from Thermo Fisher Scientific (Waltham, MA, USA). 
2.9.2 Cell cycle distribution 
In order to determine the distribution throughout the cell cycle in response to treatment, 
Fluorescence assorted cell sorting (FACS) was used to assess cellular DNA content by PI 
staining (Pozarowski et al., 2004). Cells were seeded into 6-well plates and incubated for 24 
h. Cells were treated with IC50 values of cisplatin and etoposide. Following incubation with 
respective treatments for 72 h, media from each well was collected into labelled tubes and 
the wells were then washed with PBS. Cells were harvested using 200 µL trypsin/well and 
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incubated at 37oC for one min, where the cell suspension was then collected by adding 1 mL 
of 5% DMEM and centrifuged at 4oC, 2000 rpm for 3 min. The supernatant was aspirated 
and the pellet was washed twice in 1 mL of 4oC PBS and centrifuged. As intact cell 
membranes are impermeable to PI, cells were fixed with 70% ethanol dropwise (500 µL) to 
allow permeabilisation of the plasma membrane, and left at 4oC for a minimum of 30 min. 
Cell were then washed twice in phosphate-citrate buffer (Na2HPO4; 192 mM, Citric acid; 4 
mM (pH 7.8)) and centrifuged at 4oC, 2000 rpm for 3 min. Supernatant was discarded and 
cells then treated with 50 µL of 100 µg/mL RNAse A to remove potential binding between 
PI and RNA. PI was then added and the cells were incubated at 4oC in the dark for 1 h before 
the degree of staining was assessed using a FACS machine with a 15 mW, air-cooled argon-
ion laser. Cells were gated using SSC-H (measure of side scatter, reflective of internal 
complexity), FSC-H (measure of forward scatter, reflective of particle size) FL2-A (pulse 
area) and FL2-W (pulse width). A dot-plot of FSC-H vs. SSC-H was used to gate the debris 
by discriminating between healthy cells and cellular debris. Finally, a histogram plot was 
gated excluding the cells that were determined in the previous two dot plots to be likely to 
be cellular debris or clumped cells. A minimum of 10,000 cells passing through both gates 
were analysed using FlowJo® VX software. 
2.9.3 Mitochondrial membrane integrity 
Mitochondrial dysfunction has been shown to participate in the induction of apoptosis 
and has been suggested to be central to the apoptotic pathway (Ly et al., 2003). The opening 
of mitochondrial permeability transition pore has been demonstrated to induce 
depolarisation of the transmembrane potential (Δψm), release of apoptogenic factors and 
loss of oxidative phosphorylation. In some apoptotic systems, loss of Δψm may be an early 
event in the apoptotic process. TMRE is a fluorescent dye that is readily sequestered by 
active mitochondria, allowing for flow cytometric or imaging analysis to assess for apoptosis 
or mitochondrial depolarisation (Crowley et al., 2016). Non-apoptotic or cells with polarised 
mitochondria will fluoresce red while apoptotic or cells with depolarised mitochondria will 
have diminished levels of red fluorescence, which can further be quantified. 
Cells were seeded into 6-well plates and incubated for 24 h. Cells were treated with IC50 
values of cisplatin and etoposide. Following incubation with respective treatments for 72 h, 
media from each well was collected into labelled tubes and the wells were then washed with 
PBS. Cells were harvested using 200 µL trypsin/well and incubated at 37oC for one min, 
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where the cell suspension was then collected by adding 1 mL of 5% DMEM and centrifuged 
at 4oC, 2000 rpm for 3 min. Cells were resuspended in 5% DMEM, TMRE was added to 
give a final concentration of 40 nM, which were incubated at 37oC for 10 min. Cells were 
then centrifuged and washed in PBS then resuspended in 5% DMEM. 
Following FACS, using FlowJo® VX software, Cells were gated using SSC-H (measure 
of side scatter, reflective of internal complexity), FSC-H (measure of forward scatter, 
reflective of particle size). Then, using a histogram vs PE on a logarithmic scale and a gate 
to the left of the high-intensity peak seen in untreated control samples, gave the percentage 
of cells with low-intensity fluorescence indicating compromised mitochondria. 
 STATISTICAL ANALYSIS 
For all cell viability MTT assay, Western blotting, qPCR and scratch assay analysis, 
GraphPad Prism software was utilised to average and normalise the absorbance values as a 
percentage of the control mean ± the standard error of the mean following technical 
replicates. Significance was determined by analysing the difference of the means, using an 
unpaired two-tailed t-test or one-way way analysis of variance (ANOVA) with Dunnett’s 
post-hoc test or a two-way ANOVA with a Sidak’s multiple comparisons test. IC50 values 
were analysed as dose response curves and average of log IC50 values were calculated (Hall 
et al., 2010). All the experiments were presented as mean ± SEM and p-value between the 
compared groups was considered significant if less than 0.05 (p<0.05) and was considered 
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3 CATHEPSIN D: RESULTS AND DISCUSSION 
 BACKGROUND 
MSCs migrate to sites of injury and inflammation as part of the tissue repair. They detect 
tumour sites in similar way to other sites of inflammation and migrate to the tumour area 
(Dvorak, 1986). Migration of MSCs to tumour sites is facilitated through cross-talk between 
the MSCs and tumour cells (Gewirtz, 2014; Park et al., 2000). This cross-talk is mediated 
via paracrine signalling, which involves chemokines, cytokines, enzymes, growth factors 
and other signalling molecules (Melzer et al., 2016) which are released into the extracellular 
space near the tumour cells. The paracrine signalling also results in changes in ECM 
remodelling in which the proteases, including MMPs and aspartyl acid proteases play a 
significant role (Yuzhalin et al., 2018). After migrating to the tumour sites, the MSCs reside 
in the tumour sites and become the part of tumour stroma where they can show either pro-
tumourigenic or anti-tumourigenic properties. 
The supporting tumour microenvironment plays a critical role in the growth, expansion 
and metastasis of cancer to secondary sites (Joyce et al., 2009; Lorusso et al., 2008; Park et 
al., 2000). Since MSCs are one of the cell types contributing to the microenvironment, this 
study aims to look into the factors involved in the homing of MSCs to tumour sites. The 
chemokines and cytokines in this process are better studied than the proteases. Moreover, 
some of the effects of chemokines and cytokines are via proteases and their involvement in 
ECM remodelling facilitating the migration of MSCs (Brand et al., 2005; Cui et al., 2014; 
Lejmi et al., 2015). This study investigates the role of proteases, especially cathepsin D 
(cath D), previously unknown in this context, in the migration of MSCs towards the tumour 
cells. To investigate this in vitro, migration and invasion assays were carried out in a Boyden 
chamber setup (Chen, 2005).  
Hypothesis: Given the presence of mesenchymal stem cells (MSCs) in the tumour 
stroma, it is predicted that these cells can migrate towards the tumour stroma due to the 
proteases secreted by the tumour cells. It is also predicted that the proteases alone would 
increase MSC migration (Figure 2).  
Aim: To determine the effect and expression of the protease cath D in cancer cells 
and investigate how decreasing cath D might affect tumour stroma development.   
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 STUDY DESIGN 
3.2.1 Cell lines as experimental tools 
In this study, to investigate the role of cath D, the most explored protease as a tumour 
marker in breast (Jacobson-Raber et al., 2011) and colon cancers (Talieri et al., 2004), two 
different cell lines that secrete cath D were selected (Huet et al., 1994; Knopfova et al., 2012; 
Tsao et al., 2009). One was the triple negative breast cancer (TNBC) cell line MDA-MB-
231 and the other was colorectal cancer cell line HT29. The TNBC subtype was chosen over 
the other subtypes of breast cancers as it is an aggressive form of tumour, typically associated 
with poor prognosis, which lacks the established hormone receptor targets often used for 
breast cancer therapy (Mersin et al., 2008; Metzger-Filho et al., 2012). Of the TNBC cell 
lines, MDA-MB-231 cells were one of the cell types suggested to be targeted by cath D 
inhibitors by computer aided pharmacophore modelling, molecular docking and in vitro 
assays (Anantaraju et al., 2016). MDA-MB-231 cells also express the mesenchymal marker 
vimentin and possess the epithelial to mesenchymal transition (Fristrup et al.) phenotype 
that offers high motility, proliferation, migration, metastatic potential and elevated resistance 
to apoptosis (Liu et al., 2010).  
Colorectal cancers also exhibit high malignancy compared to the other cancer types 
(Akhtar et al., 2014). HT29 colon carcinoma cells were found to secrete cath D and so were 
suitable for this study (Hennebicq Reig et al., 1996).  
The two cell lines in the study were also selected based on the contrasting characteristics 
and morphology, with the MDA-MB-231 triple negative breast cancer cells being spindle 
shaped (Tsai et al., 2016) whereas the HT29 colon cancer cells are round in shape and grow 
as semi spheroid clusters (Kimball et al., 1980). The differences in these cell lines are 
important for the examination of the effect of cath D in different clinical presentations of 
cancer. 
3.2.2 Boyden chamber assay 
Cell motility is an important characteristic of most living cells. Cell migration plays a 
vital role in embryogenesis, immune responses and pathological process such as tissue 
inflammation and cancer metastasis (Justus et al., 2014). The study of cell migration in 
cancer research is important because tumour sites recruit numerous other types of cells to 
73 
 
promote their growth and progression of tumours and cancer metastasis is the major cause 
of death in the cancer patients (Tlsty et al., 2006). To evaluate these in in vitro various 
methods were developed. 
The Transwell or Boyden chamber assay was first introduced to analyse the chemotactic 
responses of leukocytes (Chen, 1962). A Boyden chamber consists of upper and lower wells 
with media, which are separated by a porous membrane. The pore size of membrane 
(available at 3-12μm) should be chosen according to the cell size. Cells seeded in the upper 
part migrate towards an attractant in the lower compartment, through the pores of the 
membrane. The cells which pass through the membrane are fixed, stained or analysed with 
cytological dyes or cell viability assays and quantified. The incubation time is usually 
optimized depending on the cell type (Albini et al., 2007; Auerbach et al., 2003).  
Matrigel mimics the physiological BM (composed of type I collagen, laminin, 
fibronectin and vitronectin), however, it may not contain all the components that natural 
BMs possess (Koochekpour et al., 1995; LeBleu et al., 2007). The lower side of the upper 
well of the Boyden chamber is coated with the collagen I (one of the component of BM) for 
migration and invasion assays. Matrigel coated wells are used for invasion assays (BM-like 
material) to restrict the movement of the cells through the porous barrier. Only the cells that 
can degrade the coated Matrigel layer, and that pass through the membrane and adhere to 
the bottom of the insert will be analysed (Chen, 2005).  
Migration and invasion assays using the Boyden chamber setup are useful since they 
are easy to use, relatively inexpensive and flexible in terms of experimental design (Albini 
et al., 2007). The assay is suitable for many cell types including mesenchymal cells and 
cancer cell lines (Harisi et al., 2009; Qi et al., 2012). Transwell migration kits are 
commercially available from providers. No special equipment is required for this assay 
except the inserts. 
3.2.3 Quantification of migrated and invaded Cells 
Cell viability or the number of live cells is routinely investigated by using several 
methods which are based on alterations of plasma membrane permeability, radioisotope 
incorporation and colorimetric detection. The membrane permeability based dye exclusion 
assay includes counting cells under the microscope or in an automated cell counter with or 
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without staining with dye such as trypan blue. The dye does not cross an intact plasma 
membrane and thus only labels dead cells. However, this assay does not give a correct 
interpretation of dead cells as death in some cells is via intracellular damage keeping the 
plasma membrane intact (Husmann, 2013). 
Cells that migrate or invade through the porous upper membrane in a Boyden chamber 
assay are generally stained by cytological dyes such as crystal violet, haematoxylin, neutral 
red or with fluorescent dyes such as Hoechst, propidium Iodide (Chen, 2005; Prabst et al., 
2017). Crystal violet stain was used in this study to visualise the migrated and invaded cells; 
the cells were stained and images were taken (Appendix 1 and 2). 
Indirect methods that involve quantification of live cells include colourimetric assays. 
The colourimetric assays give the absorbance reading proportionate to the cell number by 
the use of tetrazolium dyes such as 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT) (Facci et al., 2018; Prabst et al., 2017). The MTT assay is the powerful tool 
in distinguishing between dying and dead cells. The reagent MTT is cell membrane 
impermeable, but it is sufficiently positively charged for uptake by the plasma membranes 
through endocytosis (Liu et al., 1997). The yellow MTT is reduced to purple, water insoluble 
formazan crystals by NAD(P)H and glycolytic dependent oxidoreductase enzymes of the 
mitochondria, endoplasmic reticulum, cytosol and plasma membrane in metabolically active 
cells (Bernas et al., 2002). The decrease in the metabolic activity of a subset of cells, 
reflected in changes in the oxidoreductase enzymes, will be reflected in a slower rate of MTT 
metabolism when compared to the control cells (Mirzayans et al., 2017). Also, the dead cells 
cannot uptake and metabolise MTT, thus they are devoid of tetrazolium crystals and 
granules. 
The MTT assay was chosen for the analysis of migrated and invaded cells through the 
Boyden chamber as it is rapid, reliable, quantitative, economical and does not require the 
disruption of the cells (Wang et al., 1996; Zund et al., 1999). The migration and invasion 
assays were performed in the media with no external factors influencing the mitochondrial 
activity being added that hampers the MTT metabolism. MTT assay also excludes the cells 
which have not yet detached from the plastic, unlike the colorimetric dyes such as crystal 




3.3.1 Mesenchymal stem cells migrate towards tumour stroma 
The contribution of tumour cells in attracting MSCs into the stroma was investigated by 
direct exposure of MSCs to cancer cells or their conditioned media by co-culturing the cells 
in Boyden chambers. The influence on MSCs of tumour cells and their conditioned media 
were examined separately (Fontanella et al., 2016; Lu, Zhou, et al., 2004; Zhang et al., 
2016). The Transwell migration assay allows the assessment of both tumour cells and their 
conditioned media on MSC recruitment in the same experimental setup. 
 
 
Figure 5: Boyden chamber apparatus for migration and invasion of cells. 
Upper wells were placed in a standard 24 well-plate, displaying the two compartments 
separated by a microporous membrane coated with collagen I on the inferior face of the 
insert. The upper well contained MSC cells in DMEM with 0% serum; while the lower 
compartment contained various conditions (cancer cells/cancer cell conditioned media 
with/without serum) that provide a gradient promoting MSC migration. This setup was used 
in the experiments described in Figures 9 to 12, where the upper wells were coated with 














All the upper wells contained MSCs. The lower well contained various conditions 
(cancer cells/cancer cell conditioned media with/without serum) for Figures 9 to 12. 
Migration and invasion assays were performed with the MSCs in the upper wells of the 
Boyden chambers and various different conditions in the lower wells. Lower well conditions 
included DMEM media supplemented with or without bovine serum, cancer cells MDA-
MB-231 or HT29 supplemented with or without 10% serum, 1 day and 3 day conditioned 
media obtained from cancer cells supplemented with or without 10% serum. DMEM media 
with or without 10% serum was used as a control for these experiments. Different serum 
conditions model variations in available nutrition in different parts of tumour (nutrition rich 
or deficient) (Han et al., 2013), which may contribute to MSC migration and invasion. 
Conditioned media was collected from the flasks containing cancer cells after fresh DMEM 
with or without 10% serum supplemented media had been incubated with the cells for either 
1 or 3 days and stored at -80°C until used. Fresh serum containing media was not added to 
the conditioned media before use, as the addition of fresh serum containing media did not 
show any effect on the migration in earlier studies (Clarke et al., 2015).  
DMEM without serum 
MDA-MB-231/HT29 
cells without serum 
MDA-MB-231/HT29 
1d CM without serum 
MDA-MB-231/HT29 
3d CM without serum 
  DMEM with serum 
MDA-MB-231/HT29 
cells with serum 
MDA-MB-231/HT29 
3d CM with serum 
MDA-MB-231/HT29 
3d CM with serum 
Figure 6: Lower well conditions of Boyden chamber apparatus for migration and 
invasion of MSCs. 
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The effects of MDA-MB-231 cells and MDA-MB-231 conditioned media on MSC cell 
migration were investigated. The presence of MDA-MB-231 cells and MDA-MB-231 3 day 
conditioned media without serum increased MSC migration to 158.7 ± 6.7% and 212.2 ± 
18.4% of the MSCs DMEM without serum, respectively (Figure 9 (A)). The MDA-MB-231 
cells and their 3 day conditioned media with 10% serum significantly increased the migration 
of MSCs to 203.5 ± 21.4% and 210.1 ± 13.4% of the DMEM and serum control respectively 
(Figure 9 (B)).  































































































* * * * *
 
Figure 7: Effect of MDA-MB-231 cells and their conditioned media without serum and 
with 10% serum on MSC migration. 
The undersides of the Boyden chamber inserts were coated with collagen I (150 μg/mL), 
dried and placed in wells containing growth media. MSCs suspended in serum-free growth 
media were seeded at a density of 2x104 cells/well to the upper wells of Boyden chambers. 
Bottom wells contained (A) MDA-MB-231 cells in serum free media or their 1 day and 3 
day conditioned serum free DMEM media or (B) MDA-MB-231 cells in 10% serum 
containing media or their conditioned media with 10% serum. After 48 h, the MSC cells that 
migrated to the lower side of the membrane were quantified using the MTT assay expressed 
as % of control (which was serum free DMEM or 10% serum containing DMEM). Bars 
represent the mean ± SEM, and the results were from three independent experiments 
performed in triplicates. The data were analysed using one-way ANOVA with Dunnett's 
post-hoc test. A significant difference between individual treatment and control was 




As the co-culture with MDA-MB-231 cells showed an increase in the migration of 
MSCs, the effects of HT29 cells and HT29 conditioned media on MSC migration was also 
investigated. In the presence of HT29 3 day conditioned media without serum, MSC cell 
migration was significantly increased to 145.9 ± 5.7% of control (DMEM without serum) 
(Figure 10 (A)). One day conditioned media and 3 day conditioned media with serum 
increased migration to 185.5 ± 18.4% and 206.6 ± 18.9% of control (DMEM with 10% 
serum) respectively (Figure 10 (B)); however, the presence of HT29 cells alone had no 
significant effect on MSC migration. 






















































































* * * *
 
Figure 8: Effect of HT29 cells and their conditioned media without serum and with 10% 
serum on MSC migration. 
MSCs in serum-free growth media were seeded into the upper wells of Boyden chambers. 
Bottom wells contained (A) HT29 cells in serum free media or their 1 day and 3 day 
conditioned serum free media or (B) HT29 cells in 10% serum containing media or their 
conditioned media with 10% serum. After 48 h, the MSC cells that migrated to the lower 
side of the membrane were quantified using the MTT assay the results were expressed as % 
of control (which was serum free DMEM and 10% serum containing DMEM). Bars 
represent the mean ± SEM, and the results were from three independent experiments 
performed in triplicate. The data were analysed using one-way ANOVA with Dunnett's post-
hoc test. A significant difference between individual treatment and control was represented 




Since the migration of the MSCs increased in the presence of both the MDA-MB-231 
cells and their conditioned media and also with HT29s conditioned media, the MSC 
invasiveness was investigated. In the invasion assay the upper wells of the Boyden chamber 
were coated with Matrigel and seeded with MSC cells with the rest of conditions being same 
as the migration experiments. 
Invasion of MSCs in the presence of 1 day and 3 day conditioned media of MDA-MB-
231 cells without serum increased to 123.6 ± 6.2% and 124.5 ± 6.4% of control (DMEM 
without serum), respectively (Figure 11 (A)). With the addition of serum to the media, 
invasion in the presence of 1 day conditioned media increased to 150.8 ± 7.7% of control 
(DMEM with 10% serum) (Figure 11 (B)). The presence of MDA-MB-231 1 day 
conditioned media increased MSC invasion when compared to DMEM 0% or DMEM 10% 


































































































Figure 9: Effect of MDA-MB-231 cells and their conditioned media without serum and 
with 10% serum on MSC invasion. 
MSCs suspended in serum-free growth media in the upper wells of the Boyden chambers. 
Bottom wells contained (A) MDA-MB-231 cells in serum free media and their 1 day and 3 
day conditioned serum free media or (B) MDA-MB-231 cells in 10% serum containing 
media or their conditioned media with 10% serum. After 72 h, MSCs that had invaded on 
the lower side of the membrane were analysed using the MTT assay expressed as % of 
control (which was serum free DMEM or 10% serum containing DMEM). Bars represent 
the mean ± SEM, and the results were from three independent experiments performed in 
triplicates. The data were analysed using one-way ANOVA with Dunnett's post-hoc test. A 
significant difference between individual treatment and control was represented by *** 
(p<0.001), ** (p<0.01), * (p<0.05). 
 
With HT29 cells or HT29 conditioned media, invasion of MSCs in the presence of 1 
day and 3 day conditioned media without serum increased to 129.1 ± 4.6% and 139 ± 8.0% 
of the DMEM only control respectively (Figure 12 (A)). In the presence of serum invasion 
increased to 115.7 ± 0.6% with the HT29 cells and 136.1 ± 2.0% and 129.3 ± 5.1% with 1 
day and 3 day conditioned media, compared to the DMEM and serum control respectively 
(Figure 12 (B)).  
The presence of HT29 cells themselves increased the invasion only in the presence of 
serum. However, the presence of both HT29 1 and 3 day conditioned media increased MSC 
invasion in both the presence and absence of serum. HT29 cells alone did not show any 
effect on MSC migration, unlike MDA-MB-231 cell, but their 1 day conditioned media 
increased the migration of MSCs. This could be due to the experimental setup used. The 
concentration of proteins secreted from 3x104 cells in a 24-well plate into 600 µL of media 
(ratio of cells to media is 60), as in the migration assay as this might be less when compared 
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to the conditioned media from the 3x106 cells cultured in a T-75 flask in 10 mL of media 
(ratio of cells to media is 300), as used for conditioned media generation. As well, the protein 
expression and secretion from HT29 cells in the presence of MSCs could be different when 
compared to the CM which contained the proteins from HT29 cells cultured alone (Figure 
12). 
























































































* * * * * *
 
Figure 10: Effect of HT29 cells and their conditioned media without serum and with 10% 
serum on MSC invasion. 
MSCs suspended in serum-free growth media were added to the upper well of the Boyden 
chambers. Bottom wells contained (A) HT29 cells in serum free media or their 1 day and 3 
day conditioned serum free media or (B) HT29 cells in 10% serum containing media or their 
conditioned media with 10% serum. After 72 h, MSCs that had invaded on the lower side of 
the membrane were analysed using the MTT assay expressed as % of control (which was 
serum free DMEM or 10% serum containing DMEM). Bars represent the mean ± SEM, and 
the results were from three independent experiments performed in triplicate. The data were 
analysed using one-way ANOVA with Dunnett's post-hoc test. A significant difference 





3.3.2 The effect of protease inhibitors on the migration of MSCs in the presence of 
cancer cells 
The exact mechanism by which MSCs migrate to the tissues is not fully understood. It 
is assumed that the MSCs follow the same mechanism of migration as leukocyte homing 
(De Becker et al., 2016). Leukocytes migrate from the bloodstream by adhering to the 
endothelium of blood vessels via integrins, and then transmigrate from the bloodstream to 
the underlying basement membrane or extracellular matrix (ECM) with the help of signalling 
molecules such as chemokines and cytokines (De Becker et al., 2016). Similarly, the ECM 
is also an attachment for the cancer cells as well as leukocytes, and the cancer cells excrete 
specific proteolytic enzymes that mediate ECM degradation and remodelling allowing space 
for the invasion (Mason et al., 2011). In mammary carcinomas, the tumoural invasion is 
characterised by the loss of integrity or cleavage in the basement membrane components 
such as ECM, collagen, and laminin (Clavel et al., 1988). Since leukocytes and tumour cells 
follow the same mechanism of migration, we hypothesise a similar mechanism for MSCs 
migration to the tumours as well. Thus, we focussed on role of proteases which can undertake 
ECM remodelling and explored their possible role in MSC migration and invasion by using 
protease inhibitors. 
The protease inhibitor GM6001 (Galardin) is a synthetic polypeptide that specifically 
occupies the substrate binding sites of metalloprotease. Since this drug does not show 
cytotoxicity (Boghaert et al., 1994), and specifically inhibits matrix metalloproteases 
(MMPs) -1, -2, -3, -8, -9, -14, it is a valuable tool in evaluating the role of collagenase 
enzymes on migration (Boghaert et al., 1994; Grobelny et al., 1992; Schultz et al., 1992). 
To further investigate the physiological function of collagenase enzymes on migration, the 
protease inhibitor chlorhexidine, which inhibits MMP-2 (gelatinase A), MMP-9 (gelatinase 
B) and MMP-8 (collagenase 2) activity (Gendron et al., 1999), was used. Another important 
group of proteases involved in ECM-remodelling are aspartic acid peptidases. Aspartic acid 
peptidases are a group of proteolytic enzymes of the pepsin family and usually function in 
acidic conditions (Dash et al., 2003). Pepstatin A is a potent inhibitor of aspartyl proteinases 
including human pepsin, gastriscin, renin, cathepsin D (cath D) and cathepsin E (cath E) 
(Binkert et al., 2006). Pepsin, gastriscin, renin are the digestive enzymes usually present in 
the gastric mucosal cells (Binkert et al., 2006). Cath D was found to be overexpressed in 
several cancers and was suggested to be used as a prognostic marker (Section 1.3.1.4). Cath 
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E is studied less when compared to cath D in terms of cancer. However, there is limited 
research done on the protein cath E in terms of cancer. Cath E was found to be expressed in 
immune cells (Zaidi, Hermann, et al., 2008) and overexpressed in pancreatic (Keliher et al., 
2013) gastric (Konno-Shimizu et al., 2013) and bladder cancers (Fristrup et al., 2012).  
MSC migration towards MDA-MB-231 and HT29 cells was assayed with the addition 
of non-toxic concentrations of the protease inhibitors GM6001, chlorhexidine and pepstatin 
A and their combinations. The non-toxic concentrations of the protease inhibitors were 
previously determined in our laboratory by Floriane Imhoff, an earlier lab member, using a 
MTT cell viability assay. The migration in the presence of the protease inhibitors was 
measured in serum free media, using the methods described previously (Section 3.1.1). 
Since, in earlier experiments, the migration and invasion of MSCs were greater in the 
absence of serum (Figure 9 (A), 10 (A), 11 (A), 12 (A)), we used these conditions with the 
protease inhibitors. 
In the presence of MDA-MB-231 cells, MSC cell migration was significantly reduced 
by the addition of protease inhibitor GM6001 to 54.5 ± 7.3% of MDA-MB-231 cells only, 
and by pepstatin A to 55.3 ± 1.8% of control (DMEM without serum), while chlorhexidine 
had no effect. The combinations of the protease inhibitors GM6001 and chlorhexidine, 
chlorhexidine and pepstatin A, pepstatin A and GM6001 also showed a significant decrease 
in migration to 70.1 ± 9.5%, 71.5 ± 5.7%, 61.1 ± 1.9% respectively, when compared to 
DMEM without serum (Figure 13 (A)). However, the combinations did not show any 
synergistic effect. 
The migration of MSC cells was significantly decreased in the presence of HT29 cells 
with the addition of protease inhibitor pepstatin A to 68.4 ± 9.7% of the migration in the 
presence of the HT29 cells alone, and its combination with chlorhexidine and GM6001, 
MSC migration was decreased to 67.0 ± 9.0% and 65.7 ± 5.9% respectively, when compared 
to the DMEM without serum (Figure 13 (B)). The combination of protease inhibitors did not 





































































































































































































Figure 11: Effect of protease inhibitors on MSC migration in the presence of MDA-MB-
231 and HT29. 
MSCs were suspended in the serum-free growth media and were seeded in top wells of 
Boyden chambers. The bottom wells were seeded with MDA-MB-231 or HT29 cells in the 
serum-free growth media. The protease inhibitors were used at GM6001 (1 μM), pepstatin 
A (20 μM), chlorhexidine (0.1 μM) or 1:1 ratio of their combinations added to both the upper 
and lower wells. MSC cells that migrated to the lower side of the membrane in the presence 
of MDA-MB-231 (A) and HT29 (B) were analysed using MTT assay after 48 h incubation 
and expressed as % of control (0% DMEM). Bars represent the mean ± SEM, and the results 
were from two independent experiments performed in triplicates and data were analysed 
using one-way ANOVA with Dunnett's post-hoc test. A significant difference between 
individual treatment and control was represented by *** p<0.001, ** (p<0.01), *(p<0.05). 
With both the MDA-MB-231 and HT29 cell lines, non-cytotoxic concentrations of the 
protease inhibitors and their combinations caused a decrease in MSC migration, with the 
exception of chlorhexidine. Together, these results demonstrated that pepstatin A, the 
aspartic acid protease inhibitor, decreased the migration of MSCs in response to both types 
of cancer cells. Like pepstatin A, GM6001 the collagenase protease inhibitor, also reduced 
the migration of MSCs. However, in contrast, chlorhexidine, a specific matrix 
metalloproteinase inhibitor did not significantly affect MSC migration in all cases. 
Therefore, it can be concluded that the proteases may play a role in the migration of MSCs 
towards the tumour cells. 
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3.3.3 Quantification of cath D in cell lysates and conditioned media 
Mounting evidence suggests that the release of cytokines, chemokines and growth 
factors from a tumour can attract MSCs towards the stroma (Birnbaum et al., 2007; De 
Becker et al., 2016; Fu et al., 2009; Hata et al., 2010; Lejmi et al., 2015; Li et al., 2007). 
The contribution of other factors such as proteases to this process remains unknown (Cruz-
Munoz et al., 2008; Kessenbrock et al., 2010). However, the protease inhibitor experiments 
with pepstatin A showed that aspartic acid proteases including cath D and cath E may also 
play an important role in migration of MSCs to the tumour stroma. Therefore, the effect of 
the proteases in incorporating the MSC in tumour stroma was further explored. 
Since cath D was found to be overexpressed and can act as a potential biomarker in 
various cancers (Section 1.3.1.4), to further investigate the role of cath D in MSC migration 
we determined the presence of fully processed cath D, the intermediate form of cath D and 
the proenzyme form procath D protein in MDA-MB-231, HT29, MSC cells and their co-
culture. For co-culture, MDA-MB-231 or HT29 cells were plated on top reservoir and MSCs 
in the bottom reservoir of a Boyden chamber and left for 48 h. Cell lysates and conditioned 
media were collected from the MSCs and analysed by Western blotting (Figure 14). 
Cell lysates expressed all forms of cath D, while conditioned media contained only 
procath D (Figure 14) (when the densitometry data was quantified). Also, the expression of 
cath D was high in both the cancer cells MDA-MB-231 and HT29 when compared to MSCs. 
In general, the formation of cath D from procath D requires slightly acidic environment 
around pH 6.8-7.0, which may explain the lack of processed cath D in the media, which has 
pH around 7.2-7.4 (Lou et al., 2007).  
Procath D and intermediate form of cath D expression was found to be increased in the 
co-culture of MSCs cell lysates with the cancer cells when compared to MSC alone (~2.5 
and ~3 fold increase with HT29 and MDA-MB-231 cell co-culture respectively when 
compared to MSC alone, when the densitometry data was quantified). This could also be 
seen in the conditioned media, where procath D levels altered with co-culture (~3 and ~2 
fold increase with HT29 and MDA-MB-231 co-culture respectively when compared to MSc 
alone, according to quantified densitometry data). Therefore, co-culture of MSCs with 
cancer cells altered the expression of cath D. This could be attributed to the influence of 
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cancer cells on MSC expression of cath D or to cath D secreted by cancer cells being taken 











(A) Western blotting analysis of cath D expression in MDA-MB-231, HT29 and MSC cells 
along with their co-cultured cells in Boyden chambers. Western blot of cell lysates from left 
to right include MSC, MDA-MB-231, HT29, MDA-MB-231 cells co-cultured in upper wells 
with MSCs in the lower wells where only the MSC cell lysates was sampled, HT29 cells co-
cultured in upper wells with MSCs in the lower wells where only the MSC cell lysates was 
sampled. (B) Cell conditioned media from left to right include MSC, MDA-MB-231, HT29, 
MDA-MB-231 cells co-cultured in upper wells with MSCs in the lower wells, where only 
conditioned media from the lower well was sampled, HT29 cells co-cultured in upper wells 
with MSCs in the lower wells, where only conditioned media from the lower well was 
sampled. β-actin was used as the loading control for the cell lysates, where conditioned 
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3.3.4 The effect of cath D inhibition on MSCs 
3.3.4.1 The impact of cath D knockdown by siRNA in MDA-MB-231 cells on MSC 
migration and invasion 
Considering that cath D may play a role in tumour cell attraction of MSCs, the protein 
was knocked down in MDA-MB-231 cells by siRNA to explore the effect on the migration 
and invasion of MSCs. Transient transfection was performed to knockdown cath D by 
siRNA using the transfection reagent Lipofectamine 2000. Out of the three transfection 
reagents (Lipofectamine 2000, Lipofectamine RNAiMAX, DharmaFECT3) trialled in 
MDA-MB-231 and HT29 cells Lipofectamine 2000 produced the most consistent results, 
and thus was used in the study. 
Two different siRNA were trialled (represented as 1 siRNA and 2 siRNA), and the 
knockdown was verified by qPCR and Western blotting. A Cy3 dye labelled scrambled 
siRNA was used as the transfection control as it does not interfere with any gene. The 
addition of fluorescent Cy3 dye label (absorption and emission at 548 and 563 nm 
respectively) to this siRNA allows for its detection upon transformation. 
As shown in Figure 15 overleaf, when MDA-MB-231 cells were incubated with the 
transfection reagent, lipofectamine 2000 alone, no significant effect on the growth rate was 
seen. However, when siRNA was also included, both the siRNAs caused significant down-
regulation of cath D mRNA with knockdown to 28.5 ± 12.7% and 21.9 ± 6.5% with siRNA 
1 and 2 respectively of the Cy3 control (Figure 14 (B)), at 48 h, and to 123 ± 21.3% of the 
non-transfected control. Cath D protein levels were reduced to 34.5 ± 4.6% and 35 ± 6.3% 
with siRNA 1 and 2 respectively, after 24 h of transfection when compared to Cy3 
transfection control (Figure 15 (C)). After 48 h of transfection cath D levels were reduced to 
35.7 ± 0.7% and 35.9 ± 2.0% with siRNA 1 and 2 respectively when compared to Cy3 








































































































































































(A) Summary graph demonstrating the viability of cells with and without transfection 
reagent (with different concentrations of Lipofectamine) in a 24-well plate. No significant 
difference in viability was found by the ANOVA. (B) qPCR analysis of cath D mRNA levels 
after treatment with siRNA in MDA-MB-231 cells after 48 h. GAPDH was used as the 
reference control. The labels on x-axis indicate the MDA-MB-231 cells Cy3 siRNA control, 
1 siRNA and 2 siRNA (two different siRNA designed to knockdown cath D mRNA). The 
percentage change in the expression levels of cath D mRNA was shown after normalising 
the data to percentage Cy3 control. Bars represent mean ± SEM from three independent 
experiments performed in triplicates. The data were analysed using one-way ANOVA with 
Dunnett's post-hoc test. A significant difference between individual treatment and control 
was represented by * (p<0.05). (C) Representative image showing the transfection level of 
Cy3 dye labelled siRNA.  
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Figure 14: Cath D protein levels decreased in MDA-MB-231 cells after treatment with 
siRNA. 
Western blotting analysis of cath D expression after treatment with siRNA in MDA-MB-
231 cells after 24 h (A) and 48 h (B). β-actin was used as the loading control. The labels 
below indicate cell lysates from the control (MDA-MB-231 cells only), Cy3 siRNA control, 
1 siRNA and 2 siRNA. A representative blot from three individual experiments is shown. 
The expression levels of cath D 24 h (C) and 48 h (D) after normalising to β-actin was 
graphed as a % of non-transfected controls. Bars represent the mean ± SEM, and the results 
were from three independent experiments performed in triplicates. The data were analysed 
using one-way ANOVA with Dunnett's post-hoc test. A significant difference between Cy3 




To test the effect of cath D knockdown on migration and invasion, MSCs were plated 
in the top well of the Boyden chamber as before, with the MDA-MB-231 cells in the bottom, 
after they had been incubated with the siRNA 6 h earlier. Migration of MSCs towards the 
MDA-MB-231 cells treated with siRNA was decreased to 54.2 ± 1.0% (siRNA 1) and 56.6 
± 4.8% (siRNA 2) of the migration levels towards MDA-MB-231 cells treated only with 
scrambled siRNA (Figure 17 (A)). Invasion was decreased to 83.3 ± 3.4% and 83.4 ± 5.4% 
in the presence of MDA-MB-231 cells transfected with siRNA 1 and 2, respectively (Figure 







































































































































Figure 15: Effect of MDA-MB-231 cells on MSC migration and invasion upon inhibition 
of cath D with siRNA. 
MDA-MB-231 cells were seeded 24 h prior to transfection in the lower wells of Boyden 
chambers. The cells were transfected with siRNA using Lipofectamine 2000 reagent and 
incubated for 6 h, and then the media was changed to serum-free DMEM. MSCs were 
suspended in the serum-free growth media in the upper wells of Boyden chambers. Cells 
that had migrated (A) and invaded (B) on the lower side of the membrane were analysed 
using the MTT assay after 48 h and results were expressed as % of control (DMEM with 
transfection control). Bars represent the values ± SEM, and the results were from three 
independent experiments performed in triplicates. The data were analysed using one-way 
ANOVA with Dunnett's post-hoc test. A significant difference between individual treatment 
and control was represented by * (p<0.05).  
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3.3.4.2 The impact of cath D knockdown by siRNA in HT29 cells on MSC migration 
and invasion 
The effects of cath D from HT29 cells on the migration and invasion of MSCs was 
determined when the protein was knocked down in HT29 cells by siRNA. Cells were 
transfected with the siRNA using Lipofectamine 2000 transfection reagent. The addition of 
Lipofectamine 2000 transfection reagent did not affect the growth rate of HT29 cells, shown 
by the MTT assay (shown in Figure 18 (A)). Transformation efficiency of the siRNAs in the 
HT29 cell line was assessed by monitoring the uptake of the Cy3 fluorescently labelled 




























































(A) Summary graph demonstrating the viability of cells with and without transfection 
reagent (with different concentrations of Lipofectamine 2000) in a 24-well plate. No 
significant difference in cell viability was found by the ANOVA. (B) Representative image 
showing the transfection level of Cy3 dye labelled siRNA. 
The two-different siRNA resulted in varying levels of protein knockdown. Western blotting 
analysis showed that siRNA 1 decreased cath D expression to 52.8 ± 11.3% of the cells with 
scrambled siRNA only, while siRNA 2 decreased cath D expression to 43.6 ± 9.2% when 
compared to control siRNA (Figure 19). There was no significant change in the cath D 
protein levels in the Cy3 siRNA HT29 cells, compared to non-transfected controls. 
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Figure 17: Expression of cath D protein levels decreased in HT29 cells after treatment 
with siRNA. 
Western blot analysis of cath D expression after treatment with siRNA in HT29 cells for 24 
h (A) and 48 h (B). β-actin was used as the loading control. The labels below indicate the 
cell lysates from control (HT29 cells only), Cy3 siRNA (control fluorescent siRNA), 1 
siRNA and 2 siRNA. A representative blot from one of the three individual experiments is 
shown. The expression levels of cath D protein after 24 h (C) and 48 h (D) of tranfection and 
after normalising to β-actin was graphed as a % of non-transfected controls. Bars represent 
the mean ± SEM, and the results were from three independent experiments performed in 
triplicates. The data were analysed using one-way ANOVA with Dunnett's post-hoc test. A 
significant difference between Cy3 controls and tranfections were represented by * (p<0.05).  
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To test the effects of cath D knockdown on migration,  MSCs were plated in the top 
wells of the Boyden chambers as before, with the HT29 cells at the bottom, after they have 
been incubated  with siRNA 6 h earlier. Migration of MSCs towards HT29 cells decreased 
to 55.9 ± 1.0% (siRNA 1) and 56.6 ± 4.8% (siRNA 2) (Figure 20 (A)) of the migration levels 
towards HT29 cells treated only with scrambled siRNA. Invasion was decreased to 65.9 ± 
4.7% and 68.3 ± 3.9%, respectively (Figure 20 (B)) due to the knockdown of cath D by 
siRNA, compared to Cy3 siRNA control. We have observed the knockdown of cath D 
expression by siRNA inhibited the migration of MSCs towards both MDA-MB-231 (Figure 
17) and HT29 cells (Figure 20) in a co-culture migration and invasion assay. Even though 
the knockdown levels were relatively low, at around 50%, effects were still found on the 
































































































Figure 18: Effect of HT29 cells on MSC migration and invasion upon inhibition of cath 
D with siRNA. 
MDA-MB-231 cells were seeded 24 h prior to transfection in the lower wells of Boyden 
chambers. The cells were transfected with siRNA using Lipofectamine 2000 reagent and 
incubated for 6 h, and then the media was changed to serum-free DMEM. MSCs were 
suspended in the serum-free growth media in the upper wells of Boyden chambers. Cells 
that had migrated (A) and invaded (B) on the lower side of the membrane were analysed 
using the MTT assay after 48 h and results were expressed as % of control (DMEM with 
transfection control). Bars represent the mean ± SEM, and the results were from three 
independent experiments performed in triplicates. The data were analysed using one-way 
ANOVA with Dunnett's post-hoc test. A significant difference between individual treatment 
and control was represented by ** (p<0.01), * (p<0.05).  
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3.3.5 Signalling pathway analysis of proteins involved in migration and invasion 
Recent studies suggested that the migration of MSCs was mediated through activation 
of the MAPK/ERK signalling pathway (Gao et al., 2009; Ryu et al., 2010). Therefore, to 
indirectly identify downstream signalling pathways involved in the promotion of MSC 
migration by cancer cells and by cath D, the activation of ERK in the MSCs and cancer cells 
was evaluated with and without co-culture and the addition of pepstatin A. Expression of 
ERK along with its phosphorylated forms (pERK) in cell lysates and co-culture cell lysates 
was evaluated by Western blotting. 
In MDA-MB-231 and HT29 cells the levels of activated pERK was decreased with the 
addition of pepstatin A, while compensatory increases in non-phosphorylated ERK protein 
were seen. The ratio of pERK/ERK was significantly decreased in each cell type and in co-
cultures after treatment with pepstatin A (Figure 21). In single cell types, the ratio decreased 
from 1.4±0.2 to 0.6±0.1 in MDA-MB-231 cells, 1.3±0.2 to 0.7±0.1 in HT29 cells and 
1.1±0.1 to 0.7±0.1 in MSCs. These changes were similar in MSCs that had been in co-culture 
with either MDA-MB-231 or HT29 cells. This indicates that the activation of ERK signalling 






















(A) Cell lysates from left to right include MSC, MDA-MB-231, HT29, MDA-MB-231 cells 
co-cultured in upper wells with MSCs in the lower wells where MSC cell lysates taken, 
HT29 cells co-cultured in upper wells with MSCs in the lower wells where MSC cell lysates 
taken with and without the treatment (pepstatin A 20 µM). Western blotting technique was 
used to evaluate the expression of ERK and pERK. Representative Western blot was shown 
from three independent experiments, and β-actin was used as the loading control. The 
relative expression levels of ERK (B) and pERK/ERK (C) were shown after comparing with 
β-actin expression. Bars represent the mean ± SEM, results were from three independent 
experiments. The data were analysed using two-way ANOVA with Sidak's multiple 
comparisons test. A significant difference between ERK and pERK was represented by **** 
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Figure 19: The relative expression levels of ERK and the effect of pepstatin A on the 
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Several studies have reported that bone marrow derived MSCs, which are known to be 
involved in tissue homeostasis and regeneration, can be recruited into primary tumours and 
become active components of the tumour microenvironment (Spaeth et al., 2009). After 
homing to the tumour sites, the MSCs contribute to the tumour cells growth and metastatic 
behaviour in a variety of cancers such as hepatocellular carcinoma (Liu et al., 2016), 
oesophageal carcinoma (Xiaoya et al., 2014), breast cancer (Karnoub et al., 2007) and 
colorectal cancer (Wu et al., 2016). In contrast, there is also evidence that MSCs reduce 
tumour growth by inhibiting angiogenesis in gliomal cells (Ho et al., 2013) and Kaposi 
sarcoma (Khakoo et al., 2006). The involvement of chemokines, cytokines and growth 
factors and their receptors in these processes have been well studied; however, by 
comparison, the role of proteases in this process is less well understood. 
The present study investigated the role of aspartyl acid endoproteinase cath D in 
promoting MSC migration and invasion towards the MDA-MB-231 and HT29 cell lines. In 
line with others (Lejmi et al., 2015), we observed that MSC migration and invasion was 
enhanced by the MDA-MB-231 and HT29 cancer cells and their conditioned media and was 
cell type specific.  
Cell migration is a complex phenomenon, involving dynamic modifications of the 
extracellular matrix through the release of proteases (Sethi et al., 2011). Treatment with the 
protease inhibitors pepstatin A, GM6001 and chlorhexidine inhibited migration of MSCs. 
The focus of this study was on the involvement of cath D in MSC migration and invasion, 
which was previously unknown. To analyse the effect of cath D mediating migration and 
invasion of MSCs in particular, cath D mRNA levels were knocked down by siRNA, 
showing a decrease in expression levels by qPCR and protein levels by Western blotting 
techniques. Inhibition of cath D by pepstatin A and siRNA inhibited the migration and 
invasion in the cancer cell lines, although not to the level predicted by the other experiments. 
Several studies have shown that MSC migration is regulated through the activation of 
MAPK/ERK and AKT signalling pathways (Lejmi et al., 2015; Ryu et al., 2010). We found 
that co-culture of cancer cells with MSCs activated the ERK pathway in MSCs and pepstatin 
A inhibited it. However, determination of the impairment of migration by ERK inhibitors or 
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inhibiting the ERK levels using siRNA were not analysed. This does not preclude induction 
of MSC migration by cath D through other signalling pathways.  
We predicted that MSCs migrate to the tumours partly due to the proteases secreted by 
the tumour cells. When we tested a panel of protease inhibitors, pepstatin A inhibited MSC 
migration. Cathepsin D, was therefore identified. We made an attempt to find the role of 
cathepsin D and its precursors in MSC migration in this study. Cathepsin D has been 
associated with high levels of metastasis and poor prognosis in several cancers and suggested 
to be a prognostic marker, but the actual role of cathepsin D in cancers and its correlation 
with high levels when compared to normal individuals was not fully understood. Our study 
was an approach to explore the role of protein cathepsin D in MSC migration. 
 DISCUSSION 
3.5.1 The factors that influence MSCs tropism towards cancer cells 
MSCs have been reported to be actively recruited to primary tumour sites and become 
part of tumour stroma (Bergfeld et al., 2010) (Section 1.1.2). The involvement of several 
chemokines, cytokines, proteases and growth factors in the tropism of MSCs to a wound or 
tumour site has been clearly proposed, using both in vitro and in vivo methods. Here, we 
investigated the role of the protease, cath D in the migration and invasion of MSCs towards 
two different cancer cell types: MDA-MB-231 breast cancer cells and HT29 colon cancer 
cells.  
Our observations from the migration and invasion assays suggested that cancer cells 
were secreting a chemical mediator(s) or protease(s) which enhanced MSCs’ migratory 
capacity or attracted them in a chemoattractive manner. We investigated the direct impact of 
the cancer cells on the MSCs’ migration and also used both first day and third day 
conditioned media in order to check whether the increase in incubation time would allow the 
cells to secrete additional chemical mediator(s) or protease(s) and further their effect on 
MSC migration (Figure 8 and 9) and invasion (Figure 10 and 11). The increase in 
conditioned media incubation time correlated with increased migration but not invasion 
(Figure 10). 
Conditioned media was investigated extensively since it demonstrates the paracrine 
effects of one cell type on the other (Mendez et al., 2015). In this study, MDA-MB-231 and 
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HT29 cells are from different organs, therefore the morphology, physiology and cell 
functions would be expected to be different and non-comparable. This could be an 
explanation for the cells and their conditioned media having different effects on migration 
(Figure 9 and 10) and invasion (Figure 11 and 12). In other studies, it was reported that even 
conditioned media from two different cancer cell types with the same tissue origin can 
secrete different proteins (Regier et al., 2016). For example, when conditioned media from 
ZR-75-1 and MDA-MB-231 cells, both originating from breast, were tested for the capacity 
to stimulate new bone formation and osteoblast proliferation, ZR-75-1 conditioned media 
showed a positive effect whereas MDA-MB-231 conditioned media had no effect 
(Mohammad et al., 2003). 
HT29 cells did not show any effect on MSC migration, like the MDA-MB-231 cells, 
but the 1 d CM did increase the migration of MSCs. This could be due to the protein 
concentration secreted from the 3x104 cells in a 24-well plate into 600 µL of media (ratio of 
cells to media is 60) being less when compared to the conditioned media from 3x106 cells in 
a T-75 flask into 10 mL of media (ratio of cells to media of 300). The protein expression and 
secretion from HT29 cells in the presence of MSCs could also be different when compared 
to the CM, which contained the proteins from HT29 cells alone in a T-75 flask (Figure 10). 
Other studies have shown the attraction of MSCs towards cancer cells to be related to 
the secretion of a range of cytokines, chemokines and growth factors by tumour cells. For 
example, stromal cell-derived factor-1 (SDF-1), secreted by a wide range of normal tissues 
and also the tumour tissues, facilitated MSC transmigration through endothelial barriers by 
interaction with the CXCR4 receptor in human umbilical cord stem cells (Ryu et al., 2010). 
Further, the secretion of SDF-1 from bone marrow-derived MSCs increased upon exposure 
to MDA-MB-231 breast cancer cell conditioned media (Gao et al., 2009). MSCs also 
migrated more avidly towards breast cancer cells due to the presence of chemokine CCL5 
(also called RANTES), secreted and released into media by 4T1 mammary cancer cells 
(Swamydas et al., 2013). These factors show that the migration of MSCs towards cancer 
cells can be initiated by chemokines, which generate crosstalk by modulating changes in 
adhesion and movement of MSCs. 
Other factors that influence the migration of the MSCs to the tumour sites include 
insulin-like growth factor -1 (IGF-1) (Li et al., 2007). IGF-1 enhanced expression level of 
CXCR4, which was inhibited by the antagonists AMD3100 and peptide R (Fontanella et al., 
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2016). When these antagonists were added individually to MSCs, they inhibited the 
migration of the MSCs, by approximately one third compared to MSCs’ migration alone 
(Fontanella et al., 2016). Platelet-derived growth factor-BB also mediated tropism for the 
MSCs towards malignant gliomas in a dose-dependent manner, with an approximately 160% 
increase in migration with 10ng/ml PDGF-BB when compared to control (Hata et al., 2010). 
Migration of MSCs towards Huh-7 human hepatoma cells was also increased by 3.5±1.3 
fold, due to increased inflammatory chemokines such as MIP-1δ and MIP-3α (Lejmi et al., 
2015).  
Another possible contributor to the enhanced migration of MSCs towards tumour cells 
or tumour cell conditioned media is ECM-remodelling. Migratory behaviour of MSCs has 
previously been found to involve MMP activity. External factors such as cytokines and 
chemokines also influence the expression of MMPs. For example, MMP-2 inhibition by Ad-
MMP2 adenovirus in medulloblastoma cells also decreased MSC migration by 40-50% 
through the inhibition of SDF1/ CXCR4 signalling, which indicates a mediatory effect for 
MMP-2 in the migration of MSCs (Bhoopathi et al., 2011). In addition, MSCs were recruited 
into the sites of injury by transforming growth factor (TGF)-β1. TGF-β1 also promoted 
MSCs’ proliferation and differentiation and enhanced tissue repair, which involved MMP-
14 (Zhao et al., 2016). Chemokines and cytokines also increased the secretion of the ECM-
degrading proteins such as MMP-1 (Lejmi et al., 2015), MMP-9 (Swamydas et al., 2013; 
Tseng et al., 2014), and also MMP-13 and 14 (Swamydas et al., 2013). Proteases such as 
cathepsins and collagenase MMPs including MMP-1, -2, and -9, are capable of altering the 
BM and ECM proteins and influencing the microenvironmental integrity allowing invasion 
and metastasis (Briozzo et al., 1988; Brown et al., 2015; Koblinski et al., 2000; Mendonsa 
et al., 2015; Swamydas et al., 2013).  
Overall, in our experiments, migration and invasion of MSCs towards cancer cell lines 
(MDA-MB-231 and HT29) or their conditioned media were observed. The chemokines, 
cytokines, growth factors and proteases are several factors suggested in earlier studies that 
affect the migration and invasion of MSCs towards cancer cells. Here we focussed our work 
on the role of the proteases involved in this process, as they cause ECM remodelling and 
have been shown to play a major role in motility, invasion, proliferation and metastasis of 
cancer cells. In order to do this, migration experiments were performed while inhibiting 
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proteases with GM6001, chlorhexidine and pepstatin A in both MDA-MB-231 and HT29 
cells (Figure 13). 
The results using GM6001, a protease inhibitor, which inhibits MMP -1,-2,-3,-8,-9,-14 
(Boghaert et al., 1994) and inhibited the migration of MSCs in our experiments (Figure 13), 
agreed with the findings discussed earlier in this section. Another protease inhibitor, 
chlorhexidine, is a widely used antimicrobial agent that possesses a broad spectrum of 
activity against oral bacteria. It also inhibits MMP-2, -8 and -9 (Gendron et al., 1999; Komori 
et al., 2009). However, in section 3.1.2 (Figure 13) a non-significant decrease in migration 
of MSCs towards HT29 cells with the addition of chlorhexidine was observed. This suggests 
that MMP-2, -8, -9 were not involved in the migration of MSCs or these MMPs were not 
secreted by cancer cells when co-culture with MSCs, which might play a role in the MSC 
migration. 
The third protease inhibitor we investigated, pepstatin A, inhibits aspartyl acid proteases 
including the intracellular enzymes cath D and cath E.  Cath D is targeted to the lysosomes 
of cells while cath E is neither secretory nor lysosomal but can be found in the endoplasmic 
reticulum, the trans-Golgi network, and the endosomal compartments of selected cells 
(Dunn, 2002). Cath D has been found to be overexpressed in cancer patients suffering from 
various types of cancers such as breast cancer, endometrial cancer, lung cancer, malignant 
glioma, melanoma, prostate cancer and also ovarian cancer (Lou et al., 2007; Mbeunkui et 
al., 2007; Pranjol et al., 2015). Therefore, we focussed on the role of cath D, since although 
it has previously been reported to play a role in the metastasis and migration of tumour cells 
(Glondu et al., 2002; Ohri et al., 2008), it had not previously been reported to be part of the 
homing process of MSCs towards tumours. 
3.5.2 Role of cath D in homing of MSCs to tumour cells 
MSCs migrate to tumour sites due to their inflammatory cytokine profile, which is 
similar to that of wounds, and they invade into the tumour sites through ECM-remodelling, 
then residing in the tumour tissue, and becoming the part of tumour stroma. This process can 
be termed “homing” (Vangala et al., 2019; Zheng et al., 2019). The role of cath D in the 
homing of MSCs to tumours was investigated by migration and invasion assays with the 
protease inhibitor pepstatin A and knockdown of cath D by siRNA transfection. 
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Pepstatin A is a protease inhibitor used for inhibition of the enzyme activity of cath D 
(Bieber et al., 1992; Hu, Roth, et al., 2008). Along with being a potent inhibitor of cath D, 
it also inhibits the other aspartyl endoproteinases such as pepsin, renin, gastriscin and cath 
E. Pepsin, renin and gastriscin are usually present only in gastric mucosal cells or gastric 
cancer cells (Binkert et al., 2006; Shen et al., 2017). Since, Pepstatin A being the potent 
inhibitor of the enzymatic activity of cath D (Rahmani et al., 2019),  which is found in breast 
cancer cells (Rochefort et al., 2000) and colon cancer cells (Kuester et al., 2008), pepstatin 
A was used to demonstrate the importance of enzymatic activity of cath D in migration of 
MSCs towards cancer cells (Figure 13).  
In our study, expression of cath D was shown in MDA-MB-231, HT29 and MSCs, but 
only cell lysates expressed all forms of cath D, while the conditioned media contained only 
procath D (Figure 14). Also interestingly, Procath D and the catalytically active intermediate 
form of cath D (also called as pseudocath D) (Deiss et al., 1996) were found only in low 
levels in MSC lysates while the cath D level was almost equal to the cancer cells. MSCs 
expressed higher levels of precursor forms of cath D after co-culture than before, suggesting 
that MSCs might take up the procath D in the media and process it within the cell to the 
active form. The presence of only procath D in the media might be due to insufficiently 
acidic culture conditions for activation. In the context of a solid tumour, the 
microenvironment is slightly acidic (Griffiths, 1991), allowing likely activation of procath 
D. The absence of active form of cath D in the media also might suggest that the protein 
could be taken up by the cells. The procath D could be taken up by cells from media through 
endocytosis. This process is partially mediated by receptors such as mannose-6-
phosphatereceptors, insulin growth factor II receptors and lipoprotein receptor related 
protein -1 depending on the cell type. However, the mechanism of endocytosis is not fully 
elucidated (Derocq et al., 2012; Glondu et al., 2002; Laurent-Matha et al., 1998). 
The aspartic peptidase group of enzymes, including cath D, are usually most functional 
in acidic conditions (Dash et al., 2003). In general, the formation of cath D from procath D 
requires an acidic environment (Lou et al., 2007). The microenvironment of solid tumour is 
slightly acidic, in general pH 6.8-7.2 (Griffiths, 1991), which is  thought to allow the 
activation of procath D. The in vitro studies performed here used slightly basic media (pH 
7.2-7.4) and acidic media conditions were not explored in this study. 
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Cath D has been shown to be overexpressed in the cell lysates of various solid tumours, 
leading some researchers to suggest that it could be targeted clinically and used as a 
prognostic marker in cancer (Mimae et al., 2012). It is of note that procath D secretion was 
8-16 times greater in mammary cancer cells when compared to primary mammary epithelial 
cells, also suggesting that it is a potential target for cancer therapy (Capony et al., 1989; Ohri 
et al., 2007; Vashishta et al., 2006; Vetvicka et al., 2012). Enzymatically active intermediate 
cath D also could be a target for cancer therapy. 
Procath D, the enzymatically inactive precursor, has a short half life. It undergoes 
autocatalytic cleavege at acidic conditions to the intermediate or pseudocath D which is 
enzymatically active (Beyer et al., 1996; Richo et al., 1991). The enzymatic activity of both 
the intermediate form of cath D and cath D on haemoglobin were found to be 
indistinguishable and nearly identical. These two forms of the protease were also suggested 
to cleave substrates at the identical sites (Conner et al., 1992). Most researchers treat the 
procath D, intermediate form and cath D as a single entity, although antibodies against cath 
D detect all the three forms of the protein such as procath D, intermediate form and cath D, 
while, description about the protein was detected as just the cath D (Achour et al., 2016; 
Foekens et al., 1999; Khalkhali-Ellis et al., 2014; Liaudet-Coopman et al., 2006; Masson et 
al., 2010; Okitani et al., 1981; Zaidi, Maurer, et al., 2008). However there are some 
exceptions (Tandon et al., 1990; Vangala et al., 2019). This could be the reason behind not 
much information being available on pseudocath D. 
Cath D and procath D are highly expressed in cancers and are markers associated with 
poor prognosis in breast and colon cancers (Glondu et al., 2002; Hu, Roth, et al., 2008; Ohri 
et al., 2008; Waszkiewicz et al., 2012). The enhanced secretion of cath D was found to 
favour degradation of the matrix proteins that constitute the tumour environment (Achour et 
al., 2016). The down-regulation of cath D by anti-sense gene transfer in MDA-MB-231 cells 
inhibited tumour growth by 2.3 fold when compared to mock transfections, and inhibited 
lung metastasis (Glondu et al., 2002). Mutant type adenoviral expression of proteolytically 
inactive cath D inhibited proliferation and angiogenesis by 1.9 fold and apoptosis by 80% in 
3Y1-Ad12 cell rat tumour xenografts (Berchem et al., 2002). 
The inhibition of lysosomal cath D exocytosis by RNAi-Rab27A inhibited glioma cell 
invasion by approximately 50-60% at 48-72 h of transfection in an in vitro assay, and direct 
inhibition of cath D by a chemical inhibitor also inhibited glioma cell migration shown by 
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the scratch assay (Liu et al., 2012). The ECM remodelling proteins MMP-1, -9 and cath D 
were regulated by the c-myb transcription factor, which regulated proliferation and 
differentiation of the progenitor cells in the bone marrow and neurogenic niches. Inhibition 
of c-myb inhibited these proteins and thereby prevented pulmonary metastasis (observed 
only in 22%) in mice injected with 4T1 breast cancer cells (Knopfova et al., 2012). Thus, 
cath D plays an important role in the migration of cancer cells in many different settings.  
In other studies, procath D increased proliferation of breast cancer cell line MDA-MB-
231 (Ohri et al., 2008) and ZR-75-1 (Laurent-Matha et al., 2005), which was not connected 
to its proteolytic activity. Cath D expression and secretion also stimulated the proliferation 
of epithelial breast cancer MCF-7 cells in a paracrine manner, independent of its enzymatic 
activity (Glondu et al., 2001). Although this might happen via a receptor, the receptor 
involved in this activity has not yet been identified (Vetvicka et al., 2000). Others in our lab 
group tested whether the effects of cath D and procath D on MSCs involved changes in 
proliferation or adhesion and this was found not to be the case (Vangala et al., 2019). 
The activity of cath D in MSC migration apart from ECM remodelling, could also be 
due to cytoskeletal protein degradation, or cleavage of cytokines and chemokines. Cath D 
has been shown to degrade actin and myosin in myofibrils and myofilaments and this 
degradation was reversed by the inhibitor pepstatin A (Bird et al., 1977; Okitani et al., 1981; 
Schwartz et al., 1977). It may also cleave chemokines and cytokines such as macrophage 
inflammatory protein (MIP)-1α and MIP-1β, stromal derived factor (SDF-1), monocyte 
chemotactic proteins (MCP), stromal derived factor-1 (SDF-1), and interleukin-8 (IL-8) 
completely or partially, showing direct or indirect effects on MSC migration (Wolf et al., 
2003). 
In MDA-MB-231 cells, cath D was knocked down by siRNA in our experiments, but 
the inhibition level was less than hoped for, at only 60-65% in MDA-MB-231 cells and 40-
50% in HT29 cells (Figure 16 and 19). Since the cath D protein knockdown was incomplete, 
the migration and invasion of MSCs was not inhibited completely (Figure 17 and 20). The 
decrease in the migration and invasion assays after cath D knockdown was technically 
significant, but the effect may be too small to be biologically significant. The levels of cath 
D remaining may have been sufficient to induce migration or cath E might also be involved 
in the MSC migration. These could be the reasons behind migration levels being inhibited 
not as much as when pepstatin A was used.  
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Having demonstrated the role of cath D in the migration of MSCs, the next step was to 
examine the signalling pathways through which this happens, although we examined them 
indirectly. Western blotting showed that the activated form of ERK decreased in the presence 
of pepstatin A (Figure 20) in MDA-MB-231 cells, HT29 cells, MSCs and co-cultured MSCs, 
suggesting that the protease may play a role in the migration and invasion of the MSCs 
towards the cancer cells via activation of the ERK signalling pathway. 
We investigated the role of ERK in the migration and invasion of the MSCs, as several 
previous studies have reported that cancer cells promoted the homing of the MSCs through 
molecular pathways, including SDF-1/ERK, AKT and the p38 pathway (Ryu et al., 2010), 
as well as via inflammatory cytokines MIP-1δ and MIP-3δ together with the ERK pathway 
(Lejmi et al., 2015). The paracrine molecules secreted by cancer cells may act as ligands for 
the chemokine receptors present on the MSCs, thereby inducing the activation of the ERK 
pathway, which is then involved in the homing of the MSCs to the tumour sites (Gao et al., 
2009; Ryu et al., 2010). 
Several other studies have shown the regulation of MSC migration through the 
activation of the MAPK/ERK signalling pathway (Gao et al., 2009; Ryu et al., 2010). 
Interestingly, MSC migration was induced by TNF-α increased expression of p-ERK and 
p38. However, the TNF-α inhibitor SB203580 suppressed the chemotaxis effect, upregulated 
ICAM-1 and reduced migration of MSC (Fu et al., 2009). The induction of MSC migration 
by MIP-1δ and MIP-3α may activate several signalling pathways, also including the 
activation of MMP-1 (Lejmi et al., 2015). Sphingosine-1-phosphate-induced MSC 
mobilisation and migration required the cooperation of MMPs in ECM remodelling with the 
RhoA/Rho kinase and MAP/ERK signalling pathways (Meriane et al., 2006).  
We have shown that the pERK levels were decreased by pepstatin A treatment when 
compared to the non-treated cancer cells (Figure 21), and this could be part of the driving 
force of migration through cath D. This suggests that activation through any of the Ras/ERK 
or JAK/STAT3 intracellular cascades could be taking place. However, to evaluate the direct 
role of Ras/ERK or JAK/STAT3, intracellular cascade proteins such as AKT, JNK and Ras 
would need to be investigated, to understand precisely which parts of the pathways are 
regulating migration. Also, the use of ERK inhibitors or the knockdown of ERK by the 
addition of siRNA would help to show its role more clearly. 
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In previous studies, ERK was shown to be involved in MSC migration. However, this 
might be direct or indirect. Pepstatin A might have off-target effects which were not 
investigated in our study. Pepstatin A also inhibits cath E which should not be ignored, and 
may also be involved in the off-target effects. In another study, the role of pepstatin A other 
than as a proteinase inhibitor was investigated. Pepstatin A was found to suppress the 
receptor that activated the NF-ĸB ligand (Costello et al.), which in turn induced osteoclast 
differentiation (Yoshida et al., 2006). In another study, pepstatin partially inhibited VEGF-
C-induced VEGF receptor-3 downregulation (Han et al., 2014). These off-target effects of 
pepstatin A are yet to be more fully investigated. 
In summary, our study showed that the protease, cath D is secreted by both MDA-MB-
231 breast cancer and HT29 colon cancer cells, which might act enzymatically to enhance 











CHAPTER – 4 








The adult type ovarian granulosa cell tumour (GCT) is characterised by slow 
progression, poor diagnosis, resistance to treatment and a high recurrence rate, which results 
in 80% mortality within five years (Amsterdam et al., 1997). A major breakthrough in the 
understanding of this cancer type was the identification of a single missense point mutation 
in the gene of the transcription factor FOXL2 (Shah et al., 2009) in about 97% of female 
patients with adult type GCT (Kobel et al., 2009). FOXL2 has multiple functions in the cell, 
including involvement in sex determination and apoptosis promotion (Rosario et al., 2014). 
A comparative study of the functions of the wild-type and mutant FOXL2 in the GCT 
KGN cell line was performed to evaluate the possible mechanisms by which the mutant type 
contributes to the development and progression of this cancer type. The study demonstrated 
that the wild-type FOXL2 induces cell death through caspase-dependent apoptosis by the 
upregulation of cell death receptors TNF-R1 and Fas which did not occur with the mutant 
FOXL2  (Kim et al., 2011). The identification of the functional mutation in the FOXL2 gene 
in adult type GCT raised the possibility that this cancer type could be treated by gene 
replacement therapy (Shah et al., 2009). The first line treatment drugs used for GCT, 
cisplatin, etoposide and bleomycin have low efficacy and cause unpleasant side effects 
(Skalleberg et al., 2017; Stefansdottir et al., 2016; Taguchi et al., 2003). Thus, this study 
hypothesises that the FOXL2 mutation affects the response to chemotherapeutic treatment 
and that the reinstatement of the wild-type protein could be used as targeted therapy to 
improve response rates. 
Evidence from many studies has suggested that MSCs are easy to isolate, can be 
genetically modified, and are immune privileged (Baird, 2015). Due to their tropism for 
tumour sites, MSCs could therefore be useful in targeted cancer therapy as gene/protein 
delivery vehicles (Hall et al., 2007b) (Figure 22). The efficient migration of MSCs to ovarian 
tumours has been shown previously (Hu et al., 2011; Melzer et al., 2018; Zhang et al., 2018), 
as almost half the stromal cells in ovarian tumour samples identified were found to be 
derived from the bone marrow (Kidd et al., 2012).   
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Hypothesis: We hypothesise that MSCs could be used to deliver wild-type FOXL2 
protein to tumours that affect the cancer development and cell death (Figure 22). 
In order to explore hypothesis, the study had the specific aim: 
Aim: To analyse the susceptibility of wild-type FOXL2 expressing KGN cells for cell 
death with cisplatin and etoposide and assess the effective delivery of wild-type FOXL2 by 
MSCs during the treatment with the same drugs. 
 RESULTS 
4.2.1 Overexpression of the wild-type FOXL2 protein  
A cell secretable and cell penetrable form of the transcription factor FOXL2 was 
designed based on the strategy presented for the protein Smac (Khorashadizadeh et al., 
2015). The construct used a mutant form of the viral Tat protein (Tatm) which will allow the 
protein to cross the nuclear membrane. A furin cleavage site linked the Tatm domain to the 
murine signal peptide Ig-k, which targets the protein to the Golgi complex and makes it 
secretable. The secreted FOXL2 protein would still be linked to Tatm to which would direct 
it to nucleus of another neighbouring cell. This FOXL2 construct was sub-cloned into the 
pLVX-IRES-tdTomato vector with the restriction enzymes BamHI and EcoRI (Figure 5). 
The FOXL2 plasmid (pLVX-IRES-tdTomato-FOXL2) was synthesised by GenScript. 
The orientation of the FOXL2 insert was confirmed by digestion of the pLVX-IRES-
tdTomato-FOXL2 plasmid with restriction enzymes XhoI and NotI and when the digestion 
mixture was run on a 1% agarose gel, the FOXL2 fragment (1290 bp) was identified (Figure 
23).  
Lentiviral vectors (LVs) are widely used vectors for gene expression as they are able to 
stably integrate into the target cell genome for in vivo and ex vivo gene transfer, resulting in 
persistent expression of the gene of interest (Matrai et al., 2010). LVs can easily infect both 
dividing and non-dividing cells and can be used to deliver the genes into stem cells both in 
vivo and ex vivo allowing for stable transgene expression (Matrai et al., 2010). Lentivirus 
was produced from the FOXL2 plasmid and empty plasmid by transient transfection into 
Lenti-X 293T cells (modified HEK 293 cells) using lyophilised Lent-XTM Single Shots 
provided by the manufacturer, which contained all the other components to form vesicular 
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stomatitis virus glycoproteins (VSV-G) pseudotyped lentivirus by Dr Sarah Baird in our 
laboratory. The lentiviral particles were harvested from the supernatant after 48 h and the 
particle titres were determined. 
Lentiviral transduction was performed in 500,000 KGN cells at 1000 MOI in a 6 well 
plate and the transduced cells (where vector is incorporated into the genomic DNA of target 
cells) were identified and sorted by FACS. As the pLVX-IRES-tdTomato-FOXL2 plasmid 
does not contain an antibiotic gene to allow the selection of positively transformed cells by 
antibiotic selection, cells were sorted using FACS to identify cells expressing the tdTomato 
protein by Michelle Wilson of the Department of Microbiology and Immunology. The 
tdTomato protein has an excitation maximum of 554 nm and emission maximum of 581 nm. 
The sorted cells were collected and cultured in media (DMEM/F12) with 1% antibiotic 
(penicillin-streptomycin) (Section 2.9) solution for two passages before further experiments 
were performed. 
Overexpression of FOXL2 was confirmed by fluorescent microscopy (Figure 24) and 
qPCR (Figure 25). Unfortunately, in the qPCR experiments the endogenous mutant FOXL2 
expressed by the KGN cells and the wild-type FOXL2 expressed from the plasmid could not 
be differentiated with a single missense point mutation where C is replaced by G at the 402 
position in the gene (Shah et al., 2009). In spite of this the expression of the FOXL2 gene in 
the transduced KGN cells overall (which express both the wild type and endogenous mutant 
type FOXL2 gene) was increased by 4.8 ± 0.1 fold when compared to transduced KGN cells 











The plasmids were transformed into E. coli Stbl3 and were grown in LB media with 100 
µg/mL ampicillin. Plasmids were isolated and restriction enzyme digestion was performed. 











500,000 KGN cells were plated in a 6 well plate and after 24 h, transduction was performed 
with the lentivirus containing FOXL2 and tdTomato. The cells were sorted by FACS by 
Michelle Wilson, Department of Microbiology and Immunology, University of Otago. 
Sorted cells were cultured for 48 h and the images were taken by the Cytell cell imaging 
system (Department of Biochemistry, University of Otago) at 4x magnification at an 
excitation maximum of 554 nm and emission maximum of 581 nm, bright field (left), 
fluorescent cells (centre), merged (right). Bar represents 500 µm  







Lane 1: Undigested plasmid  
Lane 2: FOXL2 plasmid digested with XhoI 
and NotI 
Lane 3: FOXL2 plasmid digested with XhoI 
Lane 4: FOXL2 plasmid digested with NotI 
White arrow: FOXL2 DNA after digestion 
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Figure 20: Verification of the pLVX-IRES-tdTomato-FOXL2 plasmids by restriction 
digestion. 
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Figure 22: Quantification of FOXL2 overexpression in KGN cells by qPCR technique. 
qPCR analysis of FOXL2 mRNA levels after transduction with lentivirus in KGN cells was 
performed. KGN cells with the empty vector were used as the control (KGN tdTomato) and 
GAPDH was used as the control. The fold change in the expression levels of FOXL2 mRNA 
was shown after normalising data to the GAPDH control. Bars represent the mean ± SEM 
from three independent experiments assayed in triplicate. The data was analysed using an 
unpaired two-tailed t test. A significant difference between KGN and KGN FOXL2 cells 
was represented by **** (p<0.0001). 
To determine the effect of FOXL2 transductions on cell growth, a cell viability assay 
was carried out (Figure 26). Lentiviral transduction did not affect the cell viability of KGN 
tdTomato cells compared to non-transduced cells, but the KGN tdTomato FOXL2 cells 
showed an overall non-statistically significant decrease in cell viability when compared to 
the non-transduced KGN cells (Figure 26). This could be due to either slower proliferation 
of the KGN tdTomato FOXL2 cells when compared to the KGN control cells or an apoptotic 
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Figure 23: Cell number analyses after transduction in KGN cells. 
KGN cells were seeded in 96 well plates at various cell densities. Relative cell number was 
determined for transduced and non-transduced cells using the MTT assay 72 h after seeding. 
Results were normalised to non-transduced controls and expressed as mean ± SEM from 
three independent experiments assayed in triplicate. Statistical analysis was carried out with 
two-way ANOVA and Sidak’s post-hoc test. However, no statistical significant differences 
were found. 
4.2.2 The effect of the wild-type FOXL2 protein on susceptibility to drug treatment 
To assess the effect of the expression of wild-type FOXL2 on KGN cells, we determined 
the drug susceptibility of these cells to two of the first line adult-type ovarian tumour 
granulosa cancer drug treatments, cisplatin and etoposide. Most adult-type ovarian tumour 
granulosa cells express mutant FOXL2, and normally respond less than hoped to cisplatin 
and etoposide treatment. The concentration of each drug required for the 50% cell death with 
and without transduction of the wild-type FOXL2 gene, IC50 was calculated. The IC50 for 
each cell line was determined by the MTT assay. The number of viable cells was determined 
72 h after treatment, for each drug in the KGN, KGN tdTomato and KGN tdTomato FOXL2 
cells. The IC50 values for both cisplatin (Figure 27) and etoposide (Figure 28) were 
significantly lower in KGN cells containing the wild-type FOXL2 gene when compared to 





Table 6: Cisplatin and etoposide IC50 values in KGN cells with and without WT 
FOXL2 gene 
Assay Cells Cisplatin Etoposide 
MTT 
assay 
KGN 1.8 ± 0.2 μM 4.6 ± 0.8 μM 
KGN tdTomato 1.8 ± 0.1 μM 4.0 ± 0.9 μM 
KGN tdTomato 
FOXL2 
0.7 ± 0.2* μM 1.5 ± 0.4* μM 
Data expressed as mean ± SEM of three independent experiments performed in triplicate 
*P<0.05 compared to KGN cells 
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Figure 24: IC50 analysis of cisplatin in KGN cells with and without FOXL2. 
KGN, KGN tdTomato and KGN tdTomato FOXL2 cells were seeded in 96-well plates at a 
density of 5x103 cells/well 24 h before the treatment. Cell viability was determined after 72 
h of cisplatin treatment by MTT assay. Control wells were treated with vehicle (PBS) and 
results were expressed as cell viability as a percentage of control. Symbols represent mean 
± SEM from three independent experiments performed in triplicate. Statistical analysis was 
carried out with two-way ANOVA and Sidak's post-hoc test. Significant differences between 
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Figure 25: IC50 analysis of etoposide in KGN cells with and without the wild-type FOXL2. 
KGN, KGN tdTomato and KGN tdTomato FOXL2 cells were seeded in 96-well plates at a 
density of 5x103 cells/well 24 h before the treatment. Cell viability was determined after 72 
h of cisplatin treatment by MTT assay. Control wells were treated with vehicle (PBS) and 
results were expressed as cell viability as a percentage of control. Symbols represent mean 
± SEM from three independent experiments performed in triplicate. Statistical analysis was 
carried out with two-way ANOVA and Sidak's post-hoc test. Significant differences between 
KGN and KGN tdTomato FOXL2 treatments are represented by ** P<0.01, * P<0.05. 
4.2.3 Mechanism of cell death 
To confirm the mechanism of action of cisplatin and etoposide in the KGN cells and 
KGN tdTomato FOXL2 cells, DNA fragmentation, mitochondrial-driven cell death and cell 
cycle distribution were examined.  
KGN cells with and without the wild-type FOXL2 gene were analysed using flow 
cytometry after treatment with cisplatin and etoposide. PI staining was used to determine the 
level of DNA fragmentation (subG1), showing apoptosis, as well as the overall DNA 
content, thereby determining the percentage of cells in each phase of the cell cycle. All the 
groups treated with cisplatin or etoposide showed significantly higher levels of sub G1 DNA, 
more cells in the G2/M phase and fewer in the G1 phase compared to the untreated KGN 
controls (Figure 29).  
The percentage of cells in the sub G1 phase increased significantly in KGN tdTomato 
FOXL2 cells after treatment with 3.5 µM etoposide to 30.9 ± 2.7% compared to KGN cells, 
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which had 4.6 ± 0.5% in the sub G1 phase. Also, the percentage of cells in the G2/M phase 
decreased significantly with the treatment of 3.5 µM etoposide to 59.1 ± 1% in KGN 
tdTomato FOXL2 cells compared to 86.2 ± 0.6% in KGN cells. 
The percentage of cells in the G2/M phase after treatment with 2 µM cisplatin decreased 
to 49.1 ± 3.2% in KGN tdTomato FOXL2 cells, compared to 68.4 ± 2.5% in KGN cells. The 
rest of the treatment groups also showed changes in the percentage of cells in the G2/M and 
G1 phases, however, none were significant (Figure 31). Representatives of the histograms 












































































































































































































































Figure 26: Cell cycle analysis of KGN, KGN tdTomato and KGN tdTomatoFOXL2 cells 
following 72 h treatment with cisplatin or etoposide. 
KGN, KGN tdTomato and KGN tdTomato FOXL2 cells were seeded in 6-well plates at a 
density of 1x105 cells/well 24 h before treatment. The KGN and KGN tdTomato FOXL2 
cells were treated with cisplatin (0.8 µM or 2 µM) or etoposide (1.5 µM or 3.5 µM). DNA 
content was assessed using propidium iodide staining and measured by FACS. Bars 
represent mean ± SEM of the percentage of gated cells at each cell cycle stage (Sub-G1; G1; 
S; G2/M). Three independent experiments were conducted in triplicate with a minimum of 
10,000 events counted for each sample. Data were analysed using two-way ANOVA with 
Sidak's multiple comparison test. A significant difference between KGN and KGN tdTomato 


















KGN, KGN tdTomato and KGN tdTomato FOXL2 cells were seeded in 6-well plates at a 
density of 1x105 cells/well 24 h before treatment. The KGN and KGN FOXL2 cells were 
treated with cisplatin (0.8 µM or 2 µM) or etoposide (1.5 µM or 3.5 µM). DNA content was 
assessed using propidium iodide staining measured by FACS. Peaks represent the percentage 
of gated cells at each cell cycle stage (Sub-G1; G1; S; G2/M). Three independent 
experiments were conducted in triplicate with a minimum of 10,000 events counted for each 
sample and representative peaks were shown.   
KGN Control 
KGN Cisplatin 0.8 μM 
KGN Cisplatin 2 μM 
KGN Etoposide 1.5 μM 
KGN Etoposide 3.5 μM 
KGN tdTomato Control 
KGN tdTomato Cisplatin 
0.8 μM 
KGN tdTomato Cisplatin 2 
μM 
KGN tdTomato Etoposide 
1.5 μM 
KGN tdTomato Etoposide 
3.5 μM 
KGN FOXL2 Control 
KGN FOXL2 Cisplatin 
0.8 μM 
KGN FOXL2 Cisplatin 2 
μM 
KGN FOXL2 Etoposide 
1.5 μM 
KGN FOXL2 Etoposide 
3.5 μM 
Figure 27: Cell cycle analysis showing peaks of KGN, KGN tdTomato and KGN tdTomato 

















































































































































































































































































































































































































































































































































































































































































































































































































Figure 28: Cell cycle distribution of KGN, KGN tdTomato and KGN tdTomato FOXL2 
cells following 72 h treatment with cisplatin or etoposide. 
KGN, KGN tdTomato and KGN tdTomato FOXL2 cells were seeded in 6-well plates at a 
density of 1x105 cells/well 24 h before the treatment. The KGN and KGN FOXL2 cells were 
treated with cisplatin (0.8 µM or 2 µM) or etoposide (1.5 µM or 3.5 µM). The DNA content 
was assessed using a propidium iodide stain and the cells were measured by FACS. Bars 
represent mean ± SEM of the percentage of gated cells at each cell cycle stage Sub-G1 (A), 
G1 (B), G2/M (C). Three independent experiments were conducted in triplicate with a 
minimum of 10,000 events counted for each sample. Data were analysed using a one-way 
ANOVA with Sidak's multiple comparison test. A significant difference comparing between 
KGN and KGN tdTomato FOXL2 treatments is represented by **** P<0.0001, * P<0.05. 
It has been reported that the FOXL2 gene is apoptotic via mitochondrial cell death (Kim 
et al., 2011). Therefore, to assess the mitochondrial cell death, we used the TMRE 
fluorescent dye, which is taken up by the intact mitochondria, and assessed the number of 
cells that took up the dye by flow cytometry. The percentage of cells with depolarised 
mitochondrial membrane potentials, indicative of classical mitochondrial-driven apoptosis, 
were analysed in the KGN cells with and without the wild-type FOXL2 gene following 
treatment with cisplatin and etoposide. 
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The drug treatment groups exhibited significantly greater mitochondrial cell death when 
compared to the KGN control cells. Since we were focusing on the drug susceptibility of the 
KGN cells with the wild-type FOXL2 gene, the significant differences after drug treatment 
in cells with and without the wild-type FOXL2 gene are represented as the percentage of 
cells with depolarised mitochondrial membrane potential (Figure 32). 
The KGN and KGN FOXL2 cells were treated with cisplatin (0.8 µM or 2 µM) and 
etoposide (1.5 µM or 3.5 µM). The percentage of KGN tdTomato FOXL2 cells with a 
depolarised mitochondrial membrane after treatment with 2 µM cisplatin increased 
significantly to 16.2 ± 0.8% when compared to KGN cells with 9.4 ± 0.9% treated with the 
same drug concentration. No significant difference was found after treatment with only 0.8 
µM cisplatin. The percentage of KGN FOXL2 cells with a depolarised mitochondrial 
membrane after treatment with 1.5 µM etoposide increased to 23.5 ± 1.1% compared to 
KGN cells with 15.9 ± 1.1%. After 3.5 µM etoposide treatment, the percentage of cells with 
a depolarised mitochondrial membrane increased to 28.1 ± 3.5% compared to KGN cells 















































































































































































































































Figure 29: Depolarization of the mitochondrial membrane potential (Ψ) of KGN, KGN 
tdTomato and KGN tdTomato FOXL2 cells following 72 h treatment with cisplatin and 
etoposide. 
KGN, KGN tdTomato and KGN tdTomato FOXL2 cells were seeded in 6-well plates at a 
density of 1x105 cells/well 24 h before the treatment. The cells were treated with cisplatin (0.8 
µM or 2 µM) or etoposide (1.5 µM or 3.5 µM). The percentage of cells with depolarised 
mitochondrial membrane potential (Ψ) was determined by TMRE fluorescence intensity by 
FACS. Results are shown as mean ± SEM. Three independent experiments were conducted in 
triplicate with a minimum of 10,000 events for each sample. Data were analysed using a two-
way ANOVA with Sidak's post-hoc test. A significant difference is represented by **** 
P<0.0001, ** P<0.01, * P<0.05. 
4.2.4 Expression of the FOXL2 gene in the MSC-hTERT-T0523 cell line 
Since the wild-type FOXL2 protein causes an increase in susceptibility of adult-type 
ovarian granulosa cell tumour KGN cells to drugs (cisplatin and etoposide), it was concluded 
that it would be useful to investigate efficient strategies to deliver the wild-type FOXL2 
protein to this tumour type. As MSCs possess an innate ability to home to cancer cells, they 
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may be able to deliver the protein to ovarian granulosa cell tumours, and a vector was designed 
to produce a cell secretable and cell penetrable FOXL2 protein, as mentioned earlier (Figure 
5).  
Thus, the wild-type FOXL2 gene was expressed in the MSC-hTERT-T0523 cell line 
using lentiviral transduction and the transduced cells (with the tdTomato gene also 
incorporated into the genomic DNA) were sorted by FACS using the tdTomato as a marker, 
with an excitation maximum at 554 nm and an emission maximum at 581 nm. Images of the 










The MSC-hTERT-T0523 cell line was infected with the lentivirus expressing FOXL2 and 
tdTomato at 1000 MOI in 500,000 cells and the cells were sorted by FACS at excitation 
maximum 554 nm and emission maximum 581 nm, by Michelle Wilson, Department of 
Microbiology and Immunology, University of Otago. Images were taken in a Cytell cell 
imaging system by digital imaging at 4x magnification, performed in the Department of 
Biochemistry, University of Otago after 48 h of transduction, bright field (left), fluorescent 
cells (centre), merged (right). Merged images of MSC with tdTomato positive cells indicate 







Bright field Fluorescent cells Merged 
500μm 
Figure 30: MSCs overexpressing FOXL2 protein after transduction with lentivirus. 
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To determine the effect of the transduction with the wild-type FOXL2 on MSC growth 
and death rates, an MTT assay assessing the change in cell number over 72 h was carried out 
(Figure 34). Lentiviral transduction, with or without the wild-type FOXL2, was shown not to 
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Figure 31: Cell number analyses after transduction in MSCs. 
MSCs were seeded in 96 well plates at various cell densities. Cell number was determined for 
infected and non-infected cells using the MTT assay 72 h after seeding. Results were 
expressed as mean ± SEM from three independent experiments performed in triplicate. 
Statistical analysis was carried out with two-way ANOVA and Sidak's post-hoc test. No 
significant differences were found between the cell numbers of MSCs with and without 
transductions. 
4.2.5 The effect of drug treatment on the wild-type FOXL2 overexpressing MSC-
hTERT-T0523 cell line 
To allow efficient delivery of the wild-type FOXL2 protein by MSCs to a tumour site 
during the cancer therapy, MSC susceptibility to the chemotherapeutic drugs used for 
treatment of GCT should not occur. To determine the susceptibility of MSCs to cisplatin and 
etoposide, IC50 values were calculated. This was done for MSCs, MSCs with tdTomato and 
MSCs with tdTomato FOXL2 by the MTT assay. Cell number was determined 72 h following 
treatment, for both the drugs. The IC50 values for both cisplatin (Figure 35) and etoposide 
(Figure 36) for MSCs with and without FOXL2 overexpression were higher than for KGN 
cells with and without the wild-type FOXL2 gene (Table 6), indicating that MSCs could 
deliver the wild-type FOXL2 protein concurrently with chemotherapeutic treatment.  
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Table 7: Cisplatin and etoposide IC50 values in MSCs with and without WT FOXL2 gene 
 Cisplatin Etoposide 
MSC 18 ± 11.5 μM 539.5 ± 81.9 μM 
MSC tdTomato 21.5 ± 2.83 μM >400 μM 
MSC tdTomato 
FOXL2 
16.4 ± 9.7 μM >400 μM 
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Figure 32: IC50 analysis of cisplatin in MSCs overexpressing FOXL2. 
MSC, MSC tdTomato and MSC tdTomato FOXL2 cells were seeded in 96-well plates at a 
density of 5x103 cells/well 24 h before treatment. Cell number was determined after 72 h of 
cisplatin treatment by MTT assay. Control wells were treated with vehicle (PBS) and the 
results were expressed as cell number, percentage of control. Symbols represent mean ± SEM 
from three independent experiments performed in triplicate. Statistical analysis was carried 
out with two-way ANOVA and Sidak's post-hoc test. No significant differences between MSC 
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Figure 33: IC50 analysis of etoposide in MSCs overexpressing FOXL2. 
MSC, MSC tdTomato and MSC tdTomato FOXL2 cells were seeded in 96-well plates at a 
density of 5x103 cells/well 24 h before treatment. Cell number was determined after 72 h of 
cisplatin treatment by MTT assay. Control wells were treated with vehicle (PBS) and the 
results were expressed as cell number, percentage of control. Symbols represent mean ± SEM 
from three independent experiments performed in triplicate. Statistical analysis was carried 
out with two-way ANOVA and Sidak's post-hoc test. No significant differences between MSC 
and MSC tdTomato FOXL2 treatments were found. 
4.2.6 Effect of the wild-type FOXL2 protein on tube formation 
Granulosa cell tumours show expression of vascular endothelial growth factor (VEGF) 
which is an important stimulator of angiogenesis (Schmidt et al., 2008). A high expression of 
VEGF also increases the proliferation of the tumour and the tumour burden via angiogenesis. 
Therefore, it is advantageous to prevent the construction of new vasculature. Vasculature 
growth can be modelled via a tube formation assay using human umbilical cord vein 
endothelial cells (HUVECs). 
In this assay, MSCs were found to line up with the HUVECs forming tubes and as the 
number of MSCs with the wild-type FOXL2 added into the assay increased, tube formation 













HUVEC and MSCs with and without the wild-type FOXL2 overexpression were seeded in 
different ratios and allowed to attach. Images were taken with a Cytell cell imaging system, 
at the Department of Biochemistry, University of Otago at 20 h after seeding. Experiments 
were conducted in triplicate and independently repeated three times. Representative images 
are shown. Magnification is 4X; the scale bar denotes 500 μm. 
 SUMMARY 
Several studies have reported that FOXL2, a member of the forkhead (FH) domain 
transcription factor family, is required for proper development of the ovary and eyelid tissue 
(Crisponi et al., 2001). Ovarian granulosa cell tumours (GCTs) originate from the sex-cord 
stromal cells, with the pathogenesis being largely unknown and recurrence being the major 
problem associated with these tumours (Schumer et al., 2003). A FOXL2 single missense 
point mutation C134W, found in 97% of adult-type GCTs has been identified (Shah et al., 
2009). This mutation was not identified in other types of ovarian tumours, indicating a specific 
role for FOXL2 in adult-type GCTs (Schrader et al., 2009). However, currently little is known 
about how the mutation of FOXL2 is associated with GCT formation. 
The present study investigated how expression of the wild-type FOXL2 gene affects the 
susceptibility of adult-type GCTs to the first-line treatment drugs cisplatin and etoposide 
(Section 4.2.2). For this, the wild-type FOXL2 was overexpressed in KGN cells (Figure 24) 





















and found to be significantly lower in KGN cells expressing the wild-type FOXL2 compared 
to the KGN control cells containing only the mutant FOXL2 gene (Figure 27 and 28). 
Further, cell cycle distribution, DNA fragmentation and mitochondrial-driven cell death 
levels were evaluated. KGN cells with the wild-type FOXL2 showed a significant increase in 
the percentage of cells in sub G1 and a decrease in cells in the G2/M phase after treatment 
with 3.5 µM etoposide, as well as a significant decrease in the percentage of cells in the G2/M 
phase after treatment with 2 µM cisplatin (Figure 29). Also mitochondrial cell death increased 
significantly with etoposide or cisplatin treatment in KGN tdTomato FOXL2 cells when 
compared to the KGN control cells (Figure 32). 
Other studies have shown that MSCs can efficiently deliver proteins to tumours. This can 
only be achieved when MSCs remain viable during the treatment. So, the wild-type FOXL2 
was expressed in MSCs and the IC50 values were determined for cisplatin and etoposide. The 
IC50 values were found to be higher in MSCs when compared to the KGN cells, by a factor of 
8 for cisplatin and more than 100 for etoposide (Table 6). 
 The breakthrough discovery of single point missense mutation in FOXL2 gene in adult 
type GCTs (Shah et al., 2009) and this mutation being confined to this particular type of cancer 
by subsequent studies (Jamieson et al., 2010; Schrader et al., 2009), laid a path for targeting 
FOXL2 gene. Therefore, this study investigated the application of the wild-type FOXL2 gene 
on drug susceptibility of cisplatin and etoposide in KGN cells in vitro. However, more studies 
are needed to confirm the delivery of WT FOXL2 gene to apply this clinically. 
 DISCUSSION 
4.4.1 The wild-type FOXL2 protein decreases proliferation of KGN cells 
A somatic missense point mutation in the FOXL2 gene was reported in almost all (97%, 
86/89) morphologically defined adult-type granulosa cell tumours (GCTs) (Shah et al., 2009). 
Therefore, development of GCT may be related to the acquisition of this mutation in the 
FOXL2 gene (Rosario et al., 2014). To study adult-type GCTs, we used the KGN cell line, 
that has proven to be a useful model in vitro, as it expresses the mutant FOXL2 gene (Schrader 
et al., 2009). To investigate the effect of the FOXL2 gene on the KGN cell line, the wild-type 
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FOXL2 gene was expressed in KGN cells (Figure 25) and its effect on the number of live cells 
was studied. 
The viability of KGN cells expressing the wild-type FOXL2 gene decreased compared to 
the KGN control cells expressing the mutant FOXL2 gene only, although this difference was 
non-significant statistically in our study (Figure 26). This result is similar to the findings of 
another study, in which a change in proliferation was reported in the cervical cancer cell lines 
SiHa and HeLa with altered FOXL2 expression (Liu et al., 2014). In that study, HeLa cells 
were transfected with the wild-type FOXL2 gene and SiHa cells had FOXL2 silenced by 
shRNA. Proliferation was significantly decreased in HeLa cells, while it increased in SiHa 
cells (Liu et al., 2014), indicating the role for FOXL2 in inhibiting cell cycle progression. 
Indeed in KGN and HeLa cells upregulation of the wild-type FOXL2 decreased proliferation 
by delaying cell cycle progression, specifically slowing down the cell cycle at the G1/S 
transition point, increasing the G0/G1 population, and decreasing the G2/M population 
(Benayoun et al., 2011). 
Another study showed that overexpression of the wild-type FOXL2, but not mutant 
FOXL2, induced production of follistatin, a molecule which blocks activin A. Activin A is 
produced in the granulosa cells of the ovary and stimulates cell proliferation. Thus, the wild-
type FOXL2 was shown to attenuate cell proliferation by inducing activin inhibition (Cheng 
et al., 2014). Therefore, in our study, the decrease in cell viability of the KGN cells 
overexpressing FOXL2 could be due to the protein itself, which could reduce the cell 
proliferation through the action of follistatin-activin inhibition or due to another interaction 
affecting the cell cycle. 
4.4.2 Drug susceptibility affected by the wild-type FOXL2 protein 
 To treat adult type ovarian GCTs, surgery would be the first step. However, the tumours 
recur after 4-7 years of primary surgery and 5 year survival rate from the first recurrence is 
55% from incompletely resected patients (Yanagida et al., 2017). Chemotherapy being the 
next step, etoposide and cisplatin were used as first line treatment drugs (Homesley et al., 
1999; Pautier et al., 2008). Cisplatin is non-selective among the rapidly dividing normal cells 
and cancer cells, leading to the side effects such as ototoxicity, acute nephrotoxicity, 
myelosuppression, chronic nephrotoxicity depending on the dose used (Duan et al., 2016; 
Skalleberg et al., 2017). Etoposide is associated with the damage in female germ cells 
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(Stefansdottir et al., 2016), anaphylaxia (Taguchi et al., 2003). The present study 
demonstrated the role of wild-type FOXL2 gene in drug susceptibility to cisplatin and 
etoposide. 
Cisplatin is a widely used anticancer agent either used alone or in combination with other 
chemotherapeutic agents, and is a key component of first-line drug treatment against ovarian 
granulosa cell tumours (Bae et al., 2017; Chiara et al., 1993). It is usually combined with 
etoposide and bleomycin for advanced granulosa cell tumours of the ovary (Gershenson et al., 
1996; Homesley et al., 1999). The overall patient response rate with this combination was 
90%, with nine clinical complete responses and nine clinical partial responses among the 
twelve patients with an average duration of treatment of 24 months (Pautier et al., 2008).  
Cisplatin’s adverse effects include excessive granulosa cell apoptosis, follicle loss and 
even premature ovarian insufficiency due to an elevation in endoplasmic reticulum stress (Wu 
et al., 2018). Systemic administration of cisplatin commonly causes severe side effects such 
as hepatotoxicity, neurotoxicity and nephrotoxicity because of its non-selective toxicity 
against all rapidly dividing cells (Duan et al., 2016). Long-term ototoxicity was reported for 
one in four women, leading to hearing loss after cisplatin treatment (Skalleberg et al., 2017). 
Etoposide is a topoisomerase II inhibitor and is also used as one of the components of the 
first line treatment for GCTs. Etoposide administered at clinical levels showed adverse effects 
on foetal ovarian development, in early stage female germ cells, prior to follicle formation 
(Stefansdottir et al., 2016). Anaphylactic reactions were also reported, where a patient 
complained of acute dyspnoea, caused by bronchospasms and cutaneous flushing which was 
reversed by decreasing the dose by 50% (Taguchi et al., 2003). 
Given these adverse effects of these treatments, there is a need to reduce the clinical dose 
of cisplatin and etoposide. However, decreasing the dose alone may not effectively treat 
ovarian tumour granulosa and is likely to lead to resistance developing in the tumour cells. 
For example, treatment with cisplatin in COV434 and KGN granulosa cell tumour cells in 
vitro induced cell death in a dose-dependent manner but the magnitude of the cell death in 
non-FOXL2 mutated COV434 cells was more pronounced when compared to KGN cells 
(Woods et al., 2008). In the present study, the wild-type FOXL2 overexpressing KGN cells 
were developed (Figure 25) and the IC50 values of cisplatin and etoposide were determined 
by cell viability assays (Table 5). 
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 KGN cells expressing the wild-type FOXL2 gene were significantly more sensitive to 
the drugs cisplatin (Figure 27) and etoposide (Figure 28 when compared to KGN cells 
expressing just the mutant FOXL2, as indicated by the IC50 values being reduced to almost 
half in the transduced cells. The present clinical effective dose of cisplatin is 20 mg/m2/day 
for 5 days a week and etoposide is 100 mg/m2/day for 5 days a week administered IV for 3 
weeks for four courses. Upon the occurrence of severe toxicity, chemotherapy would be 
delayed for a week or drug regimen would be changed, instead dose reductions (Homesley et 
al., 1999; Pautier et al., 2008). The application of the wild-type FOXL2 might reduce these 
doses to almost half and might improve the quality of life in patients. The study showed the 
decrease in IC50 values of cisplatin and etoposide in KGN (with mutant FOXL2 gene) cells 
with wild-type FOXL2 gene when compared to KGN cells by themselves. Overall, the 
reduced IC50 values could be clinically effective in decreasing side effects caused by the drug 
treatment. 
4.4.3 G2/M phase cell cycle arrest and mitochondrial cell death of the wild-type FOXL2 
expressing KGN cells 
Since the wild-type FOXL2 expressing KGN cells were found to be more sensitive to 
cisplatin and etoposide (Table 5), we evaluated cell cycle distribution (Figure 29), DNA 
fragmentation and mitochondrial-driven cell death (Figure 32) to assess whether 
overexpression of the wild-type FOXL2 changes KGN response to the drug treatments, 
compared to control cells. In KGN tdTomato FOXL2 cells we identified a significant decrease 
in the G2/M phase upon the treatment with both 2 µM cisplatin and 3.5 µM etoposide for 72 
h (Figure 31 (C)) and a significant increase in cells in the sub G1 phase upon treatment, with 
3.5 µM etoposide for 72 h (Figure 31 (A)) when compared to KGN control cells. In addition, 
a non-significant decrease of cells in the G1 phase was seen with both concentrations of 
cisplatin and 1.5 µM etoposide (Figure 31 (B)). 
Cisplatin is commonly used for the treatment of testicular, ovarian and colorectal cancers 
(Lebwohl et al., 1998). Cisplatin is a platinum based drug, which acts as a DNA crosslinking 
agent, causing platinum-DNA interactions and making both inter- and intrastrand crosslinks 
in DNA (Dilruba et al., 2016; Mansy et al., 1973). It has selectivity for adjacent GG 
dinucleotide sequences (60-65%) over AG sequences (20-25%) preventing DNA 
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replication/repair/recombination, RNA transcription and disrupting cell viability (Fong, 2016; 
Jamieson et al., 1999; Todd et al., 2009).  
Cells treated with cisplatin had G2/M phase arrest in murine leukaemia L1210 cells 
(Ormerod et al., 1994), human colorectal HT29 cells (Swift et al., 2016), human ovarian 
cancer A2780 cells (Pichler et al., 2015) and  human hepatoma BEL-7404 cells, which 
correlates with our results in KGN cells (Figure 29), in which cisplatin treatment resulted in 
G2/M arrest irrespective of its concentration and FOXL2 status.  
Etoposide is widely used for solid tumours such as small cell lung cancers, testicular and 
germ cell cancers, sarcomas and neuroblastomas (Hande, 1998; Nitiss, 2009; Pommier, 2013). 
Etoposide is a topoisomerase II α and β inhibitor and inhibits both the isoforms of the enzyme 
indiscriminately (Cornarotti et al., 1996; Willmore et al., 1998). During DNA replication, 
each subunit of topoisomerase II nicks one strand of DNA to generate a double strand break, 
which is blocked by etoposide (Deweese et al., 2009). Thus, etoposide acts as a roadblock for 
the progression of replication and transcription (Mao et al., 2001). 
Topoisomerase II is highly expressed in dividing cells, including tumour cells and is 
highly up-regulated during S and G2 phases (Goswami et al., 1996; Hsiang et al., 1988), when 
it is essential for cell proliferation, replication, transcription and segregation (Wang, 2002). 
Cells treated with etoposide had G2/M phase arrest in MCF7 breast cancer cells, DU145 
prostate cancer cells (Wei et al., 2015), human colorectal carcinoma HCT116 cells (Chen et 
al., 2018; Selvarajah et al., 2015) and p53 dependent G2/M phase arrest in neural progenitor 
cells (Nam et al., 2010), which also aligns with our results (Figure 29). 
The significant difference between the wild-type FOXL2 and mutant FOXL2 expressing 
KGN cells in cell cycle distribution, DNA fragmentation (Figure 29) and mitochondrial death 
(Figure 32) can be attributed to the increased susceptibility of cells with the wild-type FOXL2 
gene to apoptosis (Kim et al., 2011). Mitochondrial membrane potential plays an essential 
role in apoptosis, in sensing and responding to external mediators of apoptotic induction such 
as cisplatin (MacDonald et al., 2018). The mitochondrial cell death pathway is activated 
through the translocation of the Bcl-2 family proteins Bax or Bak and results in release of 
mitochondrial proteins such as cytochrome c leading to apoptosis (Er et al., 2006). Activation 
of this pathway was previously reported in KGN cells with the wild-type FOXL2 gene. Thus 
mitochondrial cell death can occur through changes in the Bcl-2 family proteins. The 
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expression of death receptor TNF-R1 is upregulated by the wild-type FOXL2, which may 
activate caspase 8, which cleaves BID to active tBID and subsequently activates Bax and 
induces it and other pro-apoptotic family members to oligomerise. This leads to release of 
cytochrome c from the mitochondria which further activate caspase 8 and caspase 9 to cleave 
caspase 3 resulting in cell apoptosis. This cell death is due to different apoptosis-inducing 
activity of the wild-type and mutant type FOXL2 protein (Kim et al., 2011). 
4.4.4 MSCs as delivery vehicles for the wild-type FOXL2 gene/protein  
MSCs are proposed as gene/protein delivery vectors for cancer treatment as they 
effectively home to and integrate into tumour sites (Section 1.2.4). MSCs were previously 
used effectively to deliver genes such as IL-2 (Nakamura et al., 2004) and  IL-18 (G. Xu et 
al., 2009) for rat glioma, IL-12 for renal cell carcinoma (Gao et al., 2010), CX3CL1 for 
multiple lung tumours (Xin et al., 2007), apoptin for hepatoma cells (Zhang et al., 2016), 
prodrug activating enzymes against various tumours (Choi et al., 2012; Kucerova et al., 2008; 
Song et al., 2011) and tumour necrosis factor-related apoptosis inducing ligand (TRAIL) 
(Mueller et al., 2011). Thus, in our study, the wild-type FOXL2 was expressed in MSCs to 
target ovarian GCTs.  
MSCs were transduced with the wild-type FOXL2 vector and the positively transduced 
cells were sorted by FACS (Figure 34). The IC50 values for cisplatin and etoposide of MSCs 
with and without the wild-type FOXL2 were determined (Table 5) to ensure effective delivery 
of MSCs during the treatment of ovarian GCTs in vivo. Since the IC50 values for cisplatin and 
etoposide in MSCs were found to be higher than the IC50 values in KGN cells (Table 5), 
Therefore, it was concluded that MSCs could deliver the wild-type FOXL2 gene/protein in 
vivo during treatment with drugs in patients without undergoing cell death themselves.  
4.4.5 MSCs with the wild-type FOXL2 inhibit tube formation 
Inhibition of vasculature formation was investigated by using a tube formation assay with 
HUVECs. As the wild-type FOXL2 expressing MSC number increased, and the HUVECs 
number was kept constant, tube formation decreased, compared to mixing HUVECs with 
MSC control cells (Figure 37). As ovarian GCTs have been shown to secrete VEGF (Schmidt 
et al., 2008); this stimulator of angiogenesis may contribute to tumour proliferation. Thus, 
angiogenesis could also be inhibited by the wild-type FOXL2 gene/protein expressing MSCs. 
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In another study, overexpression of integrin alpha x (ITGAX), a member of the integrin 
family, enhanced proliferation, migration, tube formation in HUVECs and promoted ovarian 
tumour angiogenesis and growth. Further, ITGAX overexpression activated the PI3/Akt 
pathway, leading to the enhanced expression of VEGF-A and VEGF receptor 2 (VEGFR2). 
These effects were reversed by the treatment of cells with PI3K inhibitor (Wang et al., 2019). 
Akt, JNK and NF-ĸB signalling pathways are the potential mechanisms found to be involved 
in tube formation in xenograft models of SKOV3 ovarian cancer cells (Ma et al., 2016).  
In our study, MSCs were found to line up with the HUVECs and to be involved together 
in the tube formation. Previously, a study showed that IGROV1 ovarian adenocarcinoma cells 
rapidly adhere to the HUVECs monolayer and can extravasate from the blood vessels to other 
tissues as a part of tumour metastasis. This adhesion was found to be inhibited by the anti-αv 
integrin and anti-vitronectin blocking antibodies, but not by anti-β1 integrin antibodies 
(Leroy-Dudal et al., 2005). The IGROV1 and SKOV3 ovarian cancer cells that adhere to the 
endothelial cells (HUVECs) also extravasate through them via the expression of MMP2 and 
MT1-MMP proteases secreted by the cancer cells and metastasise to various tissues (Leroy-
Dudal et al., 2005). Therefore, angiogenesis could be a potential target for reducing ovarian 
cancer metastasis. 
MSCs also differentiate into pericytes during new vascular formation and remodelling 
and then migrate to cover the newly formed vasculature (D'Amore et al., 1996). Pericytes 
formed after differentiation from MSCs are known to be closely associated with the 
endothelial cells, play a crucial role in vascular maturation and stabilisation, and support 
vascular function (Armulik et al., 2011). Differentiation of MSCs to pericytes and their 
attachment to endothelial cells was induced through several factors such as PDGF-β and 
VEGF (Dhar et al., 2010; Lindblom et al., 2003).  Thus, that MSCs with the wild-type FOXL2 
may not be differentiating into pericytes could also be one of the possibilities that cannot be 
ignored. 
In conclusion, MSCs could potentially be used as vehicles for gene/protein delivery and 
this study is the initial stages of one of such attempt. Delivery of the wild-type FOXL2 to 
ovarian GCTs through MSCs could improve susceptibility to chemotherapeutic drugs and 
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5 TIMPS: RESULTS AND DISCUSSIONBACKGROUND 
As previously described, MSCs migrate to tumour sites and also can cross the blood-brain 
barrier (Pacioni et al., 2015). The role of MSCs after becoming part of the tumour stroma can 
be contradictory. Some studies suggest that they can act in a pro-tumourigenic manner, while 
others suggest that they can be anti-tumourigenic (section 1.2.3). The effect of MSCs, after 
becoming part of tumour stroma, in cancer cell migration and invasion has not been much 
explored. Furthermore, a number of studies have also reported that MSCs being tested as 
therapy delivery vehicles showed tumour tropism and successfully expressed the protein of 
interest (Guo et al., 2016; Lee et al., 2013; Li et al., 2019; Malik et al., 2018). Therefore, 
MSCs could act as site-specific delivery mechanisms for therapeutic proteins, which if used 
as part of treatment plan, could reduce the side effects that arise after surgery, chemotherapy 
or radiation therapy (Hall et al., 2007b). 
Cancer metastasis is the major cause of death among 90% of cancer patients (Guan, 
2015). Cancer cell migration from the primary site to a different area away from the original 
site through blood vessels and lymphatic vessels is a complex process (Kalinski et al., 2017). 
This process mainly involves extra cellular matrix (ECM) rearrangement, remodelling and 
disintegration of the non-cellular component of the tissues that acts as barrier for the cells in 
the tissue. Thus, ECM and basement membrane are necessary for the cancer cells to migrate 
from primary site to the secondary site (Bourboulia et al., 2011; Kalluri, 2003; Walker et al., 
2018). Proteases such as MMPs were thought to play a key role in the breaching or 
remodelling the BM and ECM (Roy et al., 2009; Yamamoto et al., 2015). Targeting these 
proteases, especially MMPs, in a site specific manner could be used as a potential therapy to 
prevent cancer progression; especially cancer metastasis (Walker et al., 2018). Tissue 
inhibitor metalloproteinases (TIMPs) were chosen for this study based on the in vitro work by 
our previous laboratory members. In this study, MSCs were found to inhibit the movement of 
breast cancer cell lines, MDA-MB-231 and T47D cells, through the expression of the protease 
inhibitors, TIMPs (Clarke et al., 2015). The disruption in the net balance between MMPs and 
TIMPs is a major reason for infiltration or metastasis of tumours (Li et al., 2010). This study 
therefore hypothesised that MSCs overexpressing TIMPs could be a novel and effective 
therapeutic approach in prevention or reduction of tumour movement.  
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Hypothesis: We hypothesise that MSCs could be used to deliver TIMP proteins to 
tumours that affect cancer development, including metastasis (Figure 3). 
In order to explore hypothesis, the study had the specific aim: 
Aim: To confirm that MSCs play a role in tumour cell migration in vitro and determine 
the effects of TIMPs overexpressing MSCs on tumour cell migration.  
 RESULTS 
5.2.1 Cancer cell migration increased without serum and decreased with serum in the 
presence of MSCs or MSC conditioned media 
The effect of MSCs (RCB2157 cell line) on tumour metastasis was investigated in vitro 
by exposure of cancer cells indirectly to MSCs or MSC conditioned media, using co-culture 
of cells in a Boyden chamber setup. The migration assays were performed with all the upper 
wells containing cancer cells, either breast cancer (MDA-MB-231), colon cancer (HT29) or 
paediatric glioblastoma (KNS42, SF188 or UW479), and lower wells containing MSCs or 
MSC conditioned medium. Conditioned media for the study was collected on day 1 and 5 with 
and without serum. This conditioned media was not refreshed or diluted with fresh serum 
containing media, as refreshing the media did not show any differences in migration or cell 
morphology (Clarke et al., 2015).  
The results of the effect of MSCs and MSC conditioned media on the migration of MDA-
MB-231 cells are shown in Figure 38. In the absence of serum, the migration of MDA-MB-
231 cells was increased to 203.7 ± 16.3% with MSCs in serum-free media, 265.6 ± 9.6% with 
1 day conditioned media and 215.5 ± 14.3% with 5 day conditioned media compared to 
control. In the presence of 10% serum, the migration of MDA-MB-231 cells was decreased 
to 61.6 ± 7.4% with MSCs and to 60 ± 3.5% with 5 day conditioned media compared to MDA-
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Figure 35: Effect of MSCs and their conditioned media without serum and with 10% 
serum on MDA-MB-231 migration. 
MDA-MB-231 cells suspended in serum-free growth media were seeded into the upper well. 
Bottom wells contained (A) MSCs (RCB2157) and their 1 day and 5 day conditioned serum 
free DMEM media or (B) MSCs (RCB2157) and their conditioned media with 10% serum. 
After 48 h, the MDA-MB-231 cells that migrated to the lower side of the membrane were 
quantified using the MTT assay. Results were expressed as % of control (0% DMEM and 10% 
DMEM). Bars represent mean ± SEM, and the results were from three independent 
experiments performed in triplicate. The data were analysed using one-way ANOVA with 
Dunnett's post-hoc test. A significant difference between individual treatment and control was 
represented by **** P<0.0001, *** P<0.001, ** P<0.01.  
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The effect of MSCs or MSC conditioned media on the migration of HT29 cells was also 
investigated (Figure 39). In both the presence and absence of serum, the migration of HT29 
cells was decreased towards MSCs and MSC conditioned media, however, non-significantly. 




















































































Figure 36: Effect of MSCs and their conditioned media without serum and with 10% 
serum on HT29 migration. 
HT29 cells suspended in serum-free growth media were seeded into the upper well. Bottom 
wells contained (A) MSCs (RCB2157) and their 1 day and 5 day conditioned serum free 
DMEM media or (B) MSCs (RCB2157) and their conditioned media with 10% serum. After 
48 h, the HT29 cells that migrated to the lower side of the membrane were quantified using 
the MTT assay. Results were expressed as % of control (0% DMEM and 10% DMEM). Bars 
represent mean ± SEM, and the results were from three independent experiments performed 
in triplicate. The data were analysed using one-way ANOVA with Dunnett's post-hoc test. No 




The effect of MSCs or MSC conditioned media on the migration of KNS42 cells is shown 
in Figure 40. In the absence of serum, migration of KNS42 cells was increased to 153.9 ± 
10.2% with the 1 day conditioned media; however, the presence of MSCs and 5 day 
conditioned media had no effect on migration levels. In the presence of 10% serum, the 
migration of the KNS42 cells was decreased by MSCs to 61.0 ± 10.5% of control and to 53.2 
± 6.5% by 5 day conditioned media. 























































































Figure 37: Effect of MSCs and their conditioned media without serum and with 10% serum 
on KNS42 migration. 
KNS42 cells suspended in serum-free growth media were seeded into the upper well. Bottom 
wells contained (A) MSCs (RCB2157) and their 1 day and 5 day conditioned serum free 
DMEM media or (B) MSCs (RCB2157) and their conditioned media with 10% serum. After 
48 h, the KNS42 cells that migrated to the lower side of the membrane were quantified using 
the MTT assay. Results were expressed as % of control (0% DMEM and 10% DMEM). Bars 
represent mean ± SEM, and the results were from three independent experiments performed 
in triplicate. The data were analysed using one-way ANOVA with Dunnett's post-hoc test. A 




Interestingly, when another paediatric glioblastoma cell type, UW479, was used in the 
assay, the effects on MSC migration were similar to those observed with the KNS42 cells 
(Figure 41). In the absence of serum, the migration of UW479 cells increased to 151.5 ± 6.9% 
with 1 day MSC conditioned media; however, the presence of MSCs and 5 days conditioned 
media had no significant effect when compared to the control. In the presence of 10% serum, 
the migration of UW479 cells decreased to 50.9 ± 2.7% of control with MSCs and to 73.9 ± 
2.9% with 5 day conditioned media. 




















































































Figure 38: Effect of MSCs and their conditioned media without serum and with 10% serum 
on UW479 migration. 
UW479 cells suspended in serum-free growth media were seeded into the upper well. Bottom 
wells contained (A) MSCs (RCB2157) and their 1 day and 5 day conditioned serum free 
DMEM media or (B) MSCs (RCB2157) and their conditioned media with 10% serum. After 
48 h, the UW479 cells that migrated to the lower side of the membrane were quantified using 
the MTT assay. Results were expressed as % of control (0% DMEM and 10% DMEM). Bars 
represent mean ± SEM, and the results were from three independent experiments performed 
in triplicate. The data were analysed using one-way ANOVA with Dunnett's post-hoc test. A 
significant difference between individual treatment and control was represented by **** 




When the paediatric glioblastoma cell type SF188 were assessed (Figure 42), in the 
absence of serum, the migration was increased to 251.3 ± 46.3% with 5 day conditioned media 
compared to control. In the presence of 10% serum, the migration of SF188 cells showed a 
non-significant decrease when compared to control (with DMEM 10%). 






















































































Figure 39: Effect of MSCs and their conditioned media without serum and with 10% serum 
on SF188 migration. 
SF188 cells suspended in serum-free growth media were seeded into the upper well. Bottom 
wells contained (A) MSCs (RCB2157) and their 1 day and 5 day conditioned serum free 
DMEM media or (B) MSCs (RCB2157) and their conditioned media with 10% serum. After 
48 h, the SF188 cells that migrated to the lower side of the membrane were quantified using 
the MTT assay. Results were expressed as % of control (0% DMEM and 10% DMEM). Bars 
represent mean ± SEM and the results were from three independent experiments performed in 
triplicate. The data were analysed using one-way ANOVA with Dunnett's post-hoc test. A 
significant difference between individual treatment and control was represented by * P<0.05. 
Among the five different cancer cell lines assesses, all except the HT29 cell line exhibited 
an increase in migration without serum and a decrease in migration in the absence of 10% 
serum. In case of the HT29 cells, a decrease in migration was seen both in the presence and 
absence of serum. Overall, this experiment indicated that the presence of components of serum 
might play a crucial role in the migration of cancer cells or in the generation of conditioned 
media by MSCs, or both.  
Previously, in our lab, 5 day conditioned media containing 10% serum from MSCs were 
analysed using cytokine arrays to identify factors that may cause the decrease in migration of 
the cancer cells. Several factors were identified, including secretion of TIMPs (Clarke et al., 
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2015). To confirm the role of matrix metalloproteinase (MMP) inhibition in cell migration, 
this study now further investigated the migration of some of the cancer cell types in the 
presence of protease inhibitors. 
5.2.2 The effect of protease inhibitors on the migration of cancer cells towards MSCs in 
the absence of serum (RCB2157 cell line) 
In this study, three different types of protease inhibitors were used to examine the effect 
of proteases on the migration of cancer cells towards MSCs in the absence of serum. GM6001 
(Galardin), as discussed earlier in section 3.3.2, is a synthetic polypeptide, therapeutically 
acting as a potent inhibitor of the human skin collagenase. This drug does not show 
cytotoxicity in vivo (Grobelny et al., 1992) and shows specificity for metalloproteases (MMP) 
-1, -2, -3, -8, -9 and -14 (Boghaert et al., 1994; Grobelny et al., 1992; Schultz et al., 1992). 
Chlorhexidine inhibits MMP-2 (gelatinase A), MMP-9 (gelatinase B) and MMP-8 
(collagenase 2) activity (Gendron et al., 1999). Pepstatin A is a potent inhibitor of aspartyl 





Protease inhibitors decreased the migration of MDA-MB-231 cells when compared to the 
control (MDA-MB-231 cells in the upper well and MSCs in the lower well). In MDA-MB-
231 cells, migration decreased to 48.6 ± 2.2% with GM6001, 83.7 ± 11.7% with chlorhexidine 
(statistically non-significant) and 61.8 ± 6.1% with pepstatin A (Figure 43). With the 
combination of these protease inhibitors, the migration of MDA-MB-231 cells did decrease, 
however, the inhibition was not additive. MDA-MB-231 migration was decreased to 45.0 ± 
3.6% with GM6001 and chlorhexidine, 80.0 ± 11.7% with chlorhexidine and pepstatin A 
(statistically non-significant) and 65.4 ± 5.9% with pepstatin A and GM6001. The MMP 


































































































Figure 40: Effect of MSCs on MDA-MB-231 cell migration upon addition of protease 
inhibitors. 
MDA-MB-231 cells were suspended in serum-free growth media and were seeded into the 
upper wells. The bottom wells were seeded with MSCs (RCB2157) in serum-free growth 
media at a density of 5x104 cells/well. The protease inhibitors used here were non-toxic 
concentrations of GM6001 (1 μM), pepstatin A (20 μM) or chlorhexidine (0.1 μM), added to 
both the upper and lower wells. MDA-MB-231 cells that migrated to the lower side of the 
membrane were analysed using the MTT assay after 48 h incubation and the results were 
expressed as % of control (0% DMEM). Bars represent mean ± SEM and results were from 
three independent experiments performed in triplicate and data were analysed using one-way 
ANOVA with Dunnett's post-hoc test. A significant difference between an individual 
treatment and the control was represented by *** P<0.001, ** P<0.01, * P<0.05.  
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Migration was also decreased with the addition of protease inhibitors to the HT29 cells. 
In HT29 cells, migration decreased to 62.2 ± 3.0% with GM6001, 91.3 ± 13.1% with 
chlorhexidine (statistically non-significant) and 64.4 ± 8.1% with pepstatin A (Figure 44). In 
addition, there was a significant decrease in migration of HT29 cells with the combinations of 
these protease inhibitors, but again these were no lower than the single inhibitors. The 
migration was decreased to 70.8 ± 3.2% with GM6001 and chlorhexidine, 66.3 ± 8.1% with 
chlorhexidine and pepstatin A and 64.2 ± 7.2% with pepstatin A and GM6001.The MMP 
inhibitor GM6001 showed the highest decrease in migration when compared to other two 
































































































Figure 41: Effect of MSCs on HT29 cell migration upon addition of protease inhibitors. 
HT29 cells were suspended in serum-free growth media and were seeded into the upper wells. 
The bottom wells were seeded with MSCs (RCB2157) in serum-free growth media at a density 
of 5x104 cells/well. The protease inhibitors used here were non-toxic concentrations of 
GM6001 (1 μM), pepstatin A (20 μM) or chlorhexidine (0.1 μM) added to both the upper and 
lower wells. HT29 cells that migrated to the lower side of the membrane were analysed using 
the MTT assay after 48 h incubation and the results were expressed as % of control (0% 
DMEM). Bars represent mean ± SEM and results were from three independent experiments 
performed in triplicate and data were analysed using one-way ANOVA with Dunnett's post-
hoc test. A significant difference between an individual treatment and the control was 
represented by * P<0.05.  
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In the MDA-MB-231 and HT29 cells, the addition of GM6001 decreased migration by 
inhibiting MMPs (specifically MMP -1, -2, -3, -8, -9, -14). The inhibition of migration was 
greater for GM6001 - treated cells compared to chlorhexidine treatment. As chlorhexidine 
inhibits only MMPs -2, -8 and -9, this suggests that the MMPs 2, -8 and -9 are not as important 
as MMP-1, -3 and -14 in the migration of these cancer cells. The effect of protease cathepsin 
D and its inhibitor pepstatin A were studied in Chapter 3. TIMPs are natural inhibitors of 
MMPs and overexpressing these TIMPs in MSCs may also show similar effects on cancer cell 
migration. This prediction was also supported by our previous laboratory work (Clarke et al., 
2015), where TIMP-1 and TIMP-2 levels in the 5 day conditioned media of MSCs were 
increased by 43.7 and 45.8 fold, and were shown to decrease the migration of cancer cells 
towards MSC conditioned media. Therefore, our further work was focussed on beginning to 
investigate the role of TIMP proteins on cancer cell migration. 
5.2.3 Cancer cell migration in the presence of primary MSCs and primary MSC 
conditioned media 
All of the migration experiments described above was conducted with the MSC line 
RCB2157 (Section 5.2.1 and 5.2.2). This was done, as primary MSCs undergo only 6 passages 
before senescence. Since we wished to assess if TIMP overexpression could be utilized as a 
clinical therapy, the experiments in the later parts of the project were to be undertaken using 
primary MSCs. Therefore, before moving on to look at the TIMPs, we needed to verify that 
primary MSCs and conditioned media from primary MSCs had similar effects on MDA-MD-




It was found that in the absence of serum, the migration of MDA-MB-231 cells increased 
to 150.3 ± 14.6% with the primary MSCs, with no significant change in migration observed 
in the presence of conditioned media (Figure 45 A, compare to Figure 38, with the MSC line). 
In the presence of serum, the migration of MDA-MB-231 cell line decreased, although this 
was non-significant with the primary MSCs and with the 5 day conditioned media (Figure 45 
B compare to Figure 38, with the MSC line). 
























































































Figure 42: Effect of primary MSCs and their conditioned media without serum and with 
10% serum on MDA-MB-231 migration. 
MDA-MB-231 cells suspended in serum-free growth media were seeded into the upper well. 
Bottom wells contained (A) primary MSCs and their 1 day and 5 day conditioned serum free 
DMEM media or (B) primary MSCs and their conditioned media with 10% serum. After 48 
h, the MDA-MB-231 cells that migrated to the lower side of the membrane were quantified 
using the MTT assay and the results were expressed as % of control (0% DMEM and 10% 
DMEM). Bars represent mean ± SEM and the results were from three independent 
experiments performed in triplicate. The data were analysed using one-way ANOVA with 
Dunnett's post-hoc test. A significant difference between individual treatment and control was 




Using the HT29 cells, in the absence of serum, the migration increased to 124.6 ± 3.7% 
with primary MSCs, 110.5 ± 1.1% with 1 day conditioned media and 118.8 ± 1.9% with 5 day 
conditioned media (Figure 46 A, compare to Figure 39, with the MSC line). In the presence 
of serum, no statistical significant difference was noticed with primary MSCs, the 1 day or 
the 5 day conditioned media (Figure 46 B). Therefore, the migratory effects on both MDA-
MB-231 and HT29 cells were similar with primary MSCs and the MSC cell line RCB2157. 





















































































Figure 43: Effect of primary MSCs and their conditioned media without serum and with 
10% serum on HT29 migration. 
HT29 cells suspended in serum-free growth media were seeded into the upper well. Bottom 
wells contained (A) Primary MSCs and their 1 day and 5 day conditioned serum free DMEM 
media or (B) Primary MSCs and their conditioned media with 10% serum. After 48 h, the 
HT29 cells that migrated to the lower side of the membrane were quantified using the MTT 
assay and the results were expressed as % of control (0% DMEM and 10% DMEM). Bars 
represent mean ± SEM and the results were from three independent experiments performed in 
triplicate. The data were analysed using one-way ANOVA with Dunnett's post-hoc test. No 




5.2.4 Construction and expression of TIMP-expressing pLVX-IRES-tdTomato vector 
5.2.4.1 Introduction 
The MMP inhibitor, GM6001 decreased the migration of tumour cells towards MSCs 
(Section 5.2.2). TIMPs, which are the endogenous inhibitors of MMPs (Arpino et al., 2015), 
are thought to elicit similar effects to GM6001. As MSCs home to tumour sites, it was 
proposed that TIMP overexpression in the MSCs might decrease cancer cell migration. To 
investigate the effect of TIMPs on cancer cell migration, MSCs that overexpress TIMP protein 
were generated.  The construction of the TIMP overexpressing cell lines included two parts: 
(1) cloning of a delivery plasmid containing the gene of interest, and (2) the expression of this 
gene in a stable cell line. There are four human TIMPs (TIMP-1, -2, -3, -4) and all the four 
genes of the TIMP family were cloned into the lentivirus pLVX-IRES-tdTomato vector. The 
pLVX-IRES-tdTomato vector allows for the simultaneous expression of the TIMP and 
tdTomato genes when it is transfected into mammalian cells. Secondly, in this study all four 
TIMP genes were overexpressed in MSCs individually. Lentiviral expression was chosen here 
as it has been reported to produce stably expressing stem cells, although they are normally 
difficult to transform (Matrai et al., 2010). In addition, stable transformation and expression 
allows tracking of cells in vivo using fluorescent bio-imagers. Lentiviral expression of pLVX-
IRES-tdTomato in MSCs can be visualised through tdTomato expression which can be 
detected at 581 nm. 
5.2.4.2 Cloning steps 
pLVX-IRES-tdTomato was digested, with both XhoI and NotI restriction enzymes, to 
produce a linear plasmid with sticky ends (Figure 47). Total RNA was isolated from MDA-
MB-231 cells, cDNA was synthesized and PCR was performed to amplify all four TIMP genes 
using gene specific primers containing restriction site overhangs (Figure 48). Synthesised 
TIMP PCR products were digested with the same XhoI and NotI restriction enzymes as for 
the plasmid DNA and the resulting DNAs were gel purified. Ligation of the plasmid DNA 
and TIMP DNA was performed with T4 DNA ligase and the ligated plasmids were 
transformed into the One Shot™ Stbl3™ chemically competent E. coli cell line. Positive 
colonies of E.coli were selected on LB agar plates with ampicillin (100µm/mL) and these 
clones were screened by restriction digestion using XhoI (Figure 49). All selected clones were 
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assessed and those containing the TIMP gene inserts were grown in LB media (with ampicillin 
(100µm/mL)).  
To further confirm the presence of the TIMP insert, TIMP plasmids were isolated from 
the cultures, and restriction digestion was performed. The digested mixture was run on a 1% 
agarose gel to visualise the TIMP DNA dropout fragment from the plasmid (Figure 50). 
Positive plasmids which contained the TIMP inserts were sequenced to further confirm the 





















The pLVX-IRES-tdTomato vector was digested with XhoI and NotI restriction digestion 
enzymes to produce a linear plasmid with sticky ends (top left). cDNA was synthesised from 
the total RNA isolated from MDA-MB-231 cells. PCR products for all the TIMP genes were 
amplified using gene specific primers that contain restriction site overhangs. The PCR 
products were digested with XhoI and NotI restriction endonucleases to produce sticky ends 
(top right). The digested plasmid and PCR products were ligated together with T4 DNA ligase 
(centre). The plasmids with the TIMP gene were screened and then transformed into E.coli, 
multiplied, isolated and the plasmids were sent for sequencing.  
Restriction 
digestion with 










XhoI and NotI 
DNA Ligase 
Transformation 
into E.coli stbl3 
cells 






















(A) 1% Agarose gel representing the vector pLVX-IRES tdTomato digested with XhoI and 
NotI to be used as a cloning backbone as seen with the help of 10Kbp plus marker (B) Vector 
diagrammatically showing the digestion with XhoI and NotI at the multiple cloning site. 
  
 1      2      3       4 
10kbp 
Lane 1: Digested pLVX-IRES tdTomato 
with NotI 
Lane 2: Digested pLVX-IRES tdTomato 
with XhoI 
Lane 3: Digested pLVX-IRES tdTomato 
with NotI and XhoI 
Lane 4: Undigested pLVX-IRES tdTomato 
 






















Total RNA was isolated from MDA-MB-231 cells and converted to cDNA. This cDNA was 
used as the template and TIMPs were amplified by PCR and run on a 1% agarose gel with 
ethidium bromide staining. The amplified products were of the expected size as seen in gel 
electrophoresis using a 1Kbp plus marker. TIMP-1 (A), TIMP-2 (B), TIMP-3 (C) and TIMP-
4 (D) PCR products were excised from the gel under UV light using a scalpel and were 




    1          2 
Lane 1, 2: TIMP-1 (624 bp) 






 1       2       3 
Lane 1, 2, 3: TIMP-4 (675 bp) 
PCR product amplified from 
cDNA 
 




Lane 1, 2, 3: TIMP-2 (663 bp) 
PCR product amplified from 
cDNA 
 




Lane 1, 2, 3: TIMP-3 (636 bp) 
PCR product amplified from 
cDNA 
 






















Ligated pLVX-IRES-tdTomato and TIMP genes were transformed into E.coli Stbl3 
competent cells and the transformed colonies were selected using ampicillin (100µm/mL) 
before screening by XhoI digestion. TIMP-1 (A), TIMP-2 (B), TIMP-3 and TIMP-4 (C) 
positive colonies (represented by white arrows) were isolated and designated as pLVX-IRES-
tdTomato-TIMPs.  
10 kbp 
14   13    12   11   10    9     8     7      6      5      4      3    2      1 
XhoI colony digestion 
Lane 1, 2: Vector only control 
Lane 3, 4, 5, 6, 7, 8: TIMP-3 colonies 
Lane 9, 10, 11, 12, 13, 14: TIMP-4 colonies 
White arrows: Selected TIMP-3, -4 colonies 
 
Figure 47: Positive colony screening by restriction enzyme analysis of single colonies. 
10 kbp 
 6     5    4     3     2    1 
XhoI colony digestion 
Lane 1, 2: Vector only control 
Lane 3, 4, 5, 6: TIMP-1 colonies 
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XhoI colony digestion 
Lane 1, 2: Vector only control 
Lane 3, 4, 5, 6: TIMP-2 colonies 
























The positive colonies were grown in LB media with ampicillin (100µm/mL) and plasmids 
were isolated. Double digestion was performed and the TIMP DNA dropout fragment was 
verified as the right size. The plasmid DNA positive for TIMPs (TIMP-1 (A), TIMP-2 (B), 
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Figure 48: Screening of pLVX-IRES-tdTomato-TIMP plasmids by restriction digestion. 
Lane 1: Control digested plasmid with XhoI and 
Not I 
Lane 2: TIMP-1 plasmid digested with XhoI and 
NotI 
Lane 3: TIMP-I plasmid digested with XhoI 
Lane 4: TIMP-1 plasmid digested with NotI 
White arrow: TIMP-1 DNA after digestion with 
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Lane 1, 2, 3: TIMP-2 plasmid digested with 
NotI 
Lane 4, 5, 6: TIMP-2 plasmid digested with 
NotI and XhoI 
White arrows: TIMP-2 DNA after digestion 
with XhoI and NotI 
 




Lane 1: Control digested plasmid with XhoI 
and Not I 
Lane 2, 3, 4, 5: TIMP-3 plasmid digested 
with NotI 
Lane 6, 7, 8, 9: TIMP-3 plasmid digested 
with NotI and XhoI 
White arrows: TIMP-3 DNA after digestion 
with XhoI and NotI 
 
Lane 1: Control digested plasmid with XhoI 
and Not I 
Lane 2, 3, 4: TIMP-4 plasmid digested with 
NotI 
Lane 5, 6, 7: TIMP-4 plasmid digested with 
XhoI and NotI 
White arrow: TIMP-4 DNA after digestion 
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5.2.4.3 Primary MSCs overexpressing TIMPs 
Using the cloned TIMP plasmids, lentivirus was produced using vesicular stomatitis virus 
glycoproteins (VSV-G) pseudotyped lentivirus precursors by Dr Stephanie Hughes and Ms 
Holly Walker, Department of Biochemistry, University of Otago. The virus titre value was 
determined using the qPCR technique for gag viral gene expression allowing the calculation 
of the genomic multiplicity of infection. To standardise the MOI value for MSCs, they were 
transduced with tdTomato expressing lentivirus at three different genomic MOI (100, 500 and 
1000). Maximum infection was noticed with MOI 1000 (Figure 52) which was up to 80% 












The primary MSCs were transduced with lentivirus and the presence of the pLVX-IRES-
tdTomato was confirmed by the expression of the red fluorescent protein, tdTomato. 
Transduction was performed with three different genomic MOI, showing the highest level of 
transduction at MOI 1000. Images were taken at 4x magnification with a Nikon Eclipse Ti 
inverted microscope (Olympus) using a Digital DS-U3 camera, after 48 h of transduction, 
Bright field (left), Red Fluorescence (centre), Merged (right). Merged images of MSCs with 
tdTomato positive cells indicate the tdTomato protein was localised in the cells. Bar represents 
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Figure 50: Graphical representation of transduction efficiency in MSCs. 
MSCs were plated at a density of 5000 cells/well in a 96-well plate 24 h before transduction. 
MSCs were transduced with the pLVX-IRES-tdTomato using transducing reagent Polybrene 
at 5 μg/ml. Transductions were performed with three different genomic MOI, showing the 
highest level of transduction at MOI 1000. Images were taken with a Nikon Eclipse Ti inverted 
microscope (Olympus) using a Digital DS-U3 camera and the number of cells transduced was 
calculated using ImageJ software. Bars represent the mean ± SEM and the results were from 
an experiment performed in triplicate. 
MSCs were transduced with the lentivirus containing tdTomato only, tdTomato TIMP-1, 
tdTomato TIMP-2, tdTomato TIMP-3 or tdTomato TIMP-4 with 1000, 418, 500, 20 or 344 
MOI, respectively (Figure 54). These values were the highest possible titres with each virus 
strain. MSCs that were transduced therefore had an uneven transduction efficiency, and were 
sorted using FACS. After sorting of cells by FACS, the MSCs were found to be contaminated 
(See section 5.4.3 for further discussion), and further characterisation of the effects of 



















The primary MSCs were transduced with the lentiviruses expressing TIMPs and tdTomato as 
determined by the expression of red fluorescent protein (tdTomato). Images were taken at 4x 
magnification with a Nikon Eclipse Ti inverted microscope (Olympus) using a Digital DS-U3 
camera, after 48 h of transduction. Bright field (left), Red Fluorescence (centre), Merged 
(right). Merged images of MSCs with tdTomato positive cells indicate that expression was 
localised in the cells. Bar represents 500 µm.  











MSCs are actively recruited to sites of injury such as inflammation, tissue repair and 
tumours in response to mediators such as cytokines, chemokines, antimicrobial proteins or 
apoptotic proteins (Bissell et al., 2001; Dimarino et al., 2013; Hall et al., 2007a). After homing 
to the tumour stromal area, MSCs can act in a pro-tumourigenic or anti-tumourigenic way by 
providing cytokine and chemokine crosstalk which alters the extracellular matrix and 
behaviour of the neighbouring cells including the tumour cells (Hu & Polyak, 2008).  
In this study, we modelled the potential effects of MSCs after becoming part of the tumour 
stroma, which might affect cancer cell migration, as a part of the metastatic process. A co-
culture Boyden chamber setup was used with cancer cells and MSCs or MSC conditioned 
media, to demonstrate that MSCs secrete proteins which change cancer cell migration. Both 
the MSC cell line RCB2157 (Section 5.2.1) and primary MSCs (Section 5.2.3) showed similar 
trends in migration. The molecules having this effect on cancer cell migration were explored 
by the addition of protease inhibitors including GM6001, chlorhexidine and pepstatin A to the 
co-culture setup (Figure 43 and 44).  
It has been previously reported in our laboratory that the TIMPs, TIMP-1 and TIMP-2, 
were secreted in MSC conditioned media with 43.7 and 45.8 fold increases, respectively, 
compared to non-conditioned media (Clarke et al., 2015). GM6001 used in this study, a MMP 
inhibitor which showed the decrease in migration of MDA-MB-231 and HT29 cancer cells 
support our lab previous results. Thus, the overexpression of TIMPs in MSCs was thought to 
be effective therapeutically, as a long-term goal, similar to GM6001, in decreasing the 
migration of cancer cells. 
TIMP genes were cloned into the pLVX-IRES-tdTomato vector (Figure 47), which was 
confirmed by sequencing. These TIMP genes were overexpressed in MSCs by lentiviral 
transduction (Figure 54) and the non-transduced MSCs were removed by FACS sorting. The 
cells were re-cultured in flasks, which were then found to be contaminated after two days and 




5.4.1 MSCs inhibit the migration of cancer cells, but only in the presence of serum 
The tumour microenvironment contains many cell types including endothelial cells, 
myofibroblasts, inflammatory cells and MSCs (Bhowmick et al., 2005). These cells provide 
chemokine and cytokine crosstalk which alters the behaviour of nearby cells, including tumour 
cells (Hu & Polyak, 2008). The mediators secreted by these cells are considered to be often 
pro-tumourigenic, supporting tumour initiation, growth and progression, including metastasis. 
The contribution of these tumour stromal cells and their role in cancer development is not 
fully understood, as the interactions are complex (Pietras et al., 2010). 
MSCs are recruited into tumour stroma from the bone marrow after which they 
differentiate into cells including myofibroblasts (Bergfeld et al., 2010). Within tumours, some 
studies describe MSCs as possessing pro-tumourigenic and pro-metastatic roles (Karnoub et 
al., 2007; Xiaoya et al., 2014). However, there are also studies that describe MSCs as 
possessing anti-tumourigenic roles, such as when MSCs were co-injected in animals together 
with tumour cells (Khakoo et al., 2006; Sun et al., 2009). Also, some of the studies have 
investigated the anti-carcinogenic capabilities of MSCs on tumour development, with the 
focus mainly centred on MSC ability to influence apoptotic pathways; while little is known 
about the inhibitory effects of MSCs on cancer cell migration (Bergfeld et al., 2010). In our 
previous studies, the role of MSCs (as a part of tumour stroma) was evaluated in vitro using 
co-culture with MDA-MB-231 and MCF-7 breast cancer cell lines. It was determined that 
TIMP-1 and TIMP-2 accumulate in the conditioned media of the MSCs, as measured by 
cytokine array, leading to the inhibition of migration and invasion of the cancer cells (Clarke 
et al., 2015). The present study is a continuation of this previous work. 
Here, we aimed to investigate how MSCs overexpressing TIMPs, as a part of tumour 
stroma (or co-culture, in this study), affect the migration and invasion of tumour cells. To this 
end, migration assays were conducted with the MSC cell line (RCB2157) using a co-culture 
Boyden chamber set up with various cancer cell lines that are highly metastatic and invasive 
such as breast cancer MDA-MB-231 cells (Figure 38), colon cancer HT29 cells (Figure 39) 
and glioblastoma cells KNS42 (Figure 40), UW479 (Figure 41) and SF188 (Figure 42). 
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In the presence of serum containing media, all the five cell lines showed a decrease in 
migration when co-cultured with MSCs, while in contrast, in the absence of serum an increase 
was found in all cell lines, except in the HT29 cell line (Figure 39). The change in serum 
content may cause a change in the protein secretion, due to differing levels of nutrition in the 
serum in the MSC media (Yurube et al., 2019). Thus, serum concentration may play a key 
role in the secretion of proteins which in turn may play a role in the cancer cell migration. 
The migration of cancer cells with 1 day and 5 day MSC conditioned media decreased in 
the presence of serum and increased in the absence of serum. This may be due to a difference 
in the serum gradient, nutritional content and protein secretion that would have been 
developed in the conditioned media with and without serum. Conditioned media has primary 
importance in protein secretion analysis which showed greater and surprising differences in 
gene expression pattern of the cells and protein content human MSCs with and without serum 
(Clabaut et al., 2015). The secreted proteins that may be influenced by the serum content in 
the conditioned media involve extracellular matrix proteins, proteinases, growth factors, 
protein hormones, immunoregulatory chemokines, cytokines or other bioactive molecules that 
might influence the cell migration (Skalnikova et al., 2011). This pattern also may vary across 
the different co-cultured cell lines due to the individual properties of the cell lines.  
Proteins involved in tumour cell aggressiveness secreted by MSCs, such as tenascin-c 
and thrombospondin-1 (Hayashido et al., 2003), ECM remodelling proteins including various 
growth factors and MMPs (Roy et al., 2009), and mediators such as chemokines (CCL5) and 
cytokines (Coffelt et al., 2009) are known to help promote the migratory capacity of cancer 
cells. In contrast to this, MSCs may also secrete the proteins such as TIMP-1 and TIMP-2 that 
inhibit the cancer cell migration (Clarke et al., 2015). 
The degree of the migration potential seems to be dependent upon the individual 
characteristics of the cancer cell lines. Cell characteristics such as cell size, shape, 
clonogenicity, gene expression profile, rates of collagen composition when present in 
dimensional cell sheets, cell rearrangement time (process time), contact with the surrounding 
cells and so on play a role in cell migration (Hsieh et al., 2018; Pajic-Lijakovic et al., 2019). 
For example, the migration potential of the metastatic MDA-MB-231 cells has been shown to 
be higher than HCT-116 colon cancer cells (Wu et al., 2011; Zivanovic et al., 2017). A time-
lapse microscopic observation for 30 h of cell invasion into collagen gel across four different 
cell lines revealed differences in the individual behaviour of cancer cells, where the migration 
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and invasion of MDA-MB-231 cells are higher compared to MCF-7, LS180 and HT29 cancer 
cells (Sakai et al., 2011). In addition, SF188 and KNS42 had different migration rates and 
patterns when these tumour spheroids were embedded in collagen (Cockle et al., 2015). 
5.4.2 Migration of cancer cells with the addition of protease inhibitors 
The role of proteases in cancer cell migration was analysed by the addition of protease 
inhibitors (Figure 43 and 44). The activity of proteases was inhibited with the use of three 
different protease inhibitors with GM6001, which inhibits MMP -1,-2,-3,-8,-9 and -14 
(Boghaert et al., 1994), showing the highest inhibition (Figure 43 and 44), which correlated 
with our previous results (Clarke et al., 2015). 
The role of MMPs in cancer cell migration and invasion was previously shown in various 
studies. Specifically, MMP-1 was found to be involved in the gastric cancer cell invasion in 
association with HER2 overexpression. Knockdown of HER2 by shRNA resulted in a 
downregulation of MMP-1, which inhibited gastric cancer cell invasion to 60% when 
compared to control transfected cells (Bao et al., 2010). MMP-1 upregulation by RANK 
ligand significantly stimulated breast MDA-MB-231 and prostate cancer PC-3 cell migration 
and invasion (Casimiro et al., 2013). 
Downregulation of MMP-2 and MMP-9 expression by flavonoid naringin (40μM) 
decreased the U251 glioma cell migration by 72% and invasion by 84% (Aroui et al., 2016). 
This was also shown in another study with the prostacyclin analogue, iloprost. Iloprost, similar 
to naringin downregulated MMP-2 and MMP-9 expression, inhibiting migration and invasion 
of ovarian cancer cells A2780 and SKOV3 in a dose-dependent manner (Ahn et al., 2018). 
Endogenous compounds also play a role in the expression of MMPs. For example, 
neurotensin distributed throughout the brain and gastrointestinal tract was found to promote 
the cell migration and invasion of gastric cancer cells MKN-1 and MKN-45 significantly when 
compared to normal epithelial cells HFE-145 by enhancing the secretion of MMP-9 (Akter et 
al., 2015). Mesothelin, originally found in mesothelial cells, enhanced the invasion of ovarian 
cancer WF-0 cells by about 8-fold (865 ± 124%) by enhancing expression of MMP-7 (Chang 
et al., 2012). Heterogeneous nucleus ribonucleoprotein K induced MMP-12, which further 
increased the migration and invasion of nasopharyngeal carcinoma TW02 and HK1 cells in a 
dose-dependent manner (Chung et al., 2014). 
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Thus, as shown in these and many other studies, MMPs play a significant role in the 
migration of cancer cells, and it is proposed that this could be neutralised by the secretion of 
TIMPs by MSCs. To further investigate the role of TIMPs and to elucidate the use of TIMPs 
in cancer cell migration and invasion, therapeutically as a long term goal, we overexpressed 
all the four TIMPs individually in MSCs by lentiviral expression. 
5.4.3 MSCs overexpressing TIMPs 
Various studies have attempted to use synthetic MMP inhibitors that target different 
stages of cancer for the treatment of a variety of cancers. PCK3145 (Annabi et al., 2005), 
Dalteparin (Roy et al., 2009), Marimastat (Sparano et al., 2004) and Batimastat (Lein et al., 
2000) are few examples that entered clinical trials; however, they were not successful due to 
the toxic side effects as they were not site specific. This proved that site specific delivery of 
MMP inhibitors are needed for prevention of cancer metastasis. Thus, MSCs were thought to 
be the potential candidates for the TIMPs delivery at the tumour sites due to their tumour 
tropic property (De Becker et al., 2016). The overexpressed TIMPs have been chosen since 
they inhibit growth and infiltration of the tumours. This kind of treatment would halt further 
development and movement of those cells and result in their death (Bloomston et al., 2002; 
Li et al., 2001). 
In our work, the MSCs overexpressed TIMPs (Figure 54), but the cells were contaminated 
after sorting by FACS. There could be several reasons for this contamination. One of them 
could be the use of antibiotic-free media. Since the lentiviral transduction was undertaken in 
antibiotic free media, there was a chance of contamination. FACS was performed to sort the 
cells and although this was done in a sterile hood, there is a chance of contamination. This 
could be due to resistant strains of bacteria or the cleanliness of the hood and FACS machine. 
This study could not be repeated. 
Ideally we would have performed migration, invasion, proliferation and angiogenesis 
assays with all the four different TIMP-expressing MSCs individually. The TIMP or TIMPs 
which best inhibited the migration, invasion, proliferation or angiogenesis promotion by 
cancer cells would have been tested for mechanism of action. Further, the TIMP 
overexpressing MSCs which worked best against cancer cells could have been used for the 
treatment of a xenograft in a mouse model using IV injection. 
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This study so far, demonstrated that MSCs (both the cell line RCB2157 and primary cells) 
enhanced the migration of cancer cells in the absence of serum, while decreasing migration in 
the presence of serum. Further, the use of MMP inhibitor GM6001 decreased the migration 
of cancer cells indicating that the MMP inhibitors play a major role in the migration of cancer 
cells. TIMPs could therefore be effective targets to reduce tumour growth and metastasis, and 

















The number of potential therapeutic applications of MSCs has increased with the 
advances in knowledge of their multiple biological roles (Berebichez-Fridman et al., 2018; 
Uccelli et al., 2008). MSCs are well characterised and defined by the International Society for 
Cellular Therapy (Dominici et al., 2006). These defined guidelines make them easy to isolate 
(Beyer Nardi et al., 2006). They can be isolated from several sources such as bone marrow, 
adipose tissue, peripheral blood, synovial membrane and fluid, umbilical cord, dental pulp, 
endometrium muscle, skin, amniotic fluid and placenta making them relatively abundantly 
available (Barry et al., 2004; Berebichez-Fridman et al., 2018). Currently, MSCs are being 
explored clinically for various conditions including cancer, bone injuries, graft versus host 
diseases, cardiovascular diseases, autoimmune diseases, liver diseases, inflammatory bowel 
diseases, nerve injuries or neuronal degenerative diseases, skeletal and muscle injuries, lung 
injuries and cosmetic and dermatological applications  (Berebichez-Fridman et al., 2018). The 
suitability of MSCs for clinical applications, including cancer therapy is predicated on several 
distinct properties such as non-immunogenicity, tumour-tropism, stimulatory effect on anti-
inflammatory molecules and inhibitory effect on the inflammatory response (Cheng et al., 
2019). The characteristics of MSCs that make them clinically ideal for the treatment of cancer 
include proliferation without loss of biological properties, non-toxicity against healthy tissues, 
their potential for delivery and minimal ethical issues when compared to other stem cells 
(Kwon et al., 2018). 
Cancer is the leading cause of death in New Zealand in both males and females (Ministry 
of Health, 2017). The most common treatment regimens include surgery (where remnant cells 
might develop into tumours), chemotherapy (which targets dividing cells), and radiation 
(where neighbouring cells may develop into cancer). These non-selective therapies are often 
not sufficient to cure cancer. More site-specific therapeutic targets, which reduce the drug-
induced and radiation-induced stress and side effects, are essential for the improvement of 
patient’s quality of life and treatment outcome (Nicolson et al., 2008; Vanneman et al., 2012). 
To develop site-specific targets, understanding the stages of cancer development is essential. 
The three main stages of tumour development are initiation, promotion and progression (Park 
et al., 2000; Yang, Yu, et al., 2015). The studies described in this work considered the 
applications of MSCs for targeting cancer via three different approaches, each focusing on a 
different stage of tumour development.  
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 The first stage of tumour development is tumour initiation (Park et al., 2000). Tumour 
initiation occurs when a cell acquires the properties of sustained proliferative signalling and 
can escape growth suppressors (Hanahan et al., 2011). This might occur due to multiple 
genetic mutations in oncogenes and tumour suppressor genes (Yang, Yu, et al., 2015). One 
such gene mutation occurs in the transcription factor FOXL2, leading to adult type ovarian 
GCT (Shah et al., 2009), investigated in Chapter 4. The role of the wild-type FOXL2 in adult 
type ovarian GCT drug susceptibility to cisplatin and etoposide was evaluated in vitro. As 
previously described, MSCs have potential to deliver genes or proteins to the tumour sites due 
to their tumour tropic property (De Becker et al., 2016; Hall et al., 2007b; Marofi et al., 2017). 
In this study, they were considered as a way to deliver the wild-type FOXL2 gene to adult 
type GCTs in patients. Clinically this is possible if the MSCs are viable while delivering the 
wild-type FOXL2 gene while the patient is undergoing treatment with cisplatin and etoposide. 
Thus, in Chapter 4 the potency of MSCs for cisplatin and etoposide were determined and 
found to be more than 10 times higher than KGN cells. 
 The second stage of tumour development is its growth sustained by neighbouring cells 
in the tumour microenvironment (formed by various cells including MSCs) (Brenner et al., 
2016). MSCs are an important component of tumour stroma and have multiple roles in the 
tumour microenvironment (Lorusso et al., 2008). To investigate this stage of tumour 
development, the role of the protease, cath D in the migration of MSCs to the tumour 
microenvironment was analysed (Chapter 3). The results of migration assays outlined in 
Chapter 3 demonstrated the chemoattractive properties of cath D for MSCs. This suggests one 
of the mechanisms of crosstalk between cancer cells (MDA-MB-231 and HT29) and MSCs 
(RCB2157 cell line) could be due to the release of cath D by cancer cells, which induce MSCs 
to migrate to the tumour sites. The enzymatic activity of cath D on ECM remodelling and 
degradation of chemokines and cytokines was found to be interesting in attracting the MSCs 
to cancer cells. The high levels of cath D in various cancers may also correlate with the activity 
of cath D in MSC tropism. 
 The last stage of cancer is metastasis. To investigate this, overexpression in MSCs with 
TIMPs, was attempted, to reduce paediatric glioblastoma infiltration. Metastasis is a process 
in which the tumour cells migrate from the primary tumour site to a secondary tumour site 
and establish tumours in other tissues (Liotta et al., 1991), which often makes the disease 
incurable. However, understanding the pathways involved in metastasis is crucial to prevent 
and target tumour metastasis. One of the mechanisms by which metastasis might occur is the 
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disturbance in the net balance of MMPs and TIMPs. MMPs are often found to be upregulated 
in cancer, which favours metastasis through ECM remodelling and loss of cell to cell adhesion 
(Gialeli et al., 2011). TIMPs, on the other hand, are endogenous MMP inhibitors, which may 
be able to act as metastatic cancer inhibition (Cruz-Munoz et al., 2008). Previous published 
results from our laboratory demonstrated that MSCs and their conditioned media inhibited the 
migration of breast cancer cells by the secretion of TIMP-1 and TIMP-2 (Clarke et al., 2015). 
Thus, in Chapter 5 the thesis focussed on exploring the possibility of using TIMPs as therapy 
for highly metastatic paediatric glioblastoma. 
 MOUSE PILOT STUDIES 
Pilot studies were conducted to develop animal tumour models and conduct preclinical 
studies as an extension to the in vitro work in Chapters 4 and 5. KGN cells, the only cell line 
that contains a mutation in the FOXL2 gene, was chosen as the model for adult type ovarian 
granulosa cell tumours. KNS42 and UW479 paediatric cancer cells, which showed an 
increased tendency to migrate when compared to other cancer cells such as MDA-MB-231, 
HT29 and SF188 cells (used in Chapter 5), were chosen to conduct paediatric glioblastoma 
mouse pilot studies.  
A literature search was performed to obtain information about the number of cells to be 
injected; however, there were no published mouse models that used the UW479 cell line. One 
study was found that used the KNS42 cell line, in which 2x107 KNS42 cells were suspended 
in 200 µl of growth medium and injected subcutaneously to the flank of five week old male 
CB-17 mice with a tumour mass identified in mice in about 1-2 months (Sawa et al., 1996). 
Using this as a reference, we started with the same number of cells for both UW479 and 
KNS42 cell lines. We injected 5x107 KGN cells suspended in either 200 µL of Matrigel or 
growth medium subcutaneously (6 mice), or intraperitoneally to induce an orthotopic model 
(6 mice) in female NOD SCID mice. 
The scaffold provided by Matrigel accelerates tumour growth by sustaining the 
interaction between the injected tumour cells and the surrounding environment in mice 
(Fridman et al., 2012). Unfortunately, palpable tumour growth was not observed even 3 
months after injection. However, extra tissue was found around the heart in three animals out 
of twenty, while collecting the organs. This extra tissue was predicted to be a spontaneous 
lymphoma, as the tissue stained positively for the mouse thymus tissues marker THY-1. It 
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appears that the observation of spontaneous lymphoma are rare overall, but more common in 
NOD SCID mice, as it has been previously found in other studies (Kato et al., 2009; Prochazka 
et al., 1992; Yasuda et al., 2017). 
Studies have been conducted to determine the origin of spontaneous lymphomas in NOD 
SCID mice. For example, the incidence of malignant lymphomas and immunoglobulin (Ig) 
leakiness was tested in 2,184 NOG mice (generated by combining interleukin-2 receptor-γ 
chain knockout mice and NOD/Shi-SCID mice) aged 16–40 weeks, which exhibited an 
incidence of thymic lymphomas of 0.60% (13/2,184). Most of the lymphomas (10/13) 
occurred in female mice by the age of around 25 weeks. All lymphomas were derived from 
the thymus and consisted mainly of CD3-positive and CD45R-negative lymphoblastic-like 
cells (Yasuda et al., 2017). Spontaneous lymphomas that occur in laboratory animal mutants 
deficient in T and B cells are not uncommon (Monticello et al., 1994). 
The extra tissues found around the heart could be spontaneous lymphomas and may be 
caused by an immune response in NOD SCID mice. There could be an immune response 
originated from the tissue near the heart (which could be thymus) against the injected cancer 
cells and this could be a reason why there were no xenografts formed in our NOD SCID mice. 
Except one animal study conducted  in GCTs (Sawa et al., 1996), unfortunately, there are no 
published studies that report the use of these cell lines (KGN, UW479, KNS42) to interpret 
our results directly.  
However, in another study, a monoclonal antibody specific for the human analogue of the 
murine T-cell activation molecule 4-1BB was generated and was shown to react selectively 
with activated human CD4+ and CD8+ T lymphocytes. The molecule 4-1BB played a 
significant role in generating tumour immunity and blocked the murine originating 
lymphocyte-mediated suppression of tumour xenografts in SCID mice (Sabel et al., 2000). 
This immune response against the cancer cells may explain why tumours did not form in our 
experiments. Further, the low tumourigenicity of the injected tumour cells may also account 
for the non-development of xenografts. 
 CLINICAL APPLICATIONS OF MSCS IN CANCER  
The number of Investigational New Drug (IND)/Biologic License Application (BLA) 
submissions to the FDA and registered clinical trials for MSC-based products has increased 
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exponentially in the past decade (Olsen et al., 2018). According to the clinical trials database 
(ClinicalTrial.gov, 2019), there were 972 studies registered for the treatment of a wide range 
of diseases using MSCs as of 20th July 2019. Some of these clinical trials use MSCs as 
therapeutic agents for diseases including muscular dystrophy, bone defects, myocardial 
infarction, liver disease, diabetes mellitus type I and II, spinal cord injuries, Parkinson’s 
disease and cancer (Figure 55). 
 
Figure 52: MSC clinical trials by disease classification (ClinicalTrial.gov) (n=972) 
Number of cancer studies registered were found to be 47. 
These trials show that there is considerable interest in exploiting the tumour homing 
potential of MSCs to develop them as vehicles for targeted delivery to tumour tissue. Their 
inherent tumour tropic and drug resistant properties make them ideal carriers, attracting the 
attention of cancer researchers (Pessina et al., 2011). Of the 972 studies registered, 47 
registrations were for cancer treatment using MSCs till July 2019. Among them, three quarters 
of the studies were using MSCs as a regenerative therapy for patients recovering from 
chemotherapy. A few studies were evaluating the use of MSCs loaded with enzymes for 
prodrug therapy, some were using MSCs loaded directly with drugs in nanoparticles and 
others were using genetically modified MSCs delivering proteins. Other studies were the 


































Genetically engineered MSCs have been successfully used in preclinical studies to 
express therapeutic peptides and proteins for the treatment of both localised and metastatic 
tumours (Hall et al., 2007b; Marofi et al., 2017). The notable studies using modified MSCs in 
clinical trials include: MSCs secreting interferon beta (IFNβ) for the treatment of ovarian 
cancer which is in a phase I clinical trial (NCT02530047), MSCs expressing TRAIL for 
treatment of lung adenocarcinoma which is in a phase I/II clinical trial (NCT03298763) and 
MSCs infected with oncolytic adenovirus ICOVIR5 (known as celyvir) for the treatment of 
metastatic and refractory solid tumours, which is in a phase I trial (NCT01844661) 
(ClinicalTrial.gov, 2019).  
The increase in the number of investigations using MSCs for cancer treatment in the past 
decade shows that there will be many more products entering phase I trials in near future. 
Overall, the study in this thesis explored one of the mechanisms of action by which MSCs 
migrated to the tumour sites and investigated the idea of using genetically modified MSCs as 
potential therapeutic agents for protein delivery to tumours. 
 LIMITATIONS OF THE USE OF MESENCHYMAL STEM CELLS 
IN CLINIC 
In spite of potential for employing MSCs as cancer therapies, there are some limitations 
to the approach which are yet to be resolved. MSCs harvested from different tissues such as 
bone marrow, adipose tissue, placenta and umbilical cord share similar features such as 
morphology and cell surface markers, but may exhibit differences in other biological 
properties such as differentiation capabilities (Xu et al., 2017). More knowledge of stem cell 
differentiation is required, to avoid the inconsistency of differentiation abilities of MSCs 
based on the tissue of origin (Confalonieri et al., 2018).  
MSC ageing or senescence in which the proliferation rate progressively decreases until 
growth arrest may occur during in vitro expansion (Bonab et al., 2006; Shibata et al., 2007). 
This is due to the level of telomerase activity. The growth rate and senescence of MSCs have 
not been determined for MSCs in clinical settings (Kim et al., 2015), although this has 
significant implications for efficacy of treatment.  
Another potential limitation is safety. Although there is enough evidence of safety and 
efficacy of MSCs in preclinical studies, the safety and efficacy while expanding in humans 
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are still incompletely explored (Martin et al., 2016). Also, mounting evidence suggests that 
MSCs acquire cytogenetic alterations in culture both in autosomes and in sex chromosomes, 
which might be transient or stable (Meng et al., 2015; Redaelli et al., 2012; Roselli et al., 
2013; Wang et al., 2013). The lack of understanding of the in vivo fate and the dose 
relationship in humans also makes the use of MSCs challenging in clinical settings. Thus, it 
is essential to have more standardised procedures and quality control to ensure the properties 
of MSCs being used. The above mentioned limitations need to be considered before MSCs 
can be used clinically. 
 CHALLENGES FOR THE USE OF MESENCHYMAL STEM CELLS 
IN THE CLINIC 
Governing bodies such as the Food and Drug Administration (FDA) and the International 
Society for Stem Cell Research (ISSCR) have issued several guidelines for the use of stem 
cells. FDA guidelines for cells and gene therapies were to ensure that the products confirm 
desired standards for safe and effective for their use (Bailey et al., 2015; Center for Biologics 
Evaluation and Research, 1998). ISSCR has published “The ISSCR guidelines for clinical 
translation of stem cells” for promoting transparency, medical innovation, patient protection 
and maintenance of high standards of cell therapy (Hyun et al., 2008). These guidelines cover 
the issues such as licenses, consents, product manufacturing and testing, characterisation of 
products, comparability of product (Bailey et al., 2015). 
Despite the guidelines, there are some challenges to be considered for the clinical 
translation of MSCs. Some of the challenges include effective pharmacokinetic and 
pharmacodynamics profiling of MSCs such as dosage, route of administration, differentiation 
status, and survival rate of MSCs after administration, none of which are clear/known. There 
is also a need to develop effective analytic methods to track these cells into the human body 
after injection in order to solve this issue. 
Additionally, standardised good manufacturing practices (cGMP) need to be established 
for the production of MSCs. Various cell culture factors such as fetal bovine serum (FBS) 
concentration, oxygen content, growth factors and supplements such as amino acids vary 
widely, leading to the significant variation in the properties of MSCs between the 
manufacturers (Mendicino et al., 2014). For example, one of the factors, serum (FBS) 
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concentration was tried in chapter 5 of the thesis. The effect of serum on migration of cancer 
cells to MSCs was tested which showed opposite effects with and without serum. This 
confirms that the above mentioned factors has a major role on the MSCs. 
As mentioned previously in the section 1.2.3, the molecular mechanisms and pathways 
that are associated with the anti-tumourigenic and pro-tumourigenic roles are mostly unclear. 
This contradiction in the role of MSCs has to be made more apparent to enable effective 
clinical translation of MSC based therapies for targeting cancer. 
 FUTURE DIRECTIONS 
6.5.1 Cath D protease 
The approach used to knockdown cath D was through siRNA, other knockdown 
techniques such as ZFNs and TALENs or knockout techniques such as CRISPR/Cas9 could 
be used in order to get more significant knockdown. Stable cell lines expressing cath D could 
also be established to explore more accurately the role of cath D on MSC migration and 
invasion. Further investigations into the mechanisms involving upstream and downstream 
signalling pathways by which cath D is playing a role in attracting the MSCs to migrate could 
be performed. Since it is known that pH conditions influence the activity of the protein cath 
D (Laurent-Matha et al., 2005; Maynadier et al., 2013), more experiments with a wide range 
of pH conditions of the media could be performed. Depending on the results of the preliminary 
data, the role of the protein in attracting the MSCs could be explored further using preclinical 
mouse studies. This can be done by cath D gene knockout in the mice and know the effect 
with and without the protein. MSCs that are attracted to the tumour site can be identified at 
the tumour site with the help of MSC markers. 
6.5.2 Wild-type FOXL2 protein and its clinical applications 
Lentiviral transduction was chosen to overexpress the FOXL2 protein in KGN cells as it 
allows for persistent overexpression lasting for several weeks to a number of months (Escors 
et al., 2010). Wild-type FOXL2 was overexpressed in KGN cells and the mRNA 
overexpression was quantified to be approximately 5 fold higher in transduced cells compared 
to controls. The IC50 values for drugs cisplatin and etoposide were determined in the KGN 
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cells transduced by the lentivirus by the MTT assay. The preliminary studies were conducted 
in this study to achieve a longer project. 
It would be worth investigating whether FOXL2 may reduce cancer cells metastasis via 
the inhibition of migration and invasion, using the Boyden chamber assays. The effect of co-
culture with MSCs on KGN cell proliferation and cell death levels can be measured. Tumour 
metastasis is a significant cause of patient death and is common in adult type GCTs (Cho et 
al., 2009; Jamieson et al., 2012). Also, the effect of FOXL2 on cancer cell metastasis through 
the inhibition of angiogenesis could be investigated. A tumour requires new blood vessels 
once it reaches a diameter of a few millimetres (Weidner et al., 1991). Therefore, angiogenesis 
is essential for the expansion and growth of a tumour (Folkman, 1990; Weidner et al., 1991). 
Endothelial cells respond to cytokines that originate from both cancerous and migratory cells. 
Tube formation assays could also be used to investigated this by expressing the wild-type 
FOXL2 gene in HUVECs and undertaking tube-like formation assays by growing KGN cells 
with and without the wild-type FOXL2 gene on Matrigel.  
Also, cisplatin, etoposide and bleomycin are the first line drugs for the treatment of adult 
type GCTs (Homesley et al., 1999; Pautier et al., 2008). The bleomycin drug susceptibility 
with the wild-type FOXL2 protein also could also be tested along with the combination of 
these drugs. This may establish if the combination therapy can be safely applied in preclinical 
studies and if the combination efficacy can be accentuated through the delivery of the wild-
type FOXL2 protein via the MSCs. Further, the signalling pathways by which these drugs act 
in the wild-type FOXL2 expressing and non-expressing cells could be tracked by Western 
blotting and immunocytochemistry techniques to measure the protein levels such as tBID, 
caspase-8, caspase-3, BAX, cytochrome C and so on (Kim et al., 2011). 
The next step to develop MSCs as delivery vehicles is to co-culture (direct cell co-culture 
or via transwell inserts) the MSCs expressing the wild-type FOXL2 gene with KGN cells to 
assess cell viability, migration and invasion to see if the gene is delivering to the KGN cells 
and is effective or not. If this first step would be successful, then we can perform drug 
treatments with cisplatin and etoposide in the co-culture experiments. 
The studies presented in Chapter 4 have shown the potential of increasing susceptibility 
to the drugs cisplatin and etoposide in KGN cells expressing the wild-type FOXL2 gene, to 
treat adult type GCTs. However, further studies should be conducted in order to clarify some 
of the results observed here and to confirm that efficacy is retained in vivo. Thus, mouse pilot 
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studies were conducted with KGN cells, but palpable tumour formation was not noticed. The 
mouse pilot studies therefore need to be repeated by changing the route of administration or 
by keeping track of injected cells by fluorescence imaging (to check if the cells are going into 
any of the organs or if they were disappearing due to defence mechanisms of the host), or 
perhaps with a different mouse model and developing an orthotropic or xenograft model for 
animal studies. Further, if pilot studies are successful, animal studies could be conducted to 
investigate the therapeutic efficacy of the wild-type FOXL2 gene, which could be performed 
by the overexpression in MSCs and injecting them intravenously to treat adult type ovarian 
tumour granulosa. 
6.5.3 TIMP proteins and their clinical applications 
In this work, MSCs overexpressing TIMPs were developed, which is considered as the 
first step of a larger project. If the problems experienced in this work had been overcome, 
MSC-expressing-TIMPs stable cell lines could have been established. Ideally, we would have 
performed migration, invasion, adhesion, proliferation and angiogenesis assays with all four 
different TIMP expressing MSCs individually. The best working TIMP or TIMPs which 
inhibited migration, invasion, proliferation or angiogenesis of cancer cells would have been 
tested for apoptosis and inhibition of MMPs by Western blotting. Further, the TIMPs 
overexpressing MSCs which worked best against cancer cells could have been used for the 
treatment of a xenograft in a mouse model through IV injection. 
The development of an orthotopic model was previously performed to form intracranial 
tumours with U87 glioblastoma cells and also using patient derived glioblastoma cells (Bago 
et al., 2017). Therefore, the animal pilot studies using the paediatric glioblastoma cell lines 
KNS42 and UW479 could be repeated by administering the cell lines by another route such 
as developing an orthotropic model. This can be done by inserting the glioblastoma cells in 
Matrigel 2 mm below the surface of the brain, 2 mm posterior to Bregma in 6 week old nude 
BALB/c mice. The cells also could be tracked by fluorescence imaging. Such a study would 
investigate the effect of expression of TIMPs individually and the MSCs overexpressing the 
TIMP protein which was most effective in the in vitro assays would be injected intravenously 
for the treatment/prevent progression in mouse models. Tumour formation and development 
can be tracked by fluorescence imaging and tumour tissue can be collected and analysed. Also, 




 FINAL CONCLUSIONS 
In conclusion, from the findings of these studies, there is evidence to indicate that MSCs 
are being recruited into tumour stroma partially by the protease cath D and its precursors, 
possibly by activation of the ERK signalling pathways. Furthermore, we showed that 
inhibition of cath D by siRNA and by pepstatin A decreased the migration and invasion of the 
MSCs to the cancer cells. This may provide future avenues for potential research into the 
MSC-cancer stromal relationship. To our knowledge, this is the first report showing that cath 
D could act as an agent for the crosstalk of MSCs and tumour cells. 
As MSCs home to tumour sites, they have been suggested to be used as targeted therapy 
vehicles for gene/protein therapy in the treatment of cancer or cancer progression. An attempt 
was undertaken to treat/decrease the progression of adult type ovarian tumour granulosa 
through the overexpression of the wild-type FOXL2 gene. This overexpression increased 
cisplatin and etoposide susceptibility in KGN cells expressing the wild-type FOXL2. 
Overexpression of the wild-type FOXL2 decreased the IC50 values to almost half, along with 
a significant G2/M phase arrest and mitochondrial cell death, which could be expected 
clinically as well. IC50 values of cisplatin and etoposide in MSCs with and without the wild-
type FOXL2 were higher when compared to KGN cells, indicating the potential differences 
in susceptibility to drugs between malignant and healthy tissue. Therefore, this study provides 
an initial proof of concept in which MSCs would be potentially less susceptible to cisplatin 
and etoposide during the treatment of ovarian tumour granulosa in humans and could deliver 
the wild-type FOXL2 protein at tumour sites while remaining viable. 
MSCs, as a part of tumour stroma decrease the migration of cancer cells by the expression 
of TIMPs, as shown by the decrease in migration following the addition of GM6001, an MMP 
inhibitor. Thus, another attempt to use MSCs as vehicles of gene/protein delivery was made 
to treat/decrease the progression of paediatric glioblastoma. This study would have increased 
knowledge of the effect of TIMP expression within the tumour microenvironment on the 
invasive and metastatic potential of malignant tumour cells. 
Overall, it appears that the cath D protease plays an important role in the homing of MSCs 
to tumour sites. Since these MSCs become a part of tumour stroma, they can be used as 
vehicles of gene or protein delivery for cancer treatment and progression, at least when tested 
































Appendix 1. Migrated MSCs towards MDA-MB-231 or HT29 cells and their serum free 
conditioned media stained with crystal violet stain. MSCs were suspended in serum-free 
growth media into the upper chambers. Bottom wells contained MDA-MB-231 or HT29 cells 
and their 1 day and 3 day conditioned serum free DMEM media.  After 48 h, the MSC cells 
that migrated to the lower side of the membrane were stained with crystal violet stain and 
images were taken in Images were taken at 20x magnification with an EVOS XL CORE cell 
imaging system (Thermo Fisher Scientific, Bothell, WA, USA). Images from left to right and 
top to bottom are as follows: MSCs only (100%), with MDA-MB-231 (168%), with MDA-
MB-231 1 day conditioned media (CM) (120%), with MDA-MB-231 3 day CM (241%), with 
HT29s (100%), with HT29 1 day CM (100%), with HT29 3 day CM (150%). Scale bar 
represents 200μm. 
  

















Appendix 2. Migrated MSCs towards MDA-MB-231 or HT29 cells and their serum 
containing conditioned media stained with crystal violet satin. MSCs were suspended in 
serum-free growth media in to the upper chambers. Bottom wells contained MDA-MB-231 
or HT29 cells and their 1 day and 3 day conditioned DMEM media with serum.  After 48 h, 
the MSC cells that migrated to the lower side of the membrane were stained with crystal violet 
stain and images were taken in Images were taken at 20x magnification with an EVOS XL 
CORE cell imaging system (Thermo Fisher Scientific, Bothell, WA, USA). Images from left 
to right and top to bottom are as follows: MSCs only (100%), with 231s (190%), with 231 1 
day conditioned media (CM) (136%), with 231 3 day CM (207%), with HT29s (100%), with 





































Appendix 3. Determination of doubling time of UW479 cells in 96-well plate. UW479 
cells were plated in a 96-well plate over a range of densities 0-20x103 cells/well. Following 
the cell plating, cell viability was analysed by MTT assay at 24, 48 and 72 h. The values 
represent the mean absorbance ± SEM of two independent experiments.  
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Appendix 4. Determination of doubling time of SF188 cells in 96-well plate. SF188 cells 
were plated in a 96-well plate over a range of densities 0-20x103 cells/well. Following the cell 
plating, cell viability was analysed by MTT assay at 24, 48 and 72 h. The values represent the 



































Appendix 5. Determination of doubling time of KNS42 cells in 96-well plate. KNS42 cells 
were plated in a 96-well plate over a range of densities 0-25x103 cells/well. Following the cell 
plating, cell viability was analysed by MTT assay at 24, 48 and 72 h. The values represent the 








































Appendix 6. Determination of doubling time of MDA-MB-231 cells in 96-well plate. 
MDA-MB-231 cells were plated in a 96-well plate over a range of densities 1-20x103 
cells/well. Following the cell plating, cell viability was analysed by MTT assay at 24, 48 and 










































Appendix 7. Determination of doubling time of KGN cells in 96-well plate. KGN cells 
were plated in a 96-well plate over a range of densities 1-15x103 cells/well. Following the cell 
plating, cell viability was analysed by MTT assay at 24, 48 and 72 h. The values represent the 























































Appendix 8. Determination of doubling time of MSC-hTERT-T0523 cells in 96-well 
plate. MSC-hTERT-T0523 cells were plated in a 96-well plate over a range of densities 1-
12.5x103 cells/well. Following the cell plating, cell viability was analysed by MTT assay at 




































Appendix 8. Determination of doubling time of MSC RCB2157 cells in 96-well plate. 
MSC RCB2157 cells were plated in a 96-well plate over a range of densities 1-15x103 
cells/well. Following the cell plating, cell viability was analysed by MTT assay at 24, 48 and 






































Appendix 9. Sequencing results of TIMP-1 gene. TIMP-1 gene was cloned into pLVX-
IRES-tdTomato plasmid. The plasmids with the TIMP-1 gene were screened and then 
transformed into E.coli, multiplied, isolated and the plasmids were sent for sequencing. The 


























Appendix 10. Sequencing results of TIMP-2 gene. TIMP-2 gene was cloned into pLVX-
IRES-tdTomato plasmid. The plasmids with the TIMP-2 gene were screened and then 
transformed into E.coli, multiplied, isolated and the plasmids were sent for sequencing. The 



























Appendix 11. Sequencing results of TIMP-3 gene. TIMP-3 gene was cloned into pLVX-
IRES-tdTomato plasmid. The plasmids with the TIMP-3 gene were screened and then 
transformed into E.coli, multiplied, isolated and the plasmids were sent for sequencing. The 




























Appendix 12. Sequencing results of TIMP-4 gene. TIMP-4 gene was cloned into pLVX-
IRES-tdTomato plasmid. The plasmids with the TIMP-4 gene were screened and then 
transformed into E.coli, multiplied, isolated and the plasmids were sent for sequencing. The 
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